Neuphoria Therapeutics (NEUP) 20-F 14 Oct 22 2022 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Jun. 30, 2022 shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	BIONOMICS LIMITED/FI
Entity Central Index Key	0001191070
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding	1,353,350,744
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Securities Act File Number	001-41157
Entity Incorporation, State or Country Code	C3
Entity Address, Address Line One	200 Greenhill Road
Entity Address, City or Town	Eastwood SA
Entity Address, Postal Zip Code	5063
Entity Address, Country	AU
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Registration Statement	false
Document Accounting Standard	International Financial Reporting Standards
ICFR Auditor Attestation Flag	false
Auditor Name	Ernst & Young (2020: Deloitte Touche Tohmatsu)
Auditor Firm ID	1435
Auditor Location	Adelaide, Australia
Trading Symbol	BNOX
Title of 12(b) Security	American Depository Shares, each representing the right to receive one hundred eighty (180) Ordinary Shares, no par value per share
Security Exchange Name	NASDAQ
Business Contact [Member]
Document Information [Line Items]
Entity Address, Address Line One	2710 Gateway Oaks Drive
Entity Address, Address Line Two	Suite 150N
Entity Address, City or Town	Sacramento
Entity Address, Postal Zip Code	95833
Entity Address, Country	CA
City Area Code	+61
Local Phone Number	8 881507400
Contact Personnel Name	Errol De Souza, Ph.D.
Contact Personnel Email Address	edesouza@bionomics.com.au

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss and Other Comprehensive Income - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Continuing Operations
Revenue	$ 263,634		$ 46,662
Other income	5,808,231	$ 1,308,343	3,312,753
Other (losses) and gains	(582,015)	4,272,931	4,575,881
Expenses
Research and development expenses	(15,998,999)	(5,762,303)	(5,827,844)
Administrative expenses	(7,398,476)	(4,372,823)	(3,670,647)
Occupancy expenses	(262,440)	(1,272,414)	(1,180,482)
Compliance expenses	(3,736,936)	(1,614,313)	(1,436,443)
Finance expenses	(44,165)	(1,443,885)	(1,846,467)
Loss before tax	(21,951,166)	(8,884,464)	(6,026,587)
Income tax benefit	191,808	187,427	207,612
Loss after tax from continuing operations	(21,759,358)	(8,697,037)	(5,818,975)
Discontinued Operations
Loss for the year from discontinued operations			(1,299,313)
Loss for the year	(21,759,358)	(8,697,037)	(7,118,288)
Items that may be reclassified subsequently to profit or loss:
Exchange differences on translating foreign operations	1,067,134	(1,169,171)	530,915
Total Comprehensive Loss for the Year	$ (20,692,224)	$ (9,866,208)	$ (6,587,373)
LOSS PER SHARE
Basic loss per share	$ (0.02)	$ (0.01)	$ (0.01)
Diluted loss per share	$ (0.02)	$ (0.01)	$ (0.01)

Consolidated Statement of Finan

Consolidated Statement of Financial Position - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 33,564,857	$ 28,499,449
Other financial assets		435,640
Trade and other receivables	64,360	200,212
Research and development incentives receivable	6,719,761	928,073
Other assets	1,461,268	863,630
TOTAL CURRENT ASSETS	41,810,246	30,927,004
NON-CURRENT ASSETS
Property, plant and equipment	5,172	8,227
Right-to-use asset - rented property	669,358	862,716
Goodwill	12,868,122	12,400,743
Other intangible assets	9,838,274	9,945,755
Other financial assets	119,000	119,000
TOTAL NON-CURRENT ASSETS	23,499,926	23,336,441
TOTAL ASSETS	65,310,172	54,263,445
CURRENT LIABILITIES
Trade and other payables	2,786,280	1,814,390
Lease liability - rented property	160,040	174,218
Provisions	409,320	371,936
TOTAL CURRENT LIABILITIES	3,355,640	2,360,544
NON-CURRENT LIABILITIES
Lease liability - rented property	533,583	693,623
Provisions	10,460	6,782
Deferred tax liability	1,798,625	1,842,303
Contingent consideration	2,699,010	1,762,656
TOTAL NON-CURRENT LIABILITIES	5,041,678	4,305,364
TOTAL LIABILITIES	8,397,318	6,665,908
NET ASSETS	56,912,854	47,597,537
EQUITY
Issued capital	217,695,759	190,190,147
Reserves	12,523,598	11,447,891
Accumulated losses	(173,306,503)	(154,040,501)
TOTAL EQUITY	$ 56,912,854	$ 47,597,537

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - AUD ($)	Total	Issued Capital	Foreign Currency Translation Reserve	Share-Based Payments Reserve	Accumulated Losses
Equity at beginning of period at Jun. 30, 2019	$ 16,499,064	$ 144,944,233	$ 6,254,267	$ 7,365,270	$ (142,064,706)
(Loss) for the period	(7,118,288)				(7,118,288)
Exchange differences on translation of foreign operations	530,915		530,915
Total comprehensive income	(6,587,373)		530,915		(7,118,288)
Recognition of share-based payments	55,355			55,355
Recycled on disposal of subsidiaries	(496,811)		(496,811)
Transfer of expired options and warrants				(295,212)	295,212
Issue of ordinary shares as result of share options being exercised	3,260,000	3,260,000
Share issue costs	(48,228)	(48,228)
Equity at end of period at Jun. 30, 2020	12,682,007	148,156,005	6,288,371	7,125,413	(148,887,782)
(Loss) for the period	(8,697,037)				(8,697,037)
Exchange differences on translation of foreign operations	(1,169,171)		(1,169,171)
Total comprehensive income	(9,866,208)		(1,169,171)		(8,697,037)
Recognition of share-based payments	1,308,349			1,308,349
Transfer of expired options and warrants				(3,544,318)	3,544,318
Issue of ordinary shares as result of share options being exercised	21,229,874	21,229,874
Issue of ordinary shares as result of warrants being exercised	22,606,257	22,606,257
Issue of ordinary shares to employees	60,750	60,750
Share issue costs	(423,492)	(1,862,739)		1,439,247
Equity at end of period at Jun. 30, 2021	47,597,537	190,190,147	5,119,200	6,328,691	(154,040,501)
(Loss) for the period	(21,759,358)				(21,759,358)
Exchange differences on translation of foreign operations	1,067,134		1,067,134
Total comprehensive income	(20,692,224)		1,067,134		(21,759,358)
Recognition of share-based payments	2,829,689			2,829,689
Transfer of expired options and warrants				(2,493,356)	2,493,356
Issue of ordinary shares as result of share options being exercised	27,200	27,200
Issue of ordinary shares as result of warrants being exercised	480,000	480,000
Transfer from share-based payments reserve		327,760		(327,760)
Issue of ordinary shares as result of US IPO	32,383,263	32,383,263
Share issue costs	(5,712,611)	(5,712,611)
Equity at end of period at Jun. 30, 2022	$ 56,912,854	$ 217,695,759	$ 6,186,334	$ 6,337,264	$ (173,306,503)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Cash Flows from Operating Activities
Research and development incentives received		$ 2,919,541	$ 7,482,764
Receipts from customers	$ 270,975	394,815	4,883,858
Payments to suppliers and employees	(21,982,297)	(10,126,660)	(14,933,981)
Interest and bank fees paid	(44,165)	(726,420)	(1,335,834)
Net cash (used) by Operating Activities	(21,755,487)	(7,538,724)	(3,903,193)
Cash Flows from Investing Activities
Interest received	12,516	4,094	58,369
Payments for other financial assets		(118,466)	(52,174)
Proceeds from disposal of other financial assets	435,640		550,000
Payments for purchases of property, plant and equipment	(1,544)	(1,468)	(7,704)
Proceeds from sales of property, plant and equipment	175,091	35,634	264,370
Net cash out flow from disposal of subsidiaries			(1,007,992)
Net cash provided/(used) by Investing Activities	621,703	(80,206)	(195,131)
Cash Flows from Financing Activities
Repayment of borrowings		(11,087,139)	(7,460,180)
Payments for transaction costs			(281,668)
Principal elements of lease payments	(174,218)	(779,807)	(826,942)
Proceeds from share issues	32,890,463	43,836,131	3,260,000
Payments for share issue costs	(5,720,623)	(415,479)	(48,228)
Net cash provided by Financing Activities	26,995,622	31,553,706	(5,357,018)
Net Increase in Cash and Cash Equivalents	5,861,838	23,934,776	(9,455,342)
Cash and cash equivalents at the beginning of the financial year	28,499,449	4,577,747	13,985,477
Effects of exchange rate changes on the balance of cash held in foreign currencies	(796,430)	(13,074)	47,612
Cash and Cash Equivalents at the End of the Year	$ 33,564,857	$ 28,499,449	$ 4,577,747

General Information

General Information	12 Months Ended
	Jun. 30, 2022
General information [abstract]
General Information	NOTE 1: GENERAL INFO RMATION Bionomics Limited (“the Company”) is a listed public company incorporated in Australia. The address of its registered office and principal place of business is as follows: 200 Greenhill Road Eastwood, South Australia, 5063 Tel: +61 8 8150 7400 Principal Activities The principal activities of the Company and its controlled entities (“the Group”) during the period include the development of novel drug candidates focused on the treatment of serious central nervous system disorders.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2022
Disclosure Of Summary Of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES This financial report includes the consolidated financial statements and notes of the Group. (i) Statement of Compliance These financial statements comply with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). For the purposes of preparing the consolidated financial statements, the Company is a for-profit entity. (ii) Basis of Preparation The consolidated financial statements have been prepared on the basis of historical cost, except for certain non-current assets and financial instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below. Historical cost is generally based on the fair values of the consideration given in exchange for assets. All amounts are presented in Australian dollars unless otherwise noted. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Group takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at measurement date. Fair value for measurement and/or disclosure purposes in these consolidated financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of IFRS 2, leasing transactions that are within the scope of IFRS 16, and measurements that have some similarities to fair value but are not fair value, such as net realizable value in IFRS 2 or value in use in International Accounting Standards (“IAS”) 36. In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which inputs to the fair value measurements are observable market inputs and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at measurement date; • Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for that asset or liability, either directly or indirectly, and • Level 3 inputs are unobservable inputs for the asset or liability. (iii) Application of New and Revised Accounting Standards The Group has adopted all the new and revised Standards and Interpretations issued by the IASB that are relevant to its operations and effective for an accounting period that begins on or after July 1, 2021. The adoption of these new and revised Standards and Interpretations has resulted in no significant changes to the consolidated entity’s accounting policies. Standards and Interpretations issued by the IASB that are relevant to its operations from July 1, 2022 are not expected to result in significant changes to the consolidated entity's accounting policies. (iv) Accounting Policies The following significant accounting policies have been adopted in the preparation and presentation of the financial report. (a) Basis of Consolidation The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company: • has power over the investee; • is exposed, or has rights, to variable returns from its involvement with the investee, and • has the ability to use its power to affect its returns. Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Company gains control until the date when the Company ceases to control the subsidiary. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation. (b) Borrowings Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in profit or loss over the period of the borrowings using the effective interest method. Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date. (c) Borrowing Costs All borrowing costs (other than transaction costs) are recognised in profit or loss in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. (d) Business Combinations Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value which is calculated as the sum of the acquisition-date fair values of assets transferred by the Group, liabilities incurred by the Group to the former owners of the acquiree and the equity instruments issued by the Group in exchange for control of the acquiree. Acquisition-related costs are recognised in profit or loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed are recognised at their fair value, except that: • Deferred tax assets or liabilities, and assets or liabilities related to employee benefit arrangements, are recognised and measured in accordance with IAS 12 ‘Income Taxes’ and IAS 19 ‘Employee Benefits’, respectively; • Liabilities or equity instruments related to share-based payment arrangements of the acquiree, or share-based payment arrangements of the Group entered into to replace share-based payment arrangements of the acquiree are measured in accordance with IFRS 2 ‘Share-based Payment’ at the acquisition date, and • Assets (or disposal groups) that are classified as held for sale in accordance with IFRS 5 ‘Non-current Assets Held for Sale and Discontinued Operations’ are measured in accordance with that Standard. Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. If, after reassessment, the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognised immediately in profit or loss as a gain on bargain purchase. Where the consideration transferred by the Group in a business combination includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the ‘measurement period’ (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date. The subsequent accounting for changes in the fair value of contingent consideration that do not qualify as measurement period adjustments depends on how the contingent consideration is classified. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration is recognised at fair value, classified as a liability which is remeasured at subsequent reporting dates in accordance with IFRS 9 and IAS 137 ‘Provisions, Contingent Liabilities and Contingent Assets’ respectively, as appropriate, with the corresponding gain or loss being recognised in profit or loss. If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period (see above), or additional assets or liabilities are recognised, to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the amounts recognised as of that date. (e) Cash and Cash Equivalents Cash and cash equivalents include cash on hand, deposits held at call with financial institutions, other short term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities on the consolidated statement of financial position. (f) Earnings/(Loss) per Share • Basic Earnings/(Loss) per Share Basic earnings/(loss) per share is calculated by dividing the profit/(loss) after income tax attributable to equity holders of the Company, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the year, adjusted for bonus elements in ordinary shares issued during the year. • Diluted Earnings/(Loss) per Share Diluted earnings/(loss) per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to options. (g) Employee Benefits • Short-term and Long-term Employee Benefits A liability is recognised for benefits accruing to employees in respect of wages and salaries, annual leave and long service leave when it is probable that settlement will be required, and they are capable of being measured reliably. Liabilities recognised in respect of short-term employee benefits, are measured at their nominal values using the remuneration rate expected to apply at the time of settlement. Liabilities recognised in respect of long-term employee benefits are measured as the present value of the estimated future cash outflows to be made by the Group in respect of services provided by employees up to reporting date, discounted using rates applicable to high quality corporate bonds. • Superannuation Retirement benefits are contributions made to employee superannuation funds and are charged as expenses when incurred. These contributions are made to external superannuation funds and are not defined benefits programs. • Share-based Payments Share-based compensation benefits have been provided to employees via the Bionomics Employee Equity Plan (“EEP”), with the exception of share options issued to the Executive Chairman which were approved by shareholders at the Annual General Meeting held on December 2, 2021. The fair value of shares issued to employees for no cash consideration under the EEP and share options issued to the Executive Chairman are recognised as an employee benefits expense with a corresponding increase in equity. The fair value is measured at grant date and recognised on a straight-line basis over the vesting period based on the Group’s estimate of equity instruments that will eventually vest or over the period of the Consultancy Agreement, as applicable. The disclosure in Note 21 relates to the EEP and the former Employee Share Option Plan (“ESOP”). The Bionomics EEP was approved by the Board and shareholders in 2017. Staff eligible to participate in the plan are those who have been a full-time or part-time employee of the Group for a period of not less than six months or a Director of the Group. Options are granted under the plan for no consideration and vest equally over five years , or when vesting conditions are achieved, unless they are bonus options which vest immediately. The amounts disclosed as remuneration relating to options are the assessed fair values at grant date of those options allocated equally over the period from grant date to vesting date. See Note 21 for details on how the fair value of options and warrants issued during the year are calculated. (h) Financial Assets All regular way purchases or sales of financial assets are recognised and derecognized on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace. All recognised financial assets are measured subsequently in their entirety at either amortised cost or fair value, depending on the classification of the financial assets. Classification of Financial Assets at amortised costs • The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flow, and • The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payment of principal and interest on the principal amount outstanding. Debt instruments that meet the following conditions are measured subsequently at fair value through other comprehensive income (“FVTOCI”): • The financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling the financial assets, and • The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. By default, all other financial assets are measured subsequently at fair value through profit or loss (“FVTPL”). Despite the foregoing, the Group may make the following irrevocable election/designation at initial recognition of a financial asset: • The Group may irrevocably elect to present subsequent changes in fair value of an equity investment in other comprehensive income if certain criteria are met (see (ii) below); and • The Group may irrevocably designate a debt investment that meets the amortised cost or FVTOCI criteria as measured at FVTPL if doing so eliminates or significantly reduces an accounting mismatch (see (ii) below). (i) Amortised Cost and Effective Interest Method The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocation interest income over the relevant period. For financial assets other than purchased or originated credit-impaired financial assets (i.e. assets that are credit-impaired on initial recognition), the effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) excluding expected credit losses, through the expected life of the debt instrument, or, where appropriate, a shorter period, to the gross carrying amount of the debt instrument on initial recognition. For purchased or originated credit-impaired financial assets, a credit-adjusted effective interest rate is calculated by discounting the estimated future cash flows, including expected credit losses, to the amortised cost of the debt instrument on initial recognition. The amortised cost of a financial asset is the amount at which the financial asset is measured at initial recognition minus the principal repayments, plus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, adjusted for any loss allowance. The gross carrying amount of a financial asset is the amortised cost of a financial asset before adjusting for any loss allowance. Interest income is recognised using the effective interest method for debt instruments measured subsequently at amortised cost and at FVTOCI. For financial assets other than purchased or originated credit-impaired financial assets, interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset, except for financial assets that have subsequently become credit-impaired, (see below). For financial assets that have subsequently become credit-impaired, interest income is recognised by applying the effective interest rate to the amortised cost of the financial asset. If, in subsequent reporting periods, the credit risk on the credit-impaired financial instrument improves so that the financial asset is no longer credit-impaired, interest income is recognised by applying the effective interest rate to the gross carrying amount of the financial asset. For purchased or originated credit-impaired financial assets, the Group recognizes interest income by applying the credit-adjusted effective interest rate to the amortised cost of the financial asset from initial recognition. The calculation does not revert to the gross basis even if the credit risk of the financial asset subsequently improves so that the financial asset is no longer credit-impaired. Interest income is recognised in profit or loss and is included in the “other Scholes model was used to obtain income” line item. (ii) Financial Assets at FVTPL Financial assets that do not meet the criteria for being measured at amortised cost or FVTOCI are measured at FVTPL. Specifically: • Investments in equity instruments are classified as at FVTPL, unless the Group designates an equity investment that is neither held for trading nor a contingent consideration arising from a business combination as at FVTOCI on initial recognition. • Debt instruments that do not meet the amortised cost criteria or the FVTOCI criteria are classified as at FVTPL. In addition, debt instruments that meet either the amortised cost criteria or the FVTOCI criteria may be designated as at FVTPL upon initial recognition if such designation eliminates or significantly reduces a measurement or recognition inconsistency (so called ‘accounting mismatch’) that would arise from measuring assets or liabilities or recognizing the gains and losses on them on different bases. The Group has not designated any debt instructions as at FVTPL. Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any fair values gains or losses recognised in profit or loss to the extent they are not part of a designated hedging relationship (see hedge accounting policy). The net gain or loss recognised in profit or loss includes any dividend or interest earned on the financial asset and is included in the ‘other gains and losses’ line item. (iii) Impairment of Financial Assets The Group recognizes a loss allowance for expected credit losses (“ECL”) on investments in debt instruments that are measured at amortised cost or a FVTOCI, lease receivables, trade receivables and contract assets, as well as on financial guaranteed contracts. The amount of expected credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument. The Group always recognizes lifetime ECL for trade receivables, contract assets and lease receivables. The expected credit losses on these financial assets are estimated using a provision matrix based on the Group’s historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate. For all other financial instruments, the Group recognizes lifetime ECL when there has been a significant increase in credit risk since initial recognition. However, if the credit risk on the financial instrument has not increased significantly since initial recognition, the Group measures the loss allowance for that financial instrument at an amount equal to 12-month ECL. Lifetime ECL represents the expected credit losses that will result from all possible default events over the expected life of a financial instrument. In contrast, 12-month ECL represents the portion of lifetime ECL that is expected to result from default events on a financial instrument that are possible within 12 months after the reporting date. (i) Foreign Currencies The individual financial statements of each group entity are presented in the currency of the primary economic environment in which the entity operates (its functional currency). For the purpose of the consolidated financial statements, the results and financial position of each group entity are expressed in Australian dollars (“$”), which is the functional currency of the Company and the presentation currency for the consolidated financial statements. In preparing the financial statements of each individual group entity, transactions in currencies other than the entity’s functional currency (foreign currencies) are recognised at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences on monetary items are recognised in profit or loss in the period in which they arise except for exchange differences on monetary items receivable from or payable to a foreign operation for which settlement is neither planned nor likely to occur (therefore forming part of the net investment in the net investment in the foreign operation), which are recognised initially in other comprehensive income and reclassified from equity to profit or loss on repayment of the monetary items. For the purpose of presenting these consolidated financial statements, the assets and liabilities of the Group’s foreign operations are translated into Australian dollars using exchange rates prevailing at the end of the reporting period. Income and expense items are translated at the average exchange rates for the period. Exchange differences arising, if any, are recognised in other comprehensive income and accumulated in equity. Goodwill and fair value adjustments to identifiable assets acquired and liabilities assumed through acquisition of a foreign operation are treated as assets and liabilities of the foreign operation and translated at the rate of exchange prevailing at the end of each reporting period. Exchange differences arising are recognised in other comprehensive income and accumulated in equity. (j) Goods and Services Tax (“GST”) Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognised as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated statement of financial position. Cash flows are presented on a gross basis. The GST component of cash flow arising from investing or financing activities which are recoverable from, or payable to the taxation authority, are presented as operating cash flow. (k) Government Research and Development Incentives Government grants, including Research and Development incentives, are recognised at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to cost reimbursements are recognised as other income in profit or loss in the period when the costs were incurred or when the incentive meets the recognition requirements (if later). (l) Impairment of Tangible and Intangible Assets Other than Goodwill At the end of each reporting period, the Group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). When it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash generating unit (“CGU”) to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual CGUs, or otherwise they are allocated to the smallest group of CGUs for which a reasonable and consistent allocation basis can be identified. A CGU is the smallest identifiable group of assets that generates cash flow that is largely independent of cash flows from other assets or group of assets. The Company's CGU (drug development) is defined as a research programme that has the potential to be commercialized at some point in the future. Achievement of certain milestones within the current central nervous system research programme will determine when a new CGU comes into existence. Intangible assets with indefinite useful lives are tested for impairment at least annually, and whenever there is an indication that the asset may be impaired. Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease. Where an impairment loss subsequently reverses, the carrying amount of the asset (or CGU) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or CGU) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase. (m) Income Tax Income tax expense represents the sum of the tax currently payable and deferred tax. Current Tax The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit before tax as reported in the consolidated statement of profit or loss and other comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group’s current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred Tax Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. In addition, deferred tax liabilities are not recognised if the temporary difference arises from the initial recognition of goodwill. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities. Deferred tax liabilities and assets are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis. Current and Deferred Tax for the Year Current and deferred tax are recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case the current and deferred tax are also recognised in other comprehensive income or directly in equity, respectively. Where current tax or deferred tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination. Tax Consolidation Legislation Bionomics and its wholly owned Australian controlled entities have implemented the tax consolidation legislation effective 31 December 2005. The head entity, Bionomics Limited, and the controlled entities in the tax consolidated group account for their own current and deferred tax amounts. These tax amounts are measured as if each entity in the tax consolidated group continues to be a stand-alone taxpayer in its own right. In addition to its own current and deferred tax amounts, Bionomics Limited also recognizes the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from controlled entities in the tax consolidated group. Assets or liabilities arising under tax funding agreements with the tax consolidated entities are recognised as amounts receivable from or payable to other entities in the Group. Any difference between the amounts assumed and amounts receivable or payable under the tax funding agreement are recognised as a contribution to (or distribution from) wholly-owned tax consolidated entities. (n) Intangible Assets (i) Intellectual Property Acquired intellectual property is recognised as an asset at cost and amortised over its useful life. There is currently no internally generated intellectual property that has been capitalised. Intellectual property with a finite life is amortised on a straight-line basis over that life. Intellectual property with an indefinite useful life is subjected to an annual impairment review. There is currently no intellectual property with an indefinite life. 15 to 20 years. (ii) Goodwill Goodwill arising on an acquisition of a business is carried at cost as established at the date of the acquisition of the business (see Note 2(d) above) less accumulated impairment losses, if any. On disposal of the relevant CGU, the attributable amount of goodwill is included in the determinati

Critical Accounting Estimates a

Critical Accounting Estimates and Judgements	12 Months Ended
	Jun. 30, 2022
Disclosure of changes in accounting estimates [abstract]
Critical Accounting Estimates and Judgements	NOT E 3: CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS The preparation of the consolidated financial statements requires the Group to make estimates and judgements that can affect the reported amounts of assets, liabilities, revenues and expenses, as well as the disclosure of contingent assets and liabilities at the date of the financial statements. The Group analyses the estimates and judgements and base estimates and judgements on historical experience and various other assumptions that are believed to be reasonable under the circumstances. Actual results may vary from the estimates. The significant accounting policies are detailed in Note 2. Summarised below are the accounting policies of particular importance to the portrayal of the financial position and results of operations and that require the application of significant judgement or estimates by management. Impairment of Goodwill and Other Intangible Assets The Group assesses annually, or whenever there is a change in circumstances, whether goodwill or other intangible assets may be impaired. Determining whether goodwill and other intangible assets are impaired requires an estimation of the higher of value in use and fair value less cost of disposal of the CGU to which goodwill or other intangible assets have been allocated. The value in use calculation is judgmental in nature and requires the Group to make a number of estimates including the future cash flows expected to arise from the CGU based on actual current market deals for drug compounds within the CGU and over a period covering drug discovery, development, approval and marketing as well as, a suitable discount rate in order to calculate present value. The cash flow projections are further weighted based on the observable market comparables probability of realising projected milestone and royalty payments. When the carrying value of the CGU exceeds its recoverable amount, the CGU is considered impaired and the assets in the CGU are written down to their recoverable amount. Impairment losses are recognised in the consolidated statement of profit or loss and other comprehensive income. A detailed valuation was performed as of June 30, 2022 and each computed recoverable amount (based on a value-in-use model) of the CGU was in excess of the carrying amount, respectively. As a result of this evaluation, it was determined that no impairment of goodwill or other intangible assets existed at June 30, 2022. Contingent Consideration As a result of the acquisition of Eclipse Therapeutic, Inc (“Eclipse”) during the year ended June 30, 2013, the Group determines and recognizes at each reporting date the fair value of the additional consideration that may be payable to Eclipse security holders due to potential royalty payments based on achieving late-stage development success or partnering outcomes based on Eclipse assets. Such potential earn-out payments are recorded at fair value and include a number of significant estimates including adjusted revenue projections and expenses, probability of such projections and a suitable discount rate to calculate fair value (see Note 30 for further information).

Segment Information

Segment Information	12 Months Ended
	Jun. 30, 2022
Segment information [abstract]
Segment Information	NOTE 4 : SEGMENT INFORMATION The Group operates in one segment (CGU) being “drug development” in Australia. This is the basis on which its internal reports are reviewed and used by the Board of Directors (the “chief operating decision maker”) in monitoring, assessing performance and in determining the allocation of resources. The results, assets and liabilities from this segment are equivalent to the consolidated financial statements.

Revenue, Other Income and Other

Revenue, Other Income and Other Gains and Losses	12 Months Ended
	Jun. 30, 2022
Disclosure Of Revenue Other Income And Other Gains And Losses [Abstract]
Revenue, Other Income and Other Gains and Losses	NOTE 5 : REVENUE, OTHER INCOME AND OTHER GAINS AND LOSSES 2022 2021 2020 Revenue from Continuing Operations Licenses 263,634 - 46,662 263,634 - 46,662 Other Income from Continuing Operations Interest income 9,869 5,756 58,369 Rent 6,674 203,014 200,284 Government Research and Development Incentives (i) 5,791,688 928,073 2,945,600 Government assistance COVID-19 (Cash flow boost) - 50,000 50,000 Government assistance COVID-19 (Jobkeeper) - 121,500 58,500 5,808,231 1,308,343 3,312,753 (i) The Government Research and Development Incentives include cash refunds provided by the Australian Government for 43.5 % (2021: 43.5 %, 2020: 43.5 %) of eligible research and development expenditures by Australian entities having a tax loss and less than A$ 20 million in revenue. The grants are calculated at the end of the fiscal year to which they relate, based on the expenses incurred in and included in the fiscal year's Australian income tax return after registration of the research and development activities with the relevant authorities. There are no unfulfilled conditions or other contingencies attaching to the Government Research and Development Incentive. 2022 2021 2020 Other gains and losses from Continuing Operations Net (loss)/gain arising on changes in fair value of contingent consideration (Note 30) ( 936,354 ) 3,212,503 4,823,874 Net gain arising on modification of borrowings measured at amortised costs that were not derecognized (Note 18) - - 199,089 Net realised and unrealised foreign currency gains 356,166 1,081,438 ( 621,016 ) (Loss) on disposal of plant and equipment ( 1,827 ) ( 21,010 ) 173,934 ( 582,015 ) 4,272,931 4,575,881

Expenses Relating to Continuing

Expenses Relating to Continuing Operations	12 Months Ended
	Jun. 30, 2022
Expenses by nature [abstract]
Expenses Relating to Continuing Operations	NOTE 6 : EXPENSES RELATING TO CONTINUING OPERATIONS 2022 2021 2020 Loss before income tax benefit includes the following specific expenses: Finance expenses - Interest expense on bank and other loans - 618,586 1,170,027 - Interest expense on lease liabilities 26,872 26,934 79,938 - Amortisation of transaction costs (Note18) - 252,019 29,649 - Accrual of final payment (Note 18) - 528,819 544,357 - Bank fees 17,293 17,527 22,496 44,165 1,443,885 1,846,467 Employment benefit expenses of: - Wages and salaries 2,901,689 2,577,954 3,097,949 - Superannuation 266,127 148,662 213,769 - Share-based payments 2,829,689 1,308,349 55,355 5,997,505 4,034,965 3,367,073 Amortisation of non-current assets - Plant and equipment (Note 13) 2,681 45,553 91,860 - Right-of-use assets (rental property) (Note 14) 193,358 762,813 748,571 - Intellectual property (Note 16) 913,373 892,512 1,328,244 1,109,412 1,700,878 2,168,675 Rental expense on operating leases (low value assets) - Minimum lease payments 5,260 7,277 7,506

Income Taxes Relating to Contin

Income Taxes Relating to Continuing Operations	12 Months Ended
	Jun. 30, 2022
Major components of tax expense (income) [abstract]
Income Taxes Relating to Continuing Operations	NOTE 7 : INCOME TAXES RELATING TO CONTINUING OPERATIONS 2022 2021 2020 (a) Income Tax Recognised in Profit or Loss Current tax In respect of the current year - - - In respect of the prior year - - - - - - Deferred tax Recognised in current year ( 191,808 ) ( 187,427 ) ( 207,612 ) ( 191,808 ) ( 187,427 ) ( 207,612 ) Total income tax benefit ( 191,808 ) ( 187,427 ) ( 207,612 ) (b) Reconciliation to Accounting Loss 2022 2021 2020 Loss from continuing operations ( 21,951,166 ) ( 8,884,464 ) ( 6,026,587 ) Tax at the Australian tax rate of 25 % (2021 & 2020: 30 %) ( 5,487,792 ) ( 2,665,339 ) ( 1,807,976 ) Tax effect of non-deductible / non-assessable amounts Exempt income from government assistance ( 1,447,922 ) ( 293,422 ) ( 898,680 ) Entertainment expenses 1,231 727 1,355 Net gain arising on changes in fair value of contingent consideration 234,089 ( 963,751 ) ( 1,447,162 ) Share-based payments 707,422 392,505 16,607 Research and development expenditure 3,328,556 640,050 2,013,477 Amortisation of share issue costs ( 285,631 ) - - Temporary differences not recorded as an asset ( 58,374 ) ( 632,779 ) ( 68,181 ) Tax losses not recorded 2,779,547 3,253,265 1,981,695 Effect of different tax rates in other jurisdictions 37,066 81,317 1,253 ( 191,808 ) ( 187,427 ) ( 207,612 ) 2022 2021 (c) Net Deferred Tax Liability Recognised Net deferred tax liability is attributable to the following deferred tax asset/(liability) items: Intangibles denominated in USD ( 2,066,037 ) ( 2,088,608 ) Tax losses denominated in USD 267,412 246,305 ( 1,798,625 ) ( 1,842,303 ) Movement in Net Deferred Tax Liability Opening balance ( 1,842,303 ) ( 2,203,340 ) Recognized in income - Continuing operations 191,808 187,427 - Discontinuing operations - - Recognized in equity ( 148,130 ) 173,610 Derecognized on disposal of subsidiaries (Note 35) - - Closing balance ( 1,798,625 ) ( 1,842,303 ) (d) Net Deferred Tax Asset Not Recognised Revenue tax losses 25,439,594 27,181,188 Net temporary difference 3,460,261 2,851,336 28,899,855 30,032,524 Deferred tax assets have not been recognized in respect to these items as it is not probable at this time that future taxable profits will be available against which the Group can utilize the benefit. (f) Tax Consolidation Relevance of Tax Consolidation to the Group The Company and all its wholly-owned Australian resident entities are part of a tax-consolidated group under Australian taxation law. Bionomics is the head entity in the tax-consolidated group. Tax expense/benefit, deferred tax liabilities and deferred tax assets arising from temporary differences of the members of the tax-consolidated group are recognised in the separate financial statements of the members of the tax-consolidated group using the ‘separate taxpayer within group’ approach by reference to the carrying amounts in the separate financial statements of each entity and the tax values applying under tax consolidation. Current tax liabilities and assets and deferred tax assets arising from unused tax losses and relevant tax credits of the members of the tax-consolidated group are recognised by the Company (as head entity in the tax-consolidated group).

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Jun. 30, 2022
Cash and cash equivalents [abstract]
Cash and Cash Equivalents	NOTE 8 : CASH AND CASH EQUIVALENTS Cash at the end of the financial year as shown in the statements of cash flows is reconciled to items in the Consolidated Statement of Financial Position as follows: 2022 2021 Current Cash at bank and on hand 33,564,857 28,499,449 33,564,857 28,499,449 The weighted average interest rate on these deposits is 1.15 % per annum (2021: 0.1 % per annum).

Other Financial Assets

Other Financial Assets	12 Months Ended
	Jun. 30, 2022
Disclosure Of Other Financial Assets [Abstract]
Other Financial Assets	NOTE 9 : OTHER FINANCIAL ASSETS 2022 2021 Restricted deposits held as security and not available for use 119,000 554,640 Disclosed in the financial statement as: Current assets - 435,640 Non-current assets 119,000 119,000 119,000 554,640 The Group holds restricted term deposits of A$ 119,000 (2021: A$ 383,883 , $ 51,757 and A$ 119,000 ), with a maturity date of June 3, 2023 (2021: September 11, 2021 , September 23, 2021 and June 3, 2022 respectively) as security for a bank guarantee (Note 31 (ii)) that is not available for use. The term deposits will be extended on maturity until the bank guarantee ceases to be required. The effective interest rate on these deposits is 1.95 % (2021: 0.71 %).

Trade and Other Receivables

Trade and Other Receivables	12 Months Ended
	Jun. 30, 2022
Trade and other receivables [abstract]
Trade and Other Receivables	NOTE 10 : TRADE AND OTHER RECEIVABLES 2022 2021 Current Other receivables 42,483 192,885 Loss allowance - - 42,483 192,885 GST receivables 21,877 7,327 64,360 200,212

Other Assets

Other Assets	12 Months Ended
	Jun. 30, 2022
Miscellaneous current assets [abstract]
Other Assets	NOTE 11 : OTHER ASSETS 2022 2021 Current Prepayments 1,461,078 860,793 Accrued income 190 2,837 1,461,268 863,630

Subsidiaries

Subsidiaries	12 Months Ended
	Jun. 30, 2022
Disclosure of subsidiaries [abstract]
Subsidiaries	NOTE 12 : SUBSIDIARIES Details of the Group’s subsidiaries at the end of the reporting period are as follows: Percentage owned Entity Principal activity Country of incorporation 2022 2021 Head Entity Bionomics Limited Research and Development Australia Subsidiaries of Bionomics Limited Iliad Chemicals Pty Ltd Asset owner Australia 100 100 Bionomics Inc Asset owner United States 100 100

Property, Plant And Equipment

Property, Plant And Equipment	12 Months Ended
	Jun. 30, 2022
Disclosure of detailed information about property, plant and equipment [abstract]
Property, Plant And Equipment	NOTE 13 : PROPERTY, PLANT AND EQUIPMENT Plant Total Cost at Jult 1, 2020 1,373,704 1,373,704 Additions 1,468 1,468 Disposals ( 1,268,419 ) ( 1,268,419 ) Cost at June 30, 2021 106,753 106,753 Additions 1,544 1,544 Disposals ( 36,262 ) ( 36,262 ) Cost at June 30, 2022 72,035 72,035 Accumulated depreciation at July 1, 2020 ( 1,089,748 ) ( 1,089,748 ) Depreciation (a) ( 45,553 ) ( 45,553 ) Disposals 1,036,775 1,036,775 Accumulated depreciation at June 30, 2021 ( 98,526 ) ( 98,526 ) Depreciation (a) ( 2,681 ) ( 2,681 ) Disposals 34,344 34,344 Accumulated depreciation at June 30, 2022 ( 66,863 ) ( 66,863 ) Net Carrying Amounts at June 30, 2021 8,227 8,227 Net Carrying Amounts at June 30, 2022 5,172 5,172 a) Depreciation is disclosed in the Consolidated Statement of Profit or Loss and Other Comprehensive Income as follows 2022 2021 2020 Continuing operations 2,681 45,553 91,860 Discontinued operations - - 113,009 2,681 45,553 204,869

Right-of-Use Assets

Right-of-Use Assets	12 Months Ended
	Jun. 30, 2022
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use Assets	NOTE 19 : LEASE LIABILITIES 2022 2021 2020 Secured – at amortised costs Loan Movement Schedule Opening Balance – July 1 867,841 793,148 - Adoption of new leasing accounting standard - - 2,993,675 New lease for new property - being rented - 854,500 - Repayments ( 174,218 ) ( 779,807 ) ( 826,942 ) Derecognized on disposal of subsidiaries (Note 34) - - ( 1,440,322 ) Effect of foreign currency exchange differences - - 66,737 Closing Balance – June 30 693,623 867,841 793,148 Disclosed in the financial statements as: Current liabilities 160,040 174,218 767,711 Non-current liabilities 533,583 693,623 25,437 693,623 867,841 793,148 Lease liabilities relate to building leases and is effectively secured by the buildings being leased (Note 14). The total Group cash outflows for leases is set out below: 2022 2021 2020 Principal element of lease payments 174,218 779,807 826,942 Interest element of lease payments - continuing operations 26,872 26,934 79,938 Interest element of lease payments - discontinuing operations - - 33,176 Total cash outflows for leases 201,090 806,741 940,056 The Group's lease contracts include extension and termination options. These options are negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group’s business needs. Set out below are the undiscounted potential future rental payments relating to periods following the exercise date of extension options that are not included in the lease term: Within five years More than five years Total As at June 30, 2022 Extension options expected not to be exercised - 1,183,105 1,183,105 As at June 30, 2021 Extension options expected not to be exercised - 1,183,105 1,183,105
Right-of-use Assets
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use Assets	NOTE 14 : RIGHT-OF-USE ASSETS 2022 2021 Cost 854,500 2,374,100 Accumulated depreciation ( 185,142 ) ( 1,511,384 ) 669,358 862,716 Opening balance July 1 862,716 771,029 Addition of new property being rented - 854,500 Depreciation (a) ( 193,358 ) ( 762,813 ) Closing balance June 30 669,358 862,716 a) Depreciation is disclosed in the Consolidated Statement of Profit or Loss and Other Comprehensive Income as follows 2022 2021 2020 Continuing operations 193,358 762,813 748,571 Discontinued operations - - 116,075 193,358 762,813 864,646 Refer to Note 19 for information on non-current assets pledged as security for lease liabilities by the Group.

Goodwill

Goodwill	12 Months Ended
	Jun. 30, 2022
Intangible assets and goodwill [abstract]
Goodwill	NOTE 15 : GOODWILL A$ Carrying amount at July 1, 2020 12,872,387 Additions - Foreign currency exchange differences ( 471,644 ) Carrying amount at June 30, 2021 12,400,743 Additions - Foreign currency exchange differences 467,379 Carrying amount at June 30, 2022 12,868,122 Impairment Tests As identified in Note 4 the Group has only one CGU, drug development. Management tests annually whether goodwill has suffered any impairment, in accordance with the accounting policy stated in Note 2(n)(i) and (ii), and Note 2(l), respectively. For the purpose of impairment testing all goodwill is allocated to the drug development CGU. The recoverable amount of the drug development CGU is determined based on a value in use calculation which uses cash flow projections based on observable market comparables for drug compounds within the CGU over a period of twenty years covering drug discovery, development, approval and marketing, and a post-tax discount rate of 17 % (2021: 15 %). The Group is currently in its research phase and a 5 year forecast would not provide reasonable consideration of the timeframe, revenue and costs projections. The cash flow projections are weighted based on the observable market comparables probability of realising projected milestone and royalty payments. Management believes that the application of discounted cash flows of observable market comparables for one drug compound is reasonable to be applied to other compounds within the CGU at their respective development phases. Management believes that any reasonably possible change in the key assumptions on which recoverable amount is based would not cause the aggregate carrying amount to exceed the aggregate recoverable amount of the CGU. No growth rates or terminal values have been included in the forecast, as the full development lifecycle has been taken into account with the cashflows.

Other Intangible Assets

Other Intangible Assets	12 Months Ended
	Jun. 30, 2022
Disclosure of detailed information about intangible assets [abstract]
Other Intangible Assets	NOTE 16: OTHE R INTANGIBLE ASSETS Intellectual Property The acquired intellectual property relates to KV1.3 compound, VDA compound, MultiCore technology and cancer stem cell technology, and is carried at its cost as at its date of acquisition, less accumulated amortisation and impairment charges. There is currently no internally generated intellectual property capitalised. KV1.3 VDA MultiCore Cancer stem Total A$ A$ A$ A$ A$ Gross carrying amount at July 1, 2020 1,546,542 2,282,527 1,265,590 19,210,485 24,305,144 Additions - - - - - Foreign currency exchange differences - - - ( 1,529,124 ) ( 1,529,124 ) Gross carrying amount at June 30, 2021 1,546,542 2,282,527 1,265,590 17,681,361 22,776,020 Additions - - - - - Foreign currency exchange differences - - - 1,515,296 1,515,296 Gross carrying amount at June 30, 2022 1,546,542 2,282,527 1,265,590 19,196,657 24,291,316 Accumulated amortisation amount at July 1, 2020 ( 1,546,542 ) ( 2,282,527 ) ( 1,265,590 ) ( 7,444,073 ) ( 12,538,732 ) Amortisation (a) - - - ( 892,512 ) ( 892,512 ) Foreign currency exchange differences - - - 600,979 600,979 Accumulated amortisation amount at June 30, 2021 ( 1,546,542 ) ( 2,282,527 ) ( 1,265,590 ) ( 7,735,606 ) ( 12,830,265 ) Amortisation (a) - - - ( 913,373 ) ( 913,373 ) Foreign currency exchange differences - - - ( 709,404 ) ( 709,404 ) Accumulated amortisation amount at June 30, 2022 ( 1,546,542 ) ( 2,282,527 ) ( 1,265,590 ) ( 9,358,383 ) ( 14,453,042 ) Net carrying amount June 30, 2021 - - - 9,945,755 9,945,755 Net carrying amount June 30, 2022 - - - 9,838,274 9,838,274 a) Depreciation is disclosed in the Consolidated Statement of Profit or Loss and Other Comprehensive Income as follows: 2022 2021 2020 Continuing operations 913,373 892,512 1,328,244 Discontinued operations - - 45,627 913,373 892,512 1,373,871

Trade and Other Payables

Trade and Other Payables	12 Months Ended
	Jun. 30, 2022
Trade and other payables [abstract]
Trade and Other Payables	NOTE 17 : TRADE AND OTHER PAYABLES 2022 2021 Current Trade payables 1,556,881 1,028,744 Accrued expenses 1,229,399 785,646 2,786,280 1,814,390 The average credit period on purchases of goods is 45 days . No interest is paid on the trade payables. The Group has financial risk management policies in place to ensure that all payables are paid within the credit timeframe.

Borrowings

Borrowings	12 Months Ended
	Jun. 30, 2022
Disclosure of detailed information about borrowings [abstract]
Borrowings	NOTE 1 8: BORROWINGS 2022 2021 Current liabilities - - Non-current liabilities - - - - During April 2021 the equipment mortgage loans and the bank loan (which was denominated in US dollars) were fully repaid. 2022 2021 Loan Movement Schedule Opening Balance – July 1 - 11,444,129 Accrual of bank loan final payment (i) - 528,819 Repayments - principal - ( 9,170,741 ) - final payment (i) - ( 1,916,398 ) Net gain arising on modification of bank loan (due to extension of loan) that was not derecognized (ii) - - Transaction costs associated with obtaining interest only period (iii) - - Amortisation of costs (iii) - 252,019 Foreign currency exchange differences - ( 1,137,828 ) Closing Balance – June 30 - - (i) In addition to the payment of principal and interest over the term of the bank loan, a final payment was required under the bank loan, calculated at a percentage of the original principal borrowed. This liability was being accrued (using the effective interest method) over the term of the loan and the amount accrued prior to the loan being fully repaid was US$ 1,477,500 (July 1, 2020 was US$ 1,079,030 ). (ii) As a result of the bank loan being extended to January 1, 2022 (that occurred during the year ended June 30, 2020) the accrual of the bank loan final payment was remeasured resulting in a reduction in the liability that had been accrued as the modification to the loan did not qualify for derecognition of the loan . (iii) The transaction costs related to costs incurred in obtaining the six-month interest only period and extension of the bank loan. These costs were being amortized over the remaining term of the bank loan.

Lease Liabilities

Lease Liabilities	12 Months Ended
	Jun. 30, 2022
Lease liabilities [abstract]
Lease Liabilities	NOTE 19 : LEASE LIABILITIES 2022 2021 2020 Secured – at amortised costs Loan Movement Schedule Opening Balance – July 1 867,841 793,148 - Adoption of new leasing accounting standard - - 2,993,675 New lease for new property - being rented - 854,500 - Repayments ( 174,218 ) ( 779,807 ) ( 826,942 ) Derecognized on disposal of subsidiaries (Note 34) - - ( 1,440,322 ) Effect of foreign currency exchange differences - - 66,737 Closing Balance – June 30 693,623 867,841 793,148 Disclosed in the financial statements as: Current liabilities 160,040 174,218 767,711 Non-current liabilities 533,583 693,623 25,437 693,623 867,841 793,148 Lease liabilities relate to building leases and is effectively secured by the buildings being leased (Note 14). The total Group cash outflows for leases is set out below: 2022 2021 2020 Principal element of lease payments 174,218 779,807 826,942 Interest element of lease payments - continuing operations 26,872 26,934 79,938 Interest element of lease payments - discontinuing operations - - 33,176 Total cash outflows for leases 201,090 806,741 940,056 The Group's lease contracts include extension and termination options. These options are negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group’s business needs. Set out below are the undiscounted potential future rental payments relating to periods following the exercise date of extension options that are not included in the lease term: Within five years More than five years Total As at June 30, 2022 Extension options expected not to be exercised - 1,183,105 1,183,105 As at June 30, 2021 Extension options expected not to be exercised - 1,183,105 1,183,105

Provisions

Provisions	12 Months Ended
	Jun. 30, 2022
Disclosure Of Provision Abstract
Provisions	NOTE 20 : PROVISIONS 2022 2021 Current Employee benefits 409,320 371,936 Non-Current Employee benefits 10,460 6,782

Issued Capital

Issued Capital	12 Months Ended
	Jun. 30, 2022
Disclosure of classes of share capital [abstract]
Issued Capital	NOTE 2 1: ISSUED CAPITAL (a) Issued capital Movements in Ordinary Shares of the Company during the current period were as follows: Date Details Number of shares A$ Ordinary Shares July 1, 2019 Opening balance 544,647,747 144,944,233 Share issue - share placement 81,500,000 3,260,000 Transfer from treasury stock 38,125 - Share issue costs - ( 48,228 ) June 30, 2020 Closing balance 626,185,872 148,156,005 Share issue - share placements (i) 185,757,511 21,229,874 Share issue – rights (ii) 195,229,129 22,606,257 Shares issued to employees 424,232 60,750 Share issue costs - ( 423,492 ) Warrants issued -underwriting fee (iii) - ( 1,439,247 ) June 30, 2021 Closing balance 1,007,596,744 190,190,147 Shares issued on exercise of options (iv) 2,000,000 27,200 Shares issued on exercise of warrants (iv) 8,000,000 480,000 Transfer from share-based payments reserve as result of options and warrants being exercised - 327,760 Share issue in a US IPO and NASDAQ listing (v) 335,754,000 32,383,263 Share issue costs - ( 5,712,611 ) June 30, 2022 Closing balance 1,353,350,744 217,695,759 Treasury Stock July 1, 2019 Closing balance 38,125 - Share issue – Employee Share Plan Loan Agreements ( 38,125 ) - June 30, 2020 Closing balance - - Share issue – Employee Share Plan Loan Agreements - - June 30, 2021 Closing balance - - Share issue – Employee Share Plan Loan Agreements - - June 30, 2022 Closing balance - - Total Issued Capital 1,353,350,744 217,695,759 (i) During the year ended June 30, 2021, the following share placements occurred: • Issue of 54,333,000 shares at A$ 0.04 per share raising A$ 2,173,320 . The share issue was approved by shareholders at a General Meeting held on August 26, 2020; and • Issue of 131,424,511 shares at A$ 0.145 per share raising A$ 19,056,554 (ii) During the year ended June 30. 2021, the following rights issues occurred: • Issue of 54,304,446 at A$ 0.04 per share raising A$ 2,172,178 ; and • Issue of 140,924,683 shares at A$ 0.145 raising A$ 20,434,079 (iii) Shareholders at the General Meeting held on August 26, 2020 approved the issue of 150,000,000 warrants to Apeiron Investment Group Ltd (“Apeiron”) to subscribe for shares at A$ 0.06 per share as consideration of underwriting a share issue that would raise at least A$ 15,000,000 . The warrants vested on 3 March 2021 when with the assistance of Apeiron a share placement was made that raised A$ 15,991,634 . (iv) During the year ended June 30, 2022, the following shares were issued: • Issue of 2,000,000 as a result of share options being exercised that had an exercise price of A$ 0.0136 per option; and • Issue of 8,000,000 shares as a result of warrants being exercised that had an exercise price of A$ 0.06 per warrant. (v) During the year ended June 30, 2022, 335,754,000 shares were issued in a US IPO and Nasdaq listing. The IPO and Nasdaq listing were approved by shareholders at the Annual General Meeting held on December 2, 2021. Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the Company in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote and upon a poll each share is entitled to one vote . (b) Share Options When exercised, each option is convertible into one ordinary share. The Bionomics Employee Equity Plan and Bionomics Employee Share Option Plan The terms and conditions of the Bionomics Employee Equity Plan and Bionomics Employee Share Option Plan are summarised in Note 2(g)(iii). Movement in unlisted share options : 2022 2021 2020 Weighted Weighted Weighted Number average Number average Number average of options exercise of options exercise of options exercise price price price Opening balance at beginning of financial year 20,985,450 A$ 0.12 6,364,550 A$ 0.40 7,686,550 A$ 0.41 Granted during the financial year 61,216,767 A$ 0.18 15,500,000 A$ 0.04 - - Forfeited during the financial year - - ( 5,000 ) A$ 0.41 ( 582,500 ) A$ 0.44 Exercised during the financial year ( 2,000,000 ) A$ 0.01 - - - - Expired during the financial year ( 1,145,600 ) A$ 0.42 ( 874,100 ) A$ 0.45 ( 739,500 ) A$ 0.45 Closing balance at June 30 79,056,617 A$ 0.16 20,985,450 A$ 0.12 6,364,550 A$ 0.40 The number of unlisted share options vested and exercisable at June 30, 2022 is 31,065,275 (2021: 20,056,450 ). The weighted average remaining contractual life of any unlisted share options outstanding at the end of the year is 4.93 years (2021: 3.80 years). (i) Unlisted share options issued during the year ended June 30, 2022 On December 2, 2021, shareholders at the Annual General Meeting approved the issuing of 47,786,607 share options to subscribe for 47,786,607 shares at $ 0.2014 per share to Dr Errol De Souza, Executive Chairman. The options were issued on December 22, 2021, details of the issue are set out below: Exercise Fair value at Grant date Vesting date Expiry date price Number date of issue 2-Dec-21 30-Sep-21 30-Sep-26 A$ 0.2014 2,986,663 A$ 0.0740 2-Dec-21 31-Dec-21 31-Dec-26 A$ 0.2014 2,986,663 A$ 0.0760 2-Dec-21 31-Mar-22 31-Mar-27 A$ 0.2014 2,986,663 A$ 0.0780 2-Dec-21 30-Jun-22 30-Jun-27 A$ 0.2014 2,986,663 A$ 0.0790 2-Dec-21 30-Sep-22 30-Sep-27 A$ 0.2014 2,986,663 A$ 0.0810 2-Dec-21 31-Dec-22 31-Dec-27 A$ 0.2014 2,986,663 A$ 0.0820 2-Dec-21 31-Mar-23 31-Mar-28 A$ 0.2014 2,986,663 A$ 0.0840 2-Dec-21 30-Jun-23 30-Jun-28 A$ 0.2014 2,986,663 A$ 0.0850 2-Dec-21 30-Sep-23 30-Sep-28 A$ 0.2014 2,986,663 A$ 0.0860 2-Dec-21 31-Dec-23 31-Dec-28 A$ 0.2014 2,986,663 A$ 0.0880 2-Dec-21 31-Mar-24 31-Mar-24 A$ 0.2014 2,986,663 A$ 0.0890 2-Dec-21 30-Jun-24 30-Jun-24 A$ 0.2014 2,986,663 A$ 0.0900 2-Dec-21 30-Sep-24 30-Jun-24 A$ 0.2014 2,986,663 A$ 0.0910 2-Dec-21 31-Dec-24 31-Dec-29 A$ 0.2014 2,986,663 A$ 0.0920 2-Dec-21 31-Mar-25 31-Mar-30 A$ 0.2014 2,986,663 A$ 0.0930 2-Dec-21 30-Jun-25 30-Jun-30 A$ 0.2014 2,986,662 A$ 0.0940 47,786,607 A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below: Share price at date of issue A$ 0.125 Exercise price A$ 0.2014 Bionomics share volatility 85.53 % Risk free interest rate 0.413 % On December 2, 2021, shareholders at the Annual General Meeting approved the issuing of 13,430,160 share options to subscribe for 13,430,160 shares at A$ 0.09645 per share to Dr Errol De Souza, Executive Chairman. The options were issued on 22 December 2021, details of the issue are set out below: Exercise Fair value at Grant date Vesting date Expiry date price Number date of issue 2-Dec-21 31-Mar-22 31-Mar-27 A$ 0.09645 839,385 A$ 0.0900 2-Dec-21 30-Jun-22 30-Jun-27 A$ 0.09645 839,385 A$ 0.0910 2-Dec-21 30-Sep-22 30-Sep-27 A$ 0.09645 839,385 A$ 0.0920 2-Dec-21 31-Dec-22 31-Dec-27 A$ 0.09645 839,385 A$ 0.0940 2-Dec-21 31-Mar-23 31-Mar-28 A$ 0.09645 839,385 A$ 0.0950 2-Dec-21 30-Jun-23 30-Jun-28 A$ 0.09645 839,385 A$ 0.0960 2-Dec-21 30-Sep-23 30-Sep-28 A$ 0.09645 839,385 A$ 0.0970 2-Dec-21 31-Dec-23 31-Dec-28 A$ 0.09645 839,385 A$ 0.0980 2-Dec-21 31-Mar-24 31-Mar-29 A$ 0.09645 839,385 A$ 0.0980 2-Dec-21 30-Jun-24 30-Jun-29 A$ 0.09645 839,385 A$ 0.0990 2-Dec-21 30-Sep-24 30-Sep-29 A$ 0.09645 839,385 A$ 0.1000 2-Dec-21 31-Dec-24 31-Dec-29 A$ 0.09645 839,385 A$ 0.1010 2-Dec-21 31-Mar-25 31-Mar-30 A$ 0.09645 839,385 A$ 0.1020 2-Dec-21 30-Jun-25 30-Jun-30 A$ 0.09645 839,385 A$ 0.1020 2-Dec-21 30-Sep-25 30-Sep-30 A$ 0.09645 839,385 A$ 0.1030 2-Dec-21 31-Dec-25 31-Dec-30 A$ 0.09645 839,385 A$ 0.1040 13,430,160 A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below Share price at date of issue A$ 0.125 Exercise price A$ 0.0965 Bionomics share volatility 85.53 % Risk free interest rate 0.413 % (ii) Unlisted share options issued during the year ended June 30, 2021 On August 28, 2020, the Company issued 15 million share options to subscribe for 15 million shares at A$ 0.04 per share expiring on August 28, 2025 to key management personnel, details of the issue are set out below: KMP Number Vesting conditions Fair value at Dr Errol De Souza 6,000,000 Company’s share price reaching $0.14 per share A$ 0.075 Dr Errol De Souza 6,000,000 Company’s share price reaching $0.24 per share A$ 0.071 Mr Jack Moschakis 1,000,000 Company’s share price reaching $0.14 per share A$ 0.133 Mr Jack Moschakis 1,000,000 Company’s share price reaching $0.24 per share A$ 0.118 Ms Liz Doolin 500,000 Company’s share price reaching $0.14 per share A$ 0.133 Ms Liz Doolin 500,000 Company’s share price reaching $0.24 per share A$ 0.118 The share options issued to Dr Errol De Souza were approved by shareholders at the general meeting held on August 26, 2020 and the share options issued to Mr Jack Moschakis and Ms Liz Doolin were approved by Directors on 28 August 2020. A Monte Carlo model was used to obtain the fair value of the share options that were issued to Dr Errol De Souza and the share options issued to Mr Jack Moschakis and Ms Liz Doolin that vest when the Company’s share price reach A$ 0.24 . A Black-Scholes model was used to obtain the fair value of the share options issued to Mr Jack Moschakis and Ms Liz Doolin that vest when the Company’s share price reach $ 0.14 , as the share price had reached A$0.14 when these shares options were approved to be issued. Inputs used are summarised below: Dr Errol De Souza Mr Jack Moschakis Share price at date of issue A$ 0.11 A$ 0.15 Exercise price A$ 0.04 A$ 0.04 Bionomics share volatility 105 % 105 % Risk free interest rate 0.42 % 0.43 % On November 20, 2020, the company issued 500,000 share options to subscribe for 500,000 shares at A$ 0.1687 per share to Dr Jane Ryan (non-executive director). The issue of these options was approved by shareholders at the Annual General Meeting held on 20 November 2020, details of the share options issue are set out below: Grant date Vesting date Expiry date Exercise price Number Fair value at date of issue 20-Nov-20 20-Oct-21 20-Oct-26 as at 06/30/20 A$ 0.1687 100,000 A$ 0.089 20-Nov-20 20-Oct-22 20-Oct-27 A$ 0.1687 100,000 A$ 0.095 20-Nov-20 20-Oct-23 20-Oct-28 A$ 0.1687 100,000 A$ 0.099 20-Nov-20 20-Oct-24 20-Oct-29 A$ 0.1687 100,000 A$ 0.103 20-Nov-20 20-Oct-25 20 Oct-30 A$ 0.1687 100,000 A$ 0.107 A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below: Share price at date of issue A$ 0.13 Exercise price A$ 0.1687 Bionomics share volatility 89 % Risk free interest rate 0.30 % As a result of the rights issues that occurred during the year ended June 30, 2021, the exercise price of the above options was recalculated in accordance with the rules of the option plans, and the ASX listing rule 6.22.2. Unlisted share options exercised during the year ended June 30, 2022 On September 2, 2021, 2,000,000 unlisted share options were exercised at A$ 0.0136 per share. The share price at date of exercise was A$ 0.19 . The table below lists share options outstanding at June 30, 2022: Grant date Expiry date Exercise price Number of options Fair value 20-Jul-15 20-Jul-22 A$ 0.4077 15,000 A$ 0.2371 5-Sep-17 5-Sep-22 A$ 0.4136 368,050 A$ 0.2839 9-Oct-15 9-Oct-22 A$ 0.4311 5,000 A$ 0.3216 10-Oct-13 10-Oct-22 A$ 0.5750 15,000 A$ 0.5233 28-Nov-16 28-Nov-22 A$ 0.2349 200,000 A$ 0.2505 28-Nov-16 28-Nov-22 A$ 0.2866 100,000 A$ 0.2377 28-Nov-16 28-Nov-22 A$ 0.3556 5,000 A$ 0.2227 11-Dec-12 11-Dec-22 A$ 0.2912 100,000 A$ 0.2155 17-Dec-13 11-Dec-22 A$ 0.6960 100,000 A$ 0.4318 17-Dec-13 17-Dec-22 A$ 0.6611 4,000 A$ 0.4385 18-Dec-12 18-Dec-22 A$ 0.2912 5,000 A$ 0.2535 24-Dec-15 24-Dec-22 A$ 0.5125 100,000 A$ 0.1658 30-Dec-15 30-Dec-22 A$ 0.4838 50,000 A$ 0.1772 27-Apr-15 27-Apr-23 A$ 0.4765 4,000 A$ 0.2466 1-May-13 1-May-23 A$ 0.3481 64,000 A$ 0.2697 6-May-16 6-May-23 A$ 0.2936 50,000 A$ 0.1961 25-May-15 25-May-23 A$ 0.3982 260,600 A$ 0.2654 20-Jul-15 20-Jul-23 A$ 0.4077 15,000 A$ 0.2513 5-Sep-17 5-Sep-23 A$ 0.4136 10,000 A$ 0.3062 9-Oct-15 9-Oct-23 A$ 0.4311 5,000 A$ 0.3376 10-Oct-13 10-Oct-23 A$ 0.5750 5,000 A$ 0.5415 10-Oct-13 10-Oct-23 A$ 0.5750 10,000 A$ 0.5415 4-Nov-16 4-Nov-23 A$ 0.2327 4,000 A$ 0.2448 28-Nov-16 28-Nov-23 A$ 0.2349 200,000 A$ 0.2621 28-Nov-16 28-Nov-23 A$ 0.2866 200,000 A$ 0.2504 28-Nov-16 28-Nov-23 A$ 0.3556 5,000 A$ 0.2370 17-Dec-13 17-Dec-23 A$ 0.6611 4,000 A$ 0.4573 24-Dec-15 24-Dec-23 A$ 0.5125 100,000 A$ 0.1798 30-Dec-15 30-Dec-23 A$ 0.4838 50,000 A$ 0.1912 2-Dec-21 31-Mar-24 A$ 0.2014 2,986,663 A$ 0.0890 27-Apr-15 27-Apr-24 A$ 0.4765 4,000 A$ 0.2601 6-May-16 6-May-24 A$ 0.2936 50,000 A$ 0.2068 25-May-15 25-May-24 A$ 0.3982 260,600 A$ 0.2780 2-Dec-21 30-Jun-24 A$ 0.2014 2,986,663 A$ 0.0900 2-Dec-21 30-Jun-24 A$ 0.2014 2,986,663 A$ 0.0910 20-Jul-15 20-Jul-24 A$ 0.4077 15,000 A$ 0.2640 5-Sep-17 5-Sep-24 A$ 0.4136 10,000 A$ 0.3236 9-Oct-15 9-Oct-24 A$ 0.4311 5,000 A$ 0.3521 4-Nov-16 4-Nov-24 A$ 0.2327 4,000 A$ 0.2546 28-Nov-16 28-Nov-24 A$ 0.2349 200,000 A$ 0.2721 Grant date Expiry date Exercise price Number of options Fair value 28-Nov-16 28-Nov-24 A$ 0.2866 200,000 A$ 0.2616 28-Nov-16 28-Nov-24 A$ 0.3556 5,000 A$ 0.2495 24-Dec-15 24-Dec-24 A$ 0.5125 100,000 A$ 0.1925 30-Dec-15 30-Dec-24 A$ 0.4838 50,000 A$ 0.2038 27-Apr-15 27-Apr-25 A$ 0.4765 4,000 A$ 0.2722 6-May-16 6-May-25 A$ 0.2936 50,000 A$ 0.2164 25-May-15 25-May-25 A$ 0.3982 260,600 A$ 0.2893 20-Jul-15 20-Jul-25 A$ 0.4077 15,000 A$ 0.2756 28-Aug-20 28-Aug-25 A$ 0.0136 6,000,000 A$ 0.0750 28-Aug-20 28-Aug-25 A$ 0.0136 6,000,000 A$ 0.0710 28-Aug-20 28-Aug-25 A$ 0.0136 500,000 A$ 0.1330 28-Aug-20 28-Aug-25 A$ 0.0136 500,000 A$ 0.1180 5-Sep-17 5-Sep-25 A$ 0.4136 10,000 A$ 0.3388 9-Oct-15 9-Oct-25 A$ 0.4311 5,000 A$ 0.3653 4-Nov-16 4-Nov-25 A$ 0.2327 4,000 A$ 0.2633 28-Nov-16 28-Nov-25 A$ 0.2349 200,000 A$ 0.2810 28-Nov-16 28-Nov-25 A$ 0.2866 200,000 A$ 0.2716 28-Nov-16 28-Nov-25 A4 0.3556 5,000 A$ 0.2605 24-Dec-15 24-Dec-25 A4 0.5125 100,000 A$ 0.2039 30-Dec-15 30-Dec-25 A$ 0.4838 50,000 A$ 0.2152 6-May-16 6-May-26 A$ 0.2936 50,000 A$ 0.2251 5-Sep-17 5-Sep-26 A$ 0.4136 10,000 A$ 0.3520 2-Dec-21 30-Sep-26 A$ 0.2014 2,986,663 A$ 0.0740 20-Nov-20 20-Oct-26 A$ 0.1519 100,000 A$ 0.0890 4-Nov-16 4-Nov-26 A4 0.2327 4,000 A$ 0.2710 28-Nov-16 28-Nov-26 A4 0.2349 200,000 A$ 0.2890 28-Nov-16 28-Nov-26 A$ 0.2866 200,000 A$ 0.2804 28-Nov-16 28-Nov-26 A 40.3556 5,000 A$ 0.2703 2-Dec-21 31-Dec-26 A$ 0.2014 2,986,663 A$ 0.0760 2-Dec-21 31-Mar-27 A4 0.2014 2,986,663 A$ 0.0780 2-Dec-21 31-Mar-27 A$ 0.0965 839,385 A$ 0.0900 2-Dec-21 30-Jun-27 A$ 0.2014 2,986,663 A$ 0.0790 2-Dec-21 30-Jun-27 A$ 0.0965 839,385 A$ 0.0910 5-Sep-17 5-Sep-27 A$ 0.4136 10,000 A$ 0.3636 2-Dec-21 30-Sep-27 A$ 0.2014 2,986,663 A$ 0.0810 2-Dec-21 30-Sep-27 A$ 0.0965 839,385 A$ 0.0920 20-Nov-20 20-Oct-27 A$ 0.1519 100,000 A$ 0.0950 2-Dec-21 31-Dec-27 A$ 0.2014 2,986,663 A$ 0.0820 2-Dec-21 31-Dec-27 A$ 0.0965 839,385 A$ 0.0940 2-Dec-21 31-Mar-28 A$ 0.2014 2,986,663 A$ 0.0840 2-Dec-21 31-Mar-28 A$ 0.0965 839,385 A$ 0.0950 2-Dec-21 30-Jun-28 A$ 0.2014 2,986,663 A$ 0.0850 2-Dec-21 30-Jun-28 A$ 0.0965 839,385 A$ 0.0960 2-Dec-21 30-Sep-28 A$ 0.2014 2,986,663 A$ 0.0860 2-Dec-21 30-Sep-28 A$ 0.0965 839,385 A$ 0.0970 20-Nov-20 20-Oct-28 A$ 0.1519 100,000 A$ 0.0990 2-Dec-21 31-Dec-28 A$ 0.2014 2,986,663 A$ 0.0880 2-Dec-21 31-Dec-28 A$ 0.0965 839,385 A$ 0.0980 2-Dec-21 31-Mar-29 A$ 0.0965 839,385 A$ 0.0980 2-Dec-21 30-Jun-29 A$ 0.0965 839,385 A$ 0.0990 2-Dec-21 30-Sep-29 A$ 0.0965 839,385 A$ 0.1000 20-Nov-20 20-Oct-29 A$ 0.1519 100,000 A$ 0.1030 2-Dec-21 31-Dec-29 A$ 0.2014 2,986,663 A$ 0.0920 Grant date Expiry date Exercise price Number of options Fair value 2-Dec-21 31-Dec-29 A$ 0.0965 839,385 A$ 0.1010 2-Dec-21 31-Mar-30 A$ 0.2014 2,986,663 A$ 0.0930 2-Dec-21 31-Mar-30 A$ 0.0965 839,385 A$ 0.1020 2-Dec-21 30-Jun-30 A$ 0.2014 2,986,662 A$ 0.0940 2-Dec-21 30-Jun-30 A$ 0.0965 839,385 A$ 0.1020 2-Dec-21 30-Sep-30 A$ 0.0965 839,385 A$ 0.1030 20-Nov-20 20-Oct-30 A$ 0.1519 100,000 A$ 0.1070 2-Dec-21 31-Dec-30 A$ 0.0965 839,385 A$ 0.1040 79,056,617 (c) Warrants When exercised, each warrant is convertible into one ordinary share. Movement in unlisted share warrants: 2022 2021 2020 Weighted Weighted Weighted Number average Number average Number average of warrants exercise of warrants exercise of warrants exercise price price price Opening balance at beginning of financial year 166,082,988 A$ 0.11 40,207,472 A$ 0.59 40,207,472 A$ 0.59 Granted during the financial year - - 150,000,000 A$ 0.06 - - Forfeited during the financial year - - - - - - Exercised during the financial year ( 8,000,000 ) A$ 0.06 - - - - Expired during the financial year ( 16,082,988 ) A$ 0.57 ( 24,124,484 ) A$ 0.59 - - Closing balance at June 30 142,000,000 A$ 0.06 166,082,988 A$ 0.11 40,207,472 A$ 0.59 The number of unlisted warrants vested and exercisable at June 30, 2022 is 142,000,000 (2021: 166,082,988 ). The weighted average remaining contractual life of any unlisted warrants outstanding at the June 30, 2022 is 1.16 years (2021: 2.6 years). Unlisted warrants issued during the year ended June 30, 2021 On August 26, 2020, shareholders approved, as consideration for Apeiron underwriting a share issue that would raise at least A$ 15 million, that Apeiron would be issued 150 million warrants to subscribe for shares at A$ 0.06 per share with an expiry date of August 26, 2023 . With the assistance of Apeiron a share placement was made that raised A$ 15,991,634 and the warrants vested on March 3, 2021. As per IFRS 2 'Share Based Payment', the warrants have been valued based on the fair value of the services received (underwriting a share issue) which has been calculated using a risk adjusted estimated fee of 9 % of the amount that was raised. Unlisted warrants exercised during the year ended June 30, 2022 On November 11, 2021, 2,000,000 warrants were exercised at A$ 0.06 per share. The share price at date of exercise was A$ 0.125 . The table below lists warrants outstanding at June 30, 2022. Grant Date Expiry date Exercise Price No of options Fair Value 26-Aug-20 26-Aug-23 A$ 0.06 142,000,000 A$ 0.01

Reserves

Reserves	12 Months Ended
	Jun. 30, 2022
Disclosure of reserves within equity [abstract]
Reserves	NOTE 22 : RESERVES 2022 2021 Foreign Currency Translation Reserve (a) 6,186,334 5,119,200 Share-based Payments Reserve (b) 6,337,264 6,328,691 Total Reserves 12,523,598 11,447,891 (a) Foreign Currency Translation Reserve Exchange differences arising on translation of the foreign controlled entities are taken to the foreign currency translation reserve, as described in Note 2(i). The reserve is recognised in profit or loss when the investment is disposed of. (b) Share-based Payments Reserve The share-based payments reserve is used to recognise the fair value of options and warrants issued over the vesting period or the period of the Consultancy Agreement, as applicable. Further information about share-based payments is set out in Note 21.

Financial Instruments

Financial Instruments	12 Months Ended
	Jun. 30, 2022
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments	NOTE 23 : FINANCIAL INSTRUMENTS (a) Capital Risk Management The Group manages its capital to ensure that entities in the Group will be able to continue as going concerns whilst maximizing the return to stakeholders through the optimisation of the debt and equity balance. During April 2021, the Group repaid in full its bank loan and equipment mortgage. The capital structure of the Group now consists of lease liabilities for rental property (Note 19) cash and cash equivalents (Note 8) and equity attributable to equity holders of the parent, comprising issued capital (Note 21), reserves (Note 22) and retained earnings. The Group’s policy is to fund the research and development activities and operations through the issue of equity and the commercialisation of intellectual property assets. Project specific borrowings are utilized where appropriate and also minor borrowings for operational assets, as required. (b) Categories of Financial Instruments 2022 2021 Financial Assets Cash and cash equivalents 33,564,857 28,499,449 Receivables 6,784,121 1,128,285 Other financial assets 119,000 554,640 40,467,978 30,182,374 Financial Liabilities Trade and other payables 2,786,280 1,814,390 Lease liability – rental property 693,623 867,841 Contingent consideration at fair value 2,699,010 1,762,656 6,178,913 4,444,887 (c) Financial Risk Management Objectives The Board, through the Audit and Risk Management (“ARM”) Committee, is responsible for ensuring there are adequate policies in relation to risk management, compliance and internal control systems. In summary, Group policies are designed to ensure significant strategic, operational, legal, reputational and financial risks are identified, assessed, and effectively monitored and managed in a manner sufficient for a company of Bionomics’ size and stage of development to enable achievement of the Group’s business strategy and objectives. The Group’s risk management policies are managed by the key management personnel and are reviewed by the ARM Committee according to a timetable of assessment and review proposed by that committee and approved by the Board. (d) Market Risk The Group’s activities expose it primarily to the financial risks of changes in foreign currency exchange rates (see (e) below) and interest rates (see (f) below). The Group may use derivative financial instruments to manage its exposure to foreign currency risk, if and when appropriate. The Group has not entered into any interest rate derivatives. The Group measures market risk exposures using sensitivity analysis. There has been no material change to the Group’s exposure to market risks or the manner in which these risks are managed and measured. There were no derivative financial instruments outstanding as at June 30, 2022 (2021: nil ). (e) Foreign Currency Risk Management The Group undertakes certain transactions denominated in foreign currencies; consequently, exposures to exchange rate fluctuations arise. Exchange rate exposures are managed in accordance with established policies. The Group’s exposure to foreign currency risk at the end of the reporting period, expressed in Australian dollars is as follows: 2022 2021 Denominated in USD Monetary items Cash and cash equivalents 17,786,031 624,819 Trade and other payables ( 1,298,425 ) ( 672,353 ) Contingent consideration liability ( 2,699,010 ) ( 1,762,656 ) Total monetary items 13,788,596 ( 1,810,190 ) Non-monetary items Goodwill 5,921,027 5,453,648 Other intangible assets 9,838,274 9,945,755 Deferred tax liability ( 1,798,625 ) ( 1,842,303 ) Total non-monetary items 13,960,676 13,557,100 Total denominated in USD 27,749,272 11,746,910 Foreign Currency Sensitivity Analysis The following table details the Group’s sensitivity to a 10% increase and decrease in the Australian dollar against the US dollar. 10 % is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management’s assessment of the reasonably possible change in foreign currency rates. The sensitivity analysis below includes only outstanding foreign currency denominated monetary items and adjusts their translation at the year-end for a 10% change in foreign currency rates. A positive number below indicates an increase in profit or equity where the Australian dollar strengthens 10% against the relevant currency. For a 10% weakening of the Australian dollar against the relevant currency, there would be a comparable impact on the profit or equity with the balances being the opposite. 2022 2021 2020 Profit or loss (i) 1,796,641 ( 222,678 ) ( 2,181,987 ) Equity (ii) 18,815 3,135 10,403 (i) This is attributable to the exposure to outstanding USD net monetary assets at the end of the reporting period. (ii) This is attributable to the exposure to outstanding USD net monetary assets at the end of the reporting period in the subsidiaries which is denominated in USD and reflected in the foreign currency translation reserve. The Group’s sensitivity to foreign currency has increased as at June 30, 2022 mainly due to an increase in cash and cash equivalents that are denominated in USD as a result of the US IPO. The sensitivity analysis may not represent the quantum of foreign exchange risk because the exposure at the end of the reporting period does not reflect the exposure during the year. Requirements change during the financial year depending on research and development. Forward Foreign Exchange Contracts It is the policy of the Group to enter into forward foreign currency contracts to cover specific foreign currency payments and receipts when appropriate (such as when there is a legal commitment to pay or receive foreign currency or the Executive Chairman or Chief Executive Officer has a high degree of confidence (>90%) that a foreign currency exposure will arise). Under the Group’s Treasury Policy, the Chief Financial Officer will manage the foreign exchange transaction risk adopting the following guidelines: • Generally, hedge foreign exchange exposure identified above by entering into a forward currency contract. • The duration of any forward currency contract(s) will approximate the period in which the net currency exposure arises. • Recognizing the uncertainty that exists in projecting forward foreign currency flows, a maximum net foreign currency exposure position may be held at any point in time. Due to the long-term nature of the net investment in the USD denominated wholly owned subsidiaries, the investments will not be hedged into Australian dollars, with the result that the Australian dollar value of the investments will fluctuate with the market rate through the foreign currency translation reserve. There were no forward foreign currency contracts outstanding as at June 30, 2022 (2021: nil ). (f) Interest Rate Risk Management The US bank loan had a variable interest rate with a floor. At June 30, 2020 the effective interest rate was 10.78 % and this effective interest rate did not change during the year ended June 30, 2021 (the US borrowing was repaid in full during April 2021). The Group’s other borrowing are at fixed interest rates. The Group does not use interest rate swap contracts or forward interest rate contracts. The Group is exposed to interest rate risk only in relation to the cash and cash equivalent balances, as the interest rate floor on the US borrowing is above the LIBOR rate. Interest Rate Sensitivity Analysis The Group has no borrowings, other than lease liability (rental property) which is at a fixed interest rate. (g) Credit Risk Management Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Group. The Group has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, as a means of mitigating the risk of financial loss from defaults. The credit risk on liquid funds is limited because the counterparties are banks with high credit ratings assigned by international credit rating agencies. The carrying amount of financial assets recorded in the financial statements, net of any allowances for losses, represents the Group’s maximum exposure to credit risk. (h) Liquidity Risk Management Ultimate responsibility for liquidity risk management rests with the Board, which has approved an appropriate liquidity risk management framework for management of the Group’s short-, medium- and long-term funding. The Group manages liquidity risk by continuously monitoring forecast and actual cash flows and matching maturity profiles of financial assets and liabilities. (i) Liquidity and Interest Rate Risk The following tables detail the Group’s remaining contractual maturity for its financial liabilities with agreed repayment terms. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Group can be required to pay. To the extent that interest flows are at a variable rate, the undiscounted amount is derived from interest rate applicable at the end of the reporting period. The tables include both interest and principal cash flows. 2022 Weighted Less than 1 – 3 3 – 12 1 to 5 5 + Total Trade and other payables - 2,786,280 - - - - 2,786,280 Lease liability – rental property (fixed interest rate) 3.56 15,069 45,206 121,043 563,262 - 744,580 2,801,349 45,206 121,043 563,262 - 3,530,860 2021 Weighted Less than 1 – 3 3 – 12 1 to 5 5 + Total Trade and other payables - 1,814,390 - - - - 1,814,390 Lease liability – rental property (fixed interest rate) 3.56 40,141 43,764 117,184 744,579 - 945,668 1,854,531 43,764 117,184 744,579 - 2,760,058 (j) Fair Value of Financial Instruments The Group has no financial assets that are measured at fair value and the only financial liability that is measured at fair value at the end of each reporting period is contingent consideration (Note 31). The value of financial assets and other financial liabilities approximate their fair value. The following table gives information about how the fair value of the financial liability is determined. Financial Liabilities Fair value as at 30 June Fair value as at 30 June Fair value Valuation Significant Relationship Contingent consideration in a business combination (Note 31) 2,699,010 1,762,656 Level 3 Discounted cash flow Discount rate of 25% (pre-tax) and probability adjusted revenue projections. The higher the discount rate, the lower the value. The higher the possible revenue the higher value. Reconciliation of Level 3 fair value measurements 2022 2021 Contingent Contingent Opening balance 1,762,656 4,975,159 - in profit or loss 936,354 ( 3,212,503 ) Closing balance 2,699,010 1,762,656

Key Management Personnel Compen

Key Management Personnel Compensation	12 Months Ended
	Jun. 30, 2022
Key Management Personnel Compensation [Abstract]
Key Management Personnel Compensation	NOTE 24 : KEY MANAGEMENT PERSONNEL COMPENSATION The aggregate compensation made to Directors and other members of key management personnel of the Group is set out below: 2022 2021 2020 Short-term employee benefits 2,535,560 2,269,030 1,527,499 Post-employment benefits 69,039 51,982 52,106 Other long-term benefits 22,241 9,480 16,434 Share-based payments 2,819,133 1,298,208 68,518 Total key management personnel compensation 5,445,973 3,628,700 1,664,557

Commitments For Expenditure

Commitments For Expenditure	12 Months Ended
	Jun. 30, 2022
Commitments For Expenditure [Abstract]
Commitments For Expenditure	NOTE 25 : COMMITMENTS FOR EXPENDITURE (a) Operating Leases Operating leases related to photocopier with lease term of 4 years (2021: 5 years ). The following table gives information about this lease commitment, which are not included in the lease liability due to the application of the practical expedients to exclude low value leases from lease liabilities. 2022 2021 Non-cancellable Operating Lease Commitments Within one year 5,064 5,064 Later than one year but not greater than five 13,504 19,412 Later than five years - - Minimum lease payments 18,568 24,476 (b) Rental Agreements The Group previously sub-lets areas of its facility, which expired on July 12, 2021 . Rent received from these agreements was treated according to the accounting policy outlined in Note 2(s)(iii). The following table gives information about future rental income. 2022 2021 Within one year - 6,549 Later than one year but not greater than five - - - 6,549

Remuneration of Auditors

Remuneration of Auditors	12 Months Ended
	Jun. 30, 2022
Auditor's remuneration [abstract]
Remuneration of Auditors	NOTE 26 : REMUNERATION OF AUDITORS 2022 2021 2020 Audit or Review of Financial Reports - Group 969,726 86,500 110,000 - French subsidiaries - - 74,972 Other Assurance Services Agreed upon procedures in relation to French subsidiaries cash statement and debt statement as at February 28, 2020 - - 27,109 969,726 86,500 212,081 The auditor of Bionomics Limited is Ernst & Young (2020: Deloitte Touche Tohmatsu) .

Cash Flow Information

Cash Flow Information	12 Months Ended
	Jun. 30, 2022
Statement of cash flows [abstract]
Cash Flow Information	NOTE 27 : CASH FLOW INFORMATION (a) Cash and Cash Equivalents For the purposes of the consolidated statement of cash flows, cash and cash equivalents include cash on hand and in banks, net of outstanding bank overdrafts. Cash and cash equivalents at the end of the reporting period as shown in the consolidated statement of cash flows can be reconciled to the related items in the consolidated statement of financial position as follows: 2022 2021 2020 Cash and cash equivalents 33,564,857 28,499,449 4,577,747 (b) Reconciliation of Operating Loss to Net Cash Outflow from Operating Activities 2022 2021 2020 (Loss) for the year ( 21,759,358 ) ( 8,697,037 ) ( 7,118,288 ) Items in loss Depreciation and amortisation 1,109,412 1,700,878 2,443,386 Share-based payments 2,829,689 1,308,349 55,355 Loss/(Gain) on asset disposals 1,827 21,010 ( 173,934 ) Contingent consideration – change in fair value 936,354 ( 3,212,503 ) ( 4,823,874 ) Amortisation of transaction costs - 252,019 29,649 Net gain arising on modification of borrowings measured at amortised costs that were not derecognized - - 544,357 Accrual of final borrowing payment - 528,819 ( 199,089 ) Net foreign exchange differences 738,423 ( 1,067,746 ) 558,645 Loss on disposal of French operations - - 802,502 Interest received ( 9,869 ) ( 5,756 ) ( 58,369 ) Changes in Operating Assets and Liabilities (Increase)/Decrease) in receivables ( 39,148 ) 34,078 ( 202,257 ) (Increase)/Decrease in research and development incentive receivable ( 5,791,688 ) 1,991,468 4,145,659 (Increase)/Decrease in other assets ( 600,285 ) ( 85,648 ) 348,768 (Increase) in inventory - - ( 28,291 ) Increase/(Decrease) in payables 979,902 ( 63,305 ) 127,451 Increase/(Decrease) in provisions 41,062 ( 55,923 ) ( 85,407 ) (Decrease) in other liabilities - - ( 20,876 ) (Decrease) in deferred tax liability ( 191,808 ) ( 187,427 ) ( 248,580 ) Net cash outflows from operating activities ( 21,755,487 ) ( 7,538,724 ) ( 3,903,193 )

Loss Per Share

Loss Per Share	12 Months Ended
	Jun. 30, 2022
Earnings per share [abstract]
Loss Per Share	NOTE 28 : LOSS PER SHARE 2022 2021 2020 From continuing and discontinuing operations Basic loss per share (A$ 0.02 ) (A$ 0.01 ) (A$ 0.01 ) Diluted loss per share (A$ 0.02 (A$ 0.01 (A$ 0.01 The basic and diluted loss per share amounts have been calculated using the ‘Loss after income tax’ figure in the consolidated statement of profit or and other comprehensive income. 2022 2021 2021 Loss Per Share (Basic and Diluted): Loss after tax for the year from continuing and discontinuing operations ( 21,759,358 ) ( 8,697,037 ) ( 7,118,288 ) Loss after tax for the year from continuing operations ( 21,759,358 ) ( 8,697,037 ) ( 5,818,975 ) 2022 2021 2010 Weighted Average Number of Ordinary Shares - Basic Weighted average number of ordinary shares used in calculating basic loss per share: 1,353,350,744 779,941,036 544,871,870 Weighted Average Number of Ordinary Shares – Diluted Weighted average number of ordinary shares used in calculating basic loss per share: 1,353,350,744 779,941,036 544,871,870 Shares deemed to be issued for no consideration in respect of employee options 31,065,272 20,056,450 5,296,550 Potential ordinary shares which are anti-dilutive and excluded ( 31,065,272 ) ( 20,056,450 ) ( 5,296,550 ) Shares deemed to be issued for no consideration in respect of warrants 142,000,000 166,082,988 40,207,472 Potential ordinary shares which are anti-dilutive and excluded ( 142,000,000 ) ( 166,082,988 ) ( 40,207,472 ) Weighted average number of ordinary shares used in the calculation of diluted loss per share 1,353,350,744 779,941,036 544,871,870 The following potential ordinary shares are anti-dilutive and are therefore excluded from the weighted average number of ordinary shares for the purposes of diluted loss per share. 2022 2021 2020 Employee options 31,065,272 20,056,450 5,296,550 Warrants 142,000,000 166,082,988 40,207,472

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2022
Related party transactions [abstract]
Related Party Transactions	NOTE 29 : RELATED PARTY TRANSACTIONS (a) Parent Entity The immediate parent and ultimate controlling party of the Group is Bionomics Limited. Interests in subsidiaries are set out in Note 12. (b) Key Management Personnel Disclosures relating to compensation of key management personnel are set out in Note 24 and the Directors’ Report. (c) Loans to Directors and Other Key Management Personnel There were no loans to any Directors of the Company or other key management personnel of the Group during the financial year ended 30 June 30, 2022 (2021: Nil ). (d) Shares Issued to Apeiron Investment Group Limited (“Apeiron”) and Apeiron Presight Capital Fund II LP (“Presight”), (Director related entities). During the year ended June 30, 2022, 7,287,480 shares were issued to Apeiron, and 109,311,660 shares were issued to Presight at $ 0.09645 per share as a result of the US IPO (2021: 54,333,000 shares at $ 0.04 per share issued to Apeiron as a result of share placements and 26,222,424 shares issued to Apeiron at $ 0.145 per share as a result of the Rights Issue that occurred). (e) Shares Issued to BVF Partners (a Director related entity) ("BVF") During the year ended June 30, 2022, 14,574,780 shares at A$ 0.09645 per share were issued to BVF as a result of the US IPO (2021: 10,864,351 shares at A$ 0.04 per share and 36,115,866 shares at A$ 0.145 per share as a result of the rights issue that occurred). (f) Shares Issued to Directors No shares were issued to Directors during the year ended June 30, 2022. During the year ended June 30, 2021 shares were issued to the following Directors as a result of the rights issue that occurred: • 15,949 shares at A$ 0.04 per share to Mr Peter Turner; and • 15,949 shares at A$ 0.04 per share and 35,990 shares at $ 0.145 per share to Mr David Wilson. (g) Shares Issued to Other Key Management Personnel On August 28, 2020, 314,246 fully paid shares were issued to Mr Jack Moschakis and 109,986 fully paid shares were issued to Ms Liz Doolin as part of their bonus for the year ended June 30, 2020, based on the average 5-day VWAP for the period to August 28, 2020. (h) Share Options Issued to Directors and Other Key Management Personnel During the year ended June 30, 2022 share options were issued to Dr Errol De Souza, details about these share options are set out in Note 21(b) (i) to the Financial Statements.(2021: share options were issued to Dr Errol De Souza, Dr Jane Ryan, Mr Jack Moschakis and Ms Liz Doolin, details about these share options are set out in Note 21(b) (ii) to the Financial Statements). (i) Warrants Issued to Apeiron (a director related entity) On August 26, 2020, shareholders approved, as consideration for Apeiron underwriting a share issue that would raise at least A$ 15 million, that Apeiron would be issued 150 million warrants to subscribe for shares at A$ 0.06 per share with an expiry date of 23 August 2023, details about these warrants are set out in Note 21(c) to the Financial Statements. (j) Memorandum of Understanding (“MOU”) with EmpathBio Inc (“EmpathBio”) On February 17, 2021, the Company entered into a MOU with EmpathBio Inc, a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences NV (“atai’), what is a related party of Apeiron (a director related entity), when the MOU was signed. Under the MOU, the Company and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics’ BNC210 and EmpathBio's 3,4-Methylenedioxymethamphetamine (MDMA) derivative EMP-01. The parties will explore whether the different mechanisms of action of EMP-01 and BNC210 may offer the potential for developing an improved treatment regimen for the treatment of PTSD.

Contingent Consideration

Contingent Consideration	12 Months Ended
	Jun. 30, 2022
Contingent consideration [abstract]
Contingent Consideration	NOTE 30 : CONTINGENT CONSIDERATION During the year ended June 30, 2013, the Company acquired Eclipse Therapeutics, Inc (Eclipse) into its wholly owned subsidiary, Bionomics Inc. Part of the consideration are potential cash earn-outs to Eclipse security holders based on achieving late-stage development success or partnering outcomes of the Eclipse asset that was acquired. This liability is recorded at fair value; see Note 23(j), for information about the calculation of the fair value. Due to changes in the projected inputs, being the timing and quantum of expected cash outflow, which are in USD dollars, the liability increased by A$ 936,354 at June 30, 2022 (decreased by A$ 3,212,503 at June 30, 2021). Inputs used are based on the anticipated amounts and timing of potential milestone and royalty payments from licensing agreement with Carina Biotech Pty Ltd (Carina). International financial reporting standards required that in a “business combination” (the Company acquiring Eclipse) any contingent consideration liability at acquisition date needs to be recorded at the fair value and subsequent changes in the fair value is recognized in profit or loss, but any contingent assets at acquisition date are not allowed to be recorded. The Company has a contingent asset (the expected payments to be received from Carina) at June 30, 2022 which is greater than the contingent consideration liability. 2022 2021 Opening balance 1,762,656 4,975,159 Change in fair value 936,354 ( 3,212,503 ) Closing balance 2,699,010 1,762,656

Contingent Liabilities

Contingent Liabilities	12 Months Ended
	Jun. 30, 2022
Disclosure of contingent liabilities [abstract]
Contingent Liabilities	NOTE 31 : CONTINGENT LIABILITIES • In January 2012, the Company entered into a research and license agreement with Ironwood Pharmaceuticals, Inc., or Ironwood, pursuant to which Ironwood was granted worldwide development and commercialization rights for BNC210. In November 2014, the parties mutually agreed to terminate this license agreement, reverting all rights to BNC210 back to the Company. The sole obligation to Ironwood is to pay Ironwood low single digit royalties on the net sales of BNC210, if commercialized. It is not practicable to estimate the future payments of any such royalties that may arise due to the stage of development of BNC210. • The Group has provided a restricted cash deposit of A$ 119,000 (2021: A$ 554,640 ) as security for an unconditional irrevocable bank guarantee as a rent guarantee of $ 119,000 (2021: A$ 554,640 ) to the landlord of the Company’s leased office premises. • The Group has a consultancy agreement with Dr Errol De Souza who is paid US$ 43,750 per month (plus reimbursement of health care benefits of up to US$ 22,000 per year), plus a short-term incentive/bonus potential of 60% of fixed remuneration as assessed by the independent non-Executive directors against agreed financial, strategic and operational targets, for performance exceeding such applicable performance criteria the annual bonus may be increased up to 100% of Base Salary. • The Group has a contingent liability in relation to this consultancy agreement, where the arrangement is terminated by the Company without cause, redundancy or resignation for good reason, in that the Company will: o pay severance of twelve months of Base Salary plus a pro rata amount of the target bonus potential to be paid in equal instalments over the following 12-month period, and o any outstanding equity compensation awards will fully and immediately vest with respect to any amounts that would have vested as if remaining employed for an additional 24 months. • Any termination benefits in excess of the limits in the Corporations Act are subject to shareholder approval.

Events Occurring After Reportin

Events Occurring After Reporting Date	12 Months Ended
	Jun. 30, 2022
Disclosure of non-adjusting events after reporting period [abstract]
Events Occurring After Reporting Date	NOTE 32 : EVENTS OCCURRING AFTER REPORTING DATE On July 15, 2022, the Company issued 7,700,000 share options to subscribe for 7,700,000 shares at $ 0.0543 per share, under the Employee Equity Plan that was approved by shareholders at the Annual General Meeting held on December 2, 2021, including 7,500,000 share options that were issued to key management personnel (KMP). 25 % of the Options vest at the end of 12 months following the Offer Date (July 8, 2022), and 75 % vest in 12 substantially equal instalments ( 6.25 %) on the last day of each calendar quarter over the 4-year period following the end of the initial 12 months following the Offer Date. The share options expire on the date that is 5 years following each vesting date. Details of share options that were issued to the KMPs are set out below: KMP Number Mr Adrian Hinton 2,000,000 Mr Connor Bernstein 3,500,000 Ms Liz Doolin 2,000,000 On August 5, 2022, the Company received A$ 2,085,453 research and development tax incentive refund relating to the financial year ended June 2021, which as at June 30, 2022 is included as part of the Research and Development Incentives Receivable, in the Consolidated Statement of Financial Position. There are no other matters or circumstances that have arisen since the end of the financial year which significantly affect or may significantly affect the results of the operations of the Group.

Impact of Covid-19

Impact of Covid-19	12 Months Ended
	Jun. 30, 2022
Disclosure of impact of covid nineteen [abstract]
Impact of Covid-19	NOTE 33: IMPACT OF COVID-19 The Board and Management have considered the impact of COVID-19 on the Company’s operations and financial performance. Overall, operations for the year ended June 30, 2022 have not been materially affected by the COVID-19 pandemic. The clinical trials for PTSD and SAD started in US during July 2021 and January 2022, respectively and to date have not been materially affected by the COVID-19 pandemic except for postponing screening and enrolment of potential participants into the trial. However, there may be disruptions caused by COVID-19 pandemic that may result in increased costs and delays in completing the PTSD and SAD clinical trials. The Company is working closely with its clinical partners and has taken the necessary steps to allow for adjustments in the clinical trials protocol should they be required due to restrictions that may be imposed during the COVID-19 pandemic. The Company cannot predict the scope and severity of any further disruptions as a result of COVID-19 or its impact on the business. Unforeseen disruptions to the business or any of the third parties we use, including the collaborators, contract organisations, manufacturers, suppliers, clinical trial sites, and regulators could materially and negatively impact our ability to conduct business in the manner and on the timelines presently planned. The extent to which COVID-19 pandemic may continue to impact the business and financial performance will depend on future developments, which are highly uncertain and cannot be predicted with confidence. Currently, the Company is unable to determine the extent of the impact of the pandemic on the clinical trials, operations and financial performance going forward. These developments are highly uncertain and unpredictable and may materially adversely affect the Company’s future operating results and financial position.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Jun. 30, 2022
Disclosure of analysis of single amount of discontinued operations [abstract]
Discontinued Operations	NOTE 34: DISCONTINUED OPERATIONS On March 3, 2020, the Company sold its two wholly owned French subsidiaries, Neurofit SAS and PC SAS, which carried out all the Group’s contract service business. The sale price of Euro 1,790,029 is the amount of intercompany debt owed by the Company to the subsidiaries for scientific research conducted by them on the Company’s drug candidates and this debt was assumed by the purchaser upon acquisition of the two companies. Costs incurred by the Company in relation to this transaction were A$ 207,143 . The disposal of the contract service operations is consistent with the Group’s long-term policy to focus its activities on the clinical trial of BNC210 for the treatment of PTSD. (a) Analysis Assets and Liabilities Over Which Control Was Lost Year ended A$ Current assets Cash and cash equivalents 800,849 Trade and other receivables 1,047,259 Research and development incentives receivable 770,054 Inventories 692,832 Other assets 85,115 Non-current assets Property, plant and equipment 2,006,977 Right-to-use asset – rented property 1,424,365 Other intangible assets 574 Current liabilities Trade and other payables ( 2,312,900 ) Lease liability – rented property ( 161,723 ) Provisions ( 446,148 ) Other liabilities ( 204,860 ) Non-current liabilities Other payables ( 816,663 ) Lease liability – rented property ( 1,278,599 ) Deferred tax liabilities ( 514,962 ) Net assets disposed of 1,092,170 (b) Loss on Disposal of Subsidiary 2020 A$ Net assets disposed of ( 1,092,170 ) Costs relating to the disposal incurred by the Company ( 207,143 ) Loss on disposal ( 1,299,313 ) (c) Net Cash Outflow on Disposal of Subsidiaries 2020 A$ Cash and cash equivalent balances disposed of ( 800,849 ) Costs relating to the disposal incurred by the Company ( 207,143 ) Net cash outflow ( 1,007,992 ) (d) Analysis of (Loss)/Profit for the Year from Discontinued Operations The combined results of the discontinued operation (contract service business) included in the loss for the year ended June 30, 2020 are set out below. 2020 A$ Revenue 3,422,584 Other income 391,505 3,814,089 Expenses ( 4,242,502 ) Loss before income tax benefit ( 428,413 ) Income tax benefit 40,968 ( 387,445 ) Loss on disposal of operations including a cumulative gain of A$ 496,811 recycled from foreign currency translation reserve to profit and loss ( 911,868 ) Attributable income tax expenses - ( 911,868 ) Loss from discontinued operations ( 1,299,313 ) (e) Analysis of Cash Flows from Discontinued Operations The cash flows from discontinued operations for the year ended June 30, 2020 are set out below: Cash flows for the year from discontinued operations 2020 A$ Inflows from operating activities 470,767 Outflows from investing activities ( 7,704 ) Outflows from financing activities ( 100,489 ) Net cash flow 362,574

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Summary Of Significant Accounting Policies [Abstract]
Basis of Consolidation	(a) Basis of Consolidation The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company: • has power over the investee; • is exposed, or has rights, to variable returns from its involvement with the investee, and • has the ability to use its power to affect its returns. Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Company gains control until the date when the Company ceases to control the subsidiary. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.
Borrowings	(b) Borrowings Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in profit or loss over the period of the borrowings using the effective interest method. Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.
Borrowing Costs	(c) Borrowing Costs All borrowing costs (other than transaction costs) are recognised in profit or loss in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.
Business Combinations	(d) Business Combinations Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value which is calculated as the sum of the acquisition-date fair values of assets transferred by the Group, liabilities incurred by the Group to the former owners of the acquiree and the equity instruments issued by the Group in exchange for control of the acquiree. Acquisition-related costs are recognised in profit or loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed are recognised at their fair value, except that: • Deferred tax assets or liabilities, and assets or liabilities related to employee benefit arrangements, are recognised and measured in accordance with IAS 12 ‘Income Taxes’ and IAS 19 ‘Employee Benefits’, respectively; • Liabilities or equity instruments related to share-based payment arrangements of the acquiree, or share-based payment arrangements of the Group entered into to replace share-based payment arrangements of the acquiree are measured in accordance with IFRS 2 ‘Share-based Payment’ at the acquisition date, and • Assets (or disposal groups) that are classified as held for sale in accordance with IFRS 5 ‘Non-current Assets Held for Sale and Discontinued Operations’ are measured in accordance with that Standard. Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. If, after reassessment, the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognised immediately in profit or loss as a gain on bargain purchase. Where the consideration transferred by the Group in a business combination includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the ‘measurement period’ (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date. The subsequent accounting for changes in the fair value of contingent consideration that do not qualify as measurement period adjustments depends on how the contingent consideration is classified. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration is recognised at fair value, classified as a liability which is remeasured at subsequent reporting dates in accordance with IFRS 9 and IAS 137 ‘Provisions, Contingent Liabilities and Contingent Assets’ respectively, as appropriate, with the corresponding gain or loss being recognised in profit or loss. If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period (see above), or additional assets or liabilities are recognised, to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the amounts recognised as of that date.
Cash and Cash Equivalents	(e) Cash and Cash Equivalents Cash and cash equivalents include cash on hand, deposits held at call with financial institutions, other short term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities on the consolidated statement of financial position.
Earnings/(Loss) per Share	(f) Earnings/(Loss) per Share • Basic Earnings/(Loss) per Share Basic earnings/(loss) per share is calculated by dividing the profit/(loss) after income tax attributable to equity holders of the Company, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the year, adjusted for bonus elements in ordinary shares issued during the year. • Diluted Earnings/(Loss) per Share Diluted earnings/(loss) per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to options.
Employee Benefits	(g) Employee Benefits • Short-term and Long-term Employee Benefits A liability is recognised for benefits accruing to employees in respect of wages and salaries, annual leave and long service leave when it is probable that settlement will be required, and they are capable of being measured reliably. Liabilities recognised in respect of short-term employee benefits, are measured at their nominal values using the remuneration rate expected to apply at the time of settlement. Liabilities recognised in respect of long-term employee benefits are measured as the present value of the estimated future cash outflows to be made by the Group in respect of services provided by employees up to reporting date, discounted using rates applicable to high quality corporate bonds. • Superannuation Retirement benefits are contributions made to employee superannuation funds and are charged as expenses when incurred. These contributions are made to external superannuation funds and are not defined benefits programs. • Share-based Payments Share-based compensation benefits have been provided to employees via the Bionomics Employee Equity Plan (“EEP”), with the exception of share options issued to the Executive Chairman which were approved by shareholders at the Annual General Meeting held on December 2, 2021. The fair value of shares issued to employees for no cash consideration under the EEP and share options issued to the Executive Chairman are recognised as an employee benefits expense with a corresponding increase in equity. The fair value is measured at grant date and recognised on a straight-line basis over the vesting period based on the Group’s estimate of equity instruments that will eventually vest or over the period of the Consultancy Agreement, as applicable. The disclosure in Note 21 relates to the EEP and the former Employee Share Option Plan (“ESOP”). The Bionomics EEP was approved by the Board and shareholders in 2017. Staff eligible to participate in the plan are those who have been a full-time or part-time employee of the Group for a period of not less than six months or a Director of the Group. Options are granted under the plan for no consideration and vest equally over five years , or when vesting conditions are achieved, unless they are bonus options which vest immediately. The amounts disclosed as remuneration relating to options are the assessed fair values at grant date of those options allocated equally over the period from grant date to vesting date. See Note 21 for details on how the fair value of options and warrants issued during the year are calculated.
Financial Assets	(h) Financial Assets All regular way purchases or sales of financial assets are recognised and derecognized on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace. All recognised financial assets are measured subsequently in their entirety at either amortised cost or fair value, depending on the classification of the financial assets. Classification of Financial Assets at amortised costs • The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flow, and • The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payment of principal and interest on the principal amount outstanding. Debt instruments that meet the following conditions are measured subsequently at fair value through other comprehensive income (“FVTOCI”): • The financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling the financial assets, and • The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. By default, all other financial assets are measured subsequently at fair value through profit or loss (“FVTPL”). Despite the foregoing, the Group may make the following irrevocable election/designation at initial recognition of a financial asset: • The Group may irrevocably elect to present subsequent changes in fair value of an equity investment in other comprehensive income if certain criteria are met (see (ii) below); and • The Group may irrevocably designate a debt investment that meets the amortised cost or FVTOCI criteria as measured at FVTPL if doing so eliminates or significantly reduces an accounting mismatch (see (ii) below). (i) Amortised Cost and Effective Interest Method The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocation interest income over the relevant period. For financial assets other than purchased or originated credit-impaired financial assets (i.e. assets that are credit-impaired on initial recognition), the effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) excluding expected credit losses, through the expected life of the debt instrument, or, where appropriate, a shorter period, to the gross carrying amount of the debt instrument on initial recognition. For purchased or originated credit-impaired financial assets, a credit-adjusted effective interest rate is calculated by discounting the estimated future cash flows, including expected credit losses, to the amortised cost of the debt instrument on initial recognition. The amortised cost of a financial asset is the amount at which the financial asset is measured at initial recognition minus the principal repayments, plus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, adjusted for any loss allowance. The gross carrying amount of a financial asset is the amortised cost of a financial asset before adjusting for any loss allowance. Interest income is recognised using the effective interest method for debt instruments measured subsequently at amortised cost and at FVTOCI. For financial assets other than purchased or originated credit-impaired financial assets, interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset, except for financial assets that have subsequently become credit-impaired, (see below). For financial assets that have subsequently become credit-impaired, interest income is recognised by applying the effective interest rate to the amortised cost of the financial asset. If, in subsequent reporting periods, the credit risk on the credit-impaired financial instrument improves so that the financial asset is no longer credit-impaired, interest income is recognised by applying the effective interest rate to the gross carrying amount of the financial asset. For purchased or originated credit-impaired financial assets, the Group recognizes interest income by applying the credit-adjusted effective interest rate to the amortised cost of the financial asset from initial recognition. The calculation does not revert to the gross basis even if the credit risk of the financial asset subsequently improves so that the financial asset is no longer credit-impaired. Interest income is recognised in profit or loss and is included in the “other Scholes model was used to obtain income” line item. (ii) Financial Assets at FVTPL Financial assets that do not meet the criteria for being measured at amortised cost or FVTOCI are measured at FVTPL. Specifically: • Investments in equity instruments are classified as at FVTPL, unless the Group designates an equity investment that is neither held for trading nor a contingent consideration arising from a business combination as at FVTOCI on initial recognition. • Debt instruments that do not meet the amortised cost criteria or the FVTOCI criteria are classified as at FVTPL. In addition, debt instruments that meet either the amortised cost criteria or the FVTOCI criteria may be designated as at FVTPL upon initial recognition if such designation eliminates or significantly reduces a measurement or recognition inconsistency (so called ‘accounting mismatch’) that would arise from measuring assets or liabilities or recognizing the gains and losses on them on different bases. The Group has not designated any debt instructions as at FVTPL. Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any fair values gains or losses recognised in profit or loss to the extent they are not part of a designated hedging relationship (see hedge accounting policy). The net gain or loss recognised in profit or loss includes any dividend or interest earned on the financial asset and is included in the ‘other gains and losses’ line item. (iii) Impairment of Financial Assets The Group recognizes a loss allowance for expected credit losses (“ECL”) on investments in debt instruments that are measured at amortised cost or a FVTOCI, lease receivables, trade receivables and contract assets, as well as on financial guaranteed contracts. The amount of expected credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument. The Group always recognizes lifetime ECL for trade receivables, contract assets and lease receivables. The expected credit losses on these financial assets are estimated using a provision matrix based on the Group’s historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate. For all other financial instruments, the Group recognizes lifetime ECL when there has been a significant increase in credit risk since initial recognition. However, if the credit risk on the financial instrument has not increased significantly since initial recognition, the Group measures the loss allowance for that financial instrument at an amount equal to 12-month ECL. Lifetime ECL represents the expected credit losses that will result from all possible default events over the expected life of a financial instrument. In contrast, 12-month ECL represents the portion of lifetime ECL that is expected to result from default events on a financial instrument that are possible within 12 months after the reporting date.
Foreign Currencies	(i) Foreign Currencies The individual financial statements of each group entity are presented in the currency of the primary economic environment in which the entity operates (its functional currency). For the purpose of the consolidated financial statements, the results and financial position of each group entity are expressed in Australian dollars (“$”), which is the functional currency of the Company and the presentation currency for the consolidated financial statements. In preparing the financial statements of each individual group entity, transactions in currencies other than the entity’s functional currency (foreign currencies) are recognised at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences on monetary items are recognised in profit or loss in the period in which they arise except for exchange differences on monetary items receivable from or payable to a foreign operation for which settlement is neither planned nor likely to occur (therefore forming part of the net investment in the net investment in the foreign operation), which are recognised initially in other comprehensive income and reclassified from equity to profit or loss on repayment of the monetary items. For the purpose of presenting these consolidated financial statements, the assets and liabilities of the Group’s foreign operations are translated into Australian dollars using exchange rates prevailing at the end of the reporting period. Income and expense items are translated at the average exchange rates for the period. Exchange differences arising, if any, are recognised in other comprehensive income and accumulated in equity. Goodwill and fair value adjustments to identifiable assets acquired and liabilities assumed through acquisition of a foreign operation are treated as assets and liabilities of the foreign operation and translated at the rate of exchange prevailing at the end of each reporting period. Exchange differences arising are recognised in other comprehensive income and accumulated in equity.
Goods and Services Tax ("GST")	(j) Goods and Services Tax (“GST”) Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognised as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated statement of financial position. Cash flows are presented on a gross basis. The GST component of cash flow arising from investing or financing activities which are recoverable from, or payable to the taxation authority, are presented as operating cash flow.
Government Research and Development Incentives	(k) Government Research and Development Incentives Government grants, including Research and Development incentives, are recognised at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to cost reimbursements are recognised as other income in profit or loss in the period when the costs were incurred or when the incentive meets the recognition requirements (if later).
Impairment of Tangible and Intangible Assets Other than Goodwill	(l) Impairment of Tangible and Intangible Assets Other than Goodwill At the end of each reporting period, the Group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). When it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash generating unit (“CGU”) to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual CGUs, or otherwise they are allocated to the smallest group of CGUs for which a reasonable and consistent allocation basis can be identified. A CGU is the smallest identifiable group of assets that generates cash flow that is largely independent of cash flows from other assets or group of assets. The Company's CGU (drug development) is defined as a research programme that has the potential to be commercialized at some point in the future. Achievement of certain milestones within the current central nervous system research programme will determine when a new CGU comes into existence. Intangible assets with indefinite useful lives are tested for impairment at least annually, and whenever there is an indication that the asset may be impaired. Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease. Where an impairment loss subsequently reverses, the carrying amount of the asset (or CGU) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or CGU) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
Income Tax	(m) Income Tax Income tax expense represents the sum of the tax currently payable and deferred tax. Current Tax The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit before tax as reported in the consolidated statement of profit or loss and other comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group’s current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred Tax Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. In addition, deferred tax liabilities are not recognised if the temporary difference arises from the initial recognition of goodwill. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities. Deferred tax liabilities and assets are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis. Current and Deferred Tax for the Year Current and deferred tax are recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case the current and deferred tax are also recognised in other comprehensive income or directly in equity, respectively. Where current tax or deferred tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination. Tax Consolidation Legislation Bionomics and its wholly owned Australian controlled entities have implemented the tax consolidation legislation effective 31 December 2005. The head entity, Bionomics Limited, and the controlled entities in the tax consolidated group account for their own current and deferred tax amounts. These tax amounts are measured as if each entity in the tax consolidated group continues to be a stand-alone taxpayer in its own right. In addition to its own current and deferred tax amounts, Bionomics Limited also recognizes the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from controlled entities in the tax consolidated group. Assets or liabilities arising under tax funding agreements with the tax consolidated entities are recognised as amounts receivable from or payable to other entities in the Group. Any difference between the amounts assumed and amounts receivable or payable under the tax funding agreement are recognised as a contribution to (or distribution from) wholly-owned tax consolidated entities.
Intangible Assets	(n) Intangible Assets (i) Intellectual Property Acquired intellectual property is recognised as an asset at cost and amortised over its useful life. There is currently no internally generated intellectual property that has been capitalised. Intellectual property with a finite life is amortised on a straight-line basis over that life. Intellectual property with an indefinite useful life is subjected to an annual impairment review. There is currently no intellectual property with an indefinite life. 15 to 20 years. (ii) Goodwill Goodwill arising on an acquisition of a business is carried at cost as established at the date of the acquisition of the business (see Note 2(d) above) less accumulated impairment losses, if any. On disposal of the relevant CGU, the attributable amount of goodwill is included in the determination of the profit or loss on disposal. (iii) Intangible Assets Acquired in a Business Combination Intangible assets acquired in a business combination and recognised separately from goodwill are initially recognised at their fair value at the acquisition date (which is regarded as their cost).
Issued Capital	(o) Issued Capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options, or for the acquisition of a business, are deducted directly from equity.
Leases	(p) Leases The Group assesses whether a contract is or contains a lease, at inception of the contract. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group as Lessee The Group assesses whether a contract is or contains a lease, at inception of the contract. The Group recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets (such as tablets and personal computers, small items of office furniture and telephones). For these leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the lessee entity uses its incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise: • Fixed lease payments (including in-substance fixed payments), less any lease incentives receivable; • Variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date; • The amount expected to be payable by the lessee under residual value guarantees; • The exercise price of purchase options, if the lessee is reasonably certain to exercise the options, and • Payments of penalties for terminating the lease if the lease term reflects the exercise of an option to terminate the lease. The lease liability is presented as a separate line in the consolidated statement of financial position. The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever: • The lease term has changed or there is a significant event or change in circumstances resulting in a change in the assessment of exercise of a purchase option, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate. • The lease payments change due to changes in an index or rate or a change in expected payment under a guaranteed residual value, in which cases the lease liability is remeasured by discounting the revised lease payments using an unchanged discount rate (unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used). • A lease contract is modified, and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification. The Group did not make any such adjustments during the periods presented. The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses. Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. Current useful life of right-to-use assets is 5 years. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Group expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The depreciation starts at the commencement date of the lease. The right-of-use assets are presented as a separate line in the consolidated statement of financial position. The Group applies IAS 36 to determine whether a right-of-use asset is impaired and accounts for any identified impairment loss as described in Note 2(l) above. Group as Lessor Leases in which the Group does not transfer substantially all the risks and rewards incidental to ownership of an asset are classified as operating leases. Rental income arising is accounted for on a straight-line basis over the lease term and is included in revenue in the statement of profit or loss due to its operating nature. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised over the lease term on the same basis as rental income. Contingent rents are recognised as revenue in the period in which they are earned.
Property, Plant and Equipment	(q) Property, Plant and Equipment Plant and equipment are stated at cost less accumulated depreciation or accumulated impairment losses, where applicable. Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives, using the diminishing value or straight-line methods, depending on the type of asset. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period. The depreciation rates for plant and equipment are 20 – 40 %. An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in profit or loss.
Research and Development	(r) Research and Development Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognised as an expense when it is incurred. Expenditures on development activities are capitalised only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably. Development costs have a finite life and are amortised on a systematic basis matched to the future economic benefits over the useful life of the project. At year end there are currently no capitalised development costs.
Revenue Recognition	(s) Revenue Recognition (i) License revenues in connection with licensing of the Group's intellectual property (including patents) to collaborators are recognised as a right to use the entity's intellectual property as it exists at the point in time at which the license is granted. This is because the contracts for the license of intellectual property are distinct and do not require, nor does the customer reasonably expect, that the Group will undertake further activities that significantly affect the intellectual property to which the collaborator has rights. (ii) Although the Group is entitled to sales-based royalties from any eventual sales of goods and services to third parties using the intellectual property transferred, these royalty arrangements do not of themselves indicate that the collaborator would reasonably expect the Group to undertake such activities, and no such activities are undertaken or contracted in practice. Accordingly, the promise to provide rights to the Group's intellectual property is accounted for as a performance obligation satisfied at a point in time. The following consideration is received in exchange for licenses of intellectual property: (a) Up-front payments - These are fixed amounts and are recognised at the point in time when the Group transfers the intellectual property to the collaborator. (b) Milestone payments - These are variable considerations that depends upon the collaborator reaching certain milestones in relation to the intellectual property licensed. Such amounts are only recognised when it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur when the uncertainty associated with the variable consideration (that is, the collaborator meeting the conditions to trigger payment) is subsequently resolved. (c) Sales-based royalties - These are variable consideration amounts promised in exchange for the license of intellectual property that occur late in the collaborator's development of the intellectual property and are recognised when the sales to third parties occur (as the performance obligation to transfer the intellectual property to the collaborator is already satisfied). (iii) The Group, until March 3, 2020 when its French subsidiaries were sold, performed contracted research and development. For the year ended June 30, 2020 this revenue was disclosed under discontinued operations (see Note 36 for additional information). For this contracted research and development work, the customer controlled all the work in progress as the work was being carried out, as the work is called out to the customer’s specification and if a contract was terminated by the customer, then the Group was entitled to reimbursement of the costs incurred to date, including a reasonable margin. Invoices were issued according to contractual terms and invoiced amounts are presented as other receivables. Any amounts received from customers prior to the performance obligations being completed were recorded as unearned income and held on the balance sheet, until the relevant performance obligations had been completed in line with the policies above. The Group had no contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the Group did not adjust any of the transaction prices for the time value of money (iv) Rental income is recognised on a straight-line basis over the term of the lease (refer to note 2(p) “Group as lessor” for further comments).

Revenue, Other Income and Oth_2

Revenue, Other Income and Other Gains and Losses (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Revenue Other Income And Other Gains And Losses [Abstract]
Summary of Revenue from Continuing Operations	2022 2021 2020 Revenue from Continuing Operations Licenses 263,634 - 46,662 263,634 - 46,662 Other Income from Continuing Operations Interest income 9,869 5,756 58,369 Rent 6,674 203,014 200,284 Government Research and Development Incentives (i) 5,791,688 928,073 2,945,600 Government assistance COVID-19 (Cash flow boost) - 50,000 50,000 Government assistance COVID-19 (Jobkeeper) - 121,500 58,500 5,808,231 1,308,343 3,312,753 (i) The Government Research and Development Incentives include cash refunds provided by the Australian Government for 43.5 % (2021: 43.5 %, 2020: 43.5 %) of eligible research and development expenditures by Australian entities having a tax loss and less than A$ 20 million in revenue. The grants are calculated at the end of the fiscal year to which they relate, based on the expenses incurred in and included in the fiscal year's Australian income tax return after registration of the research and development activities with the relevant authorities. There are no unfulfilled conditions or other contingencies attaching to the Government Research and Development Incentive.
Summary of Other gains and losses from Continuing Operations	2022 2021 2020 Other gains and losses from Continuing Operations Net (loss)/gain arising on changes in fair value of contingent consideration (Note 30) ( 936,354 ) 3,212,503 4,823,874 Net gain arising on modification of borrowings measured at amortised costs that were not derecognized (Note 18) - - 199,089 Net realised and unrealised foreign currency gains 356,166 1,081,438 ( 621,016 ) (Loss) on disposal of plant and equipment ( 1,827 ) ( 21,010 ) 173,934 ( 582,015 ) 4,272,931 4,575,881

Expenses Relating to Continui_2

Expenses Relating to Continuing Operations (Tables)	12 Months Ended
	Jun. 30, 2022
Expenses by nature [abstract]
Schedule of Expenses Related to Continuing Operations	2022 2021 2020 Loss before income tax benefit includes the following specific expenses: Finance expenses - Interest expense on bank and other loans - 618,586 1,170,027 - Interest expense on lease liabilities 26,872 26,934 79,938 - Amortisation of transaction costs (Note18) - 252,019 29,649 - Accrual of final payment (Note 18) - 528,819 544,357 - Bank fees 17,293 17,527 22,496 44,165 1,443,885 1,846,467 Employment benefit expenses of: - Wages and salaries 2,901,689 2,577,954 3,097,949 - Superannuation 266,127 148,662 213,769 - Share-based payments 2,829,689 1,308,349 55,355 5,997,505 4,034,965 3,367,073 Amortisation of non-current assets - Plant and equipment (Note 13) 2,681 45,553 91,860 - Right-of-use assets (rental property) (Note 14) 193,358 762,813 748,571 - Intellectual property (Note 16) 913,373 892,512 1,328,244 1,109,412 1,700,878 2,168,675 Rental expense on operating leases (low value assets) - Minimum lease payments 5,260 7,277 7,506

Income Taxes Relating to Cont_2

Income Taxes Relating to Continuing Operations (Tables)	12 Months Ended
	Jun. 30, 2022
Major components of tax expense (income) [abstract]
Summary of Income Tax Recognised in Profit or Loss	2022 2021 2020 (a) Income Tax Recognised in Profit or Loss Current tax In respect of the current year - - - In respect of the prior year - - - - - - Deferred tax Recognised in current year ( 191,808 ) ( 187,427 ) ( 207,612 ) ( 191,808 ) ( 187,427 ) ( 207,612 ) Total income tax benefit ( 191,808 ) ( 187,427 ) ( 207,612 )
Summary of Reconciliation to Accounting Loss and Net Deferred Tax Liability Recognised	(b) Reconciliation to Accounting Loss 2022 2021 2020 Loss from continuing operations ( 21,951,166 ) ( 8,884,464 ) ( 6,026,587 ) Tax at the Australian tax rate of 25 % (2021 & 2020: 30 %) ( 5,487,792 ) ( 2,665,339 ) ( 1,807,976 ) Tax effect of non-deductible / non-assessable amounts Exempt income from government assistance ( 1,447,922 ) ( 293,422 ) ( 898,680 ) Entertainment expenses 1,231 727 1,355 Net gain arising on changes in fair value of contingent consideration 234,089 ( 963,751 ) ( 1,447,162 ) Share-based payments 707,422 392,505 16,607 Research and development expenditure 3,328,556 640,050 2,013,477 Amortisation of share issue costs ( 285,631 ) - - Temporary differences not recorded as an asset ( 58,374 ) ( 632,779 ) ( 68,181 ) Tax losses not recorded 2,779,547 3,253,265 1,981,695 Effect of different tax rates in other jurisdictions 37,066 81,317 1,253 ( 191,808 ) ( 187,427 ) ( 207,612 ) 2022 2021 (c) Net Deferred Tax Liability Recognised Net deferred tax liability is attributable to the following deferred tax asset/(liability) items: Intangibles denominated in USD ( 2,066,037 ) ( 2,088,608 ) Tax losses denominated in USD 267,412 246,305 ( 1,798,625 ) ( 1,842,303 ) Movement in Net Deferred Tax Liability Opening balance ( 1,842,303 ) ( 2,203,340 ) Recognized in income - Continuing operations 191,808 187,427 - Discontinuing operations - - Recognized in equity ( 148,130 ) 173,610 Derecognized on disposal of subsidiaries (Note 35) - - Closing balance ( 1,798,625 ) ( 1,842,303 )
Summary of Net Deferred Tax Asset Not Recognised	(d) Net Deferred Tax Asset Not Recognised Revenue tax losses 25,439,594 27,181,188 Net temporary difference 3,460,261 2,851,336 28,899,855 30,032,524

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Jun. 30, 2022
Cash and cash equivalents [abstract]
Disclosure of Detailed Information About Cash and Cash Equivalents	Cash at the end of the financial year as shown in the statements of cash flows is reconciled to items in the Consolidated Statement of Financial Position as follows: 2022 2021 Current Cash at bank and on hand 33,564,857 28,499,449 33,564,857 28,499,449

Other Financial Assets (Tables)

Other Financial Assets (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure of financial assets [abstract]
Schedule of Other Financial Assets	2022 2021 Restricted deposits held as security and not available for use 119,000 554,640 Disclosed in the financial statement as: Current assets - 435,640 Non-current assets 119,000 119,000 119,000 554,640

Trade and Other Receivables (Ta

Trade and Other Receivables (Tables)	12 Months Ended
	Jun. 30, 2022
Trade and other receivables [abstract]
Summary of Trade and Other Receivables	2022 2021 Current Other receivables 42,483 192,885 Loss allowance - - 42,483 192,885 GST receivables 21,877 7,327 64,360 200,212

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
	Jun. 30, 2022
Miscellaneous current assets [abstract]
Summary of Detailed Information About Other Current Assets	2022 2021 Current Prepayments 1,461,078 860,793 Accrued income 190 2,837 1,461,268 863,630

Subsidiaries (Tables)

Subsidiaries (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure of subsidiaries [abstract]
Summary of Group Subsidiaries	Details of the Group’s subsidiaries at the end of the reporting period are as follows: Percentage owned Entity Principal activity Country of incorporation 2022 2021 Head Entity Bionomics Limited Research and Development Australia Subsidiaries of Bionomics Limited Iliad Chemicals Pty Ltd Asset owner Australia 100 100 Bionomics Inc Asset owner United States 100 100

Property, Plant And Equipment (

Property, Plant And Equipment (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of Detailed Information about Property Plant and Equipment	Plant Total Cost at Jult 1, 2020 1,373,704 1,373,704 Additions 1,468 1,468 Disposals ( 1,268,419 ) ( 1,268,419 ) Cost at June 30, 2021 106,753 106,753 Additions 1,544 1,544 Disposals ( 36,262 ) ( 36,262 ) Cost at June 30, 2022 72,035 72,035 Accumulated depreciation at July 1, 2020 ( 1,089,748 ) ( 1,089,748 ) Depreciation (a) ( 45,553 ) ( 45,553 ) Disposals 1,036,775 1,036,775 Accumulated depreciation at June 30, 2021 ( 98,526 ) ( 98,526 ) Depreciation (a) ( 2,681 ) ( 2,681 ) Disposals 34,344 34,344 Accumulated depreciation at June 30, 2022 ( 66,863 ) ( 66,863 ) Net Carrying Amounts at June 30, 2021 8,227 8,227 Net Carrying Amounts at June 30, 2022 5,172 5,172 a) Depreciation is disclosed in the Consolidated Statement of Profit or Loss and Other Comprehensive Income as follows 2022 2021 2020 Continuing operations 2,681 45,553 91,860 Discontinued operations - - 113,009 2,681 45,553 204,869

Right-of-Use Assets (Tables)

Right-of-Use Assets (Tables) - Right-of-use assets [member]	12 Months Ended
	Jun. 30, 2022
Disclosure of quantitative information about right-of-use assets [line items]
Summary of Right-of-Use Assets	2022 2021 Cost 854,500 2,374,100 Accumulated depreciation ( 185,142 ) ( 1,511,384 ) 669,358 862,716 Opening balance July 1 862,716 771,029 Addition of new property being rented - 854,500 Depreciation (a) ( 193,358 ) ( 762,813 ) Closing balance June 30 669,358 862,716
Summary of Depreciation Disclosed in Consolidated Statement of Profit or Loss and Other Comprehensive Income	a) Depreciation is disclosed in the Consolidated Statement of Profit or Loss and Other Comprehensive Income as follows 2022 2021 2020 Continuing operations 193,358 762,813 748,571 Discontinued operations - - 116,075 193,358 762,813 864,646

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure of reconciliation of changes in goodwill [abstract]
Schedule of Changes in Goodwill	A$ Carrying amount at July 1, 2020 12,872,387 Additions - Foreign currency exchange differences ( 471,644 ) Carrying amount at June 30, 2021 12,400,743 Additions - Foreign currency exchange differences 467,379 Carrying amount at June 30, 2022 12,868,122

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure of detailed information about intangible assets [abstract]
Summary of Carrying Amounts of Each Class of Other Intangible Assets	KV1.3 VDA MultiCore Cancer stem Total A$ A$ A$ A$ A$ Gross carrying amount at July 1, 2020 1,546,542 2,282,527 1,265,590 19,210,485 24,305,144 Additions - - - - - Foreign currency exchange differences - - - ( 1,529,124 ) ( 1,529,124 ) Gross carrying amount at June 30, 2021 1,546,542 2,282,527 1,265,590 17,681,361 22,776,020 Additions - - - - - Foreign currency exchange differences - - - 1,515,296 1,515,296 Gross carrying amount at June 30, 2022 1,546,542 2,282,527 1,265,590 19,196,657 24,291,316 Accumulated amortisation amount at July 1, 2020 ( 1,546,542 ) ( 2,282,527 ) ( 1,265,590 ) ( 7,444,073 ) ( 12,538,732 ) Amortisation (a) - - - ( 892,512 ) ( 892,512 ) Foreign currency exchange differences - - - 600,979 600,979 Accumulated amortisation amount at June 30, 2021 ( 1,546,542 ) ( 2,282,527 ) ( 1,265,590 ) ( 7,735,606 ) ( 12,830,265 ) Amortisation (a) - - - ( 913,373 ) ( 913,373 ) Foreign currency exchange differences - - - ( 709,404 ) ( 709,404 ) Accumulated amortisation amount at June 30, 2022 ( 1,546,542 ) ( 2,282,527 ) ( 1,265,590 ) ( 9,358,383 ) ( 14,453,042 ) Net carrying amount June 30, 2021 - - - 9,945,755 9,945,755 Net carrying amount June 30, 2022 - - - 9,838,274 9,838,274 a) Depreciation is disclosed in the Consolidated Statement of Profit or Loss and Other Comprehensive Income as follows: 2022 2021 2020 Continuing operations 913,373 892,512 1,328,244 Discontinued operations - - 45,627 913,373 892,512 1,373,871

Trade and Other Payables (Table

Trade and Other Payables (Tables)	12 Months Ended
	Jun. 30, 2022
Trade and other payables [abstract]
Disclosure of Trade and Other Payables	2022 2021 Current Trade payables 1,556,881 1,028,744 Accrued expenses 1,229,399 785,646 2,786,280 1,814,390

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure of detailed information about borrowings [abstract]
Summary of Borrowings	2022 2021 Current liabilities - - Non-current liabilities - - - -
Summary of Loan Movement Schedule	During April 2021 the equipment mortgage loans and the bank loan (which was denominated in US dollars) were fully repaid. 2022 2021 Loan Movement Schedule Opening Balance – July 1 - 11,444,129 Accrual of bank loan final payment (i) - 528,819 Repayments - principal - ( 9,170,741 ) - final payment (i) - ( 1,916,398 ) Net gain arising on modification of bank loan (due to extension of loan) that was not derecognized (ii) - - Transaction costs associated with obtaining interest only period (iii) - - Amortisation of costs (iii) - 252,019 Foreign currency exchange differences - ( 1,137,828 ) Closing Balance – June 30 - - (i) In addition to the payment of principal and interest over the term of the bank loan, a final payment was required under the bank loan, calculated at a percentage of the original principal borrowed. This liability was being accrued (using the effective interest method) over the term of the loan and the amount accrued prior to the loan being fully repaid was US$ 1,477,500 (July 1, 2020 was US$ 1,079,030 ). (ii) As a result of the bank loan being extended to January 1, 2022 (that occurred during the year ended June 30, 2020) the accrual of the bank loan final payment was remeasured resulting in a reduction in the liability that had been accrued as the modification to the loan did not qualify for derecognition of the loan . (iii) The transaction costs related to costs incurred in obtaining the six-month interest only period and extension of the bank loan. These costs were being amortized over the remaining term of the bank loan.

Lease Liabilities (Tables)

Lease Liabilities (Tables)	12 Months Ended
	Jun. 30, 2022
Lease liabilities [abstract]
Schedule of Lease Liabilities Secured at Amortised Costs	2022 2021 2020 Secured – at amortised costs Loan Movement Schedule Opening Balance – July 1 867,841 793,148 - Adoption of new leasing accounting standard - - 2,993,675 New lease for new property - being rented - 854,500 - Repayments ( 174,218 ) ( 779,807 ) ( 826,942 ) Derecognized on disposal of subsidiaries (Note 34) - - ( 1,440,322 ) Effect of foreign currency exchange differences - - 66,737 Closing Balance – June 30 693,623 867,841 793,148 Disclosed in the financial statements as: Current liabilities 160,040 174,218 767,711 Non-current liabilities 533,583 693,623 25,437 693,623 867,841 793,148
Schedule of Total Group Cash Outflows for Leases	The total Group cash outflows for leases is set out below: 2022 2021 2020 Principal element of lease payments 174,218 779,807 826,942 Interest element of lease payments - continuing operations 26,872 26,934 79,938 Interest element of lease payments - discontinuing operations - - 33,176 Total cash outflows for leases 201,090 806,741 940,056
Schedule of Undiscounted Potential Future Rental Payments	Set out below are the undiscounted potential future rental payments relating to periods following the exercise date of extension options that are not included in the lease term: Within five years More than five years Total As at June 30, 2022 Extension options expected not to be exercised - 1,183,105 1,183,105 As at June 30, 2021 Extension options expected not to be exercised - 1,183,105 1,183,105

Provisions (Tables)

Provisions (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure Of Provision Abstract
Summary of Detailed Information About Provisions	2022 2021 Current Employee benefits 409,320 371,936 Non-Current Employee benefits 10,460 6,782

Issued Capital (Tables)

Issued Capital (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure of classes of share capital [abstract]
Summary of Movements in Ordinary Shares	Movements in Ordinary Shares of the Company during the current period were as follows: Date Details Number of shares A$ Ordinary Shares July 1, 2019 Opening balance 544,647,747 144,944,233 Share issue - share placement 81,500,000 3,260,000 Transfer from treasury stock 38,125 - Share issue costs - ( 48,228 ) June 30, 2020 Closing balance 626,185,872 148,156,005 Share issue - share placements (i) 185,757,511 21,229,874 Share issue – rights (ii) 195,229,129 22,606,257 Shares issued to employees 424,232 60,750 Share issue costs - ( 423,492 ) Warrants issued -underwriting fee (iii) - ( 1,439,247 ) June 30, 2021 Closing balance 1,007,596,744 190,190,147 Shares issued on exercise of options (iv) 2,000,000 27,200 Shares issued on exercise of warrants (iv) 8,000,000 480,000 Transfer from share-based payments reserve as result of options and warrants being exercised - 327,760 Share issue in a US IPO and NASDAQ listing (v) 335,754,000 32,383,263 Share issue costs - ( 5,712,611 ) June 30, 2022 Closing balance 1,353,350,744 217,695,759 Treasury Stock July 1, 2019 Closing balance 38,125 - Share issue – Employee Share Plan Loan Agreements ( 38,125 ) - June 30, 2020 Closing balance - - Share issue – Employee Share Plan Loan Agreements - - June 30, 2021 Closing balance - - Share issue – Employee Share Plan Loan Agreements - - June 30, 2022 Closing balance - - Total Issued Capital 1,353,350,744 217,695,759 (i) During the year ended June 30, 2021, the following share placements occurred: • Issue of 54,333,000 shares at A$ 0.04 per share raising A$ 2,173,320 . The share issue was approved by shareholders at a General Meeting held on August 26, 2020; and • Issue of 131,424,511 shares at A$ 0.145 per share raising A$ 19,056,554 (ii) During the year ended June 30. 2021, the following rights issues occurred: • Issue of 54,304,446 at A$ 0.04 per share raising A$ 2,172,178 ; and • Issue of 140,924,683 shares at A$ 0.145 raising A$ 20,434,079 (iii) Shareholders at the General Meeting held on August 26, 2020 approved the issue of 150,000,000 warrants to Apeiron Investment Group Ltd (“Apeiron”) to subscribe for shares at A$ 0.06 per share as consideration of underwriting a share issue that would raise at least A$ 15,000,000 . The warrants vested on 3 March 2021 when with the assistance of Apeiron a share placement was made that raised A$ 15,991,634 . (iv) During the year ended June 30, 2022, the following shares were issued: • Issue of 2,000,000 as a result of share options being exercised that had an exercise price of A$ 0.0136 per option; and • Issue of 8,000,000 shares as a result of warrants being exercised that had an exercise price of A$ 0.06 per warrant. (v) During the year ended June 30, 2022, 335,754,000 shares were issued in a US IPO and Nasdaq listing. The IPO and Nasdaq listing were approved by shareholders at the Annual General Meeting held on December 2, 2021.
Summary of Movement in Unlisted Share Options	Movement in unlisted share options : 2022 2021 2020 Weighted Weighted Weighted Number average Number average Number average of options exercise of options exercise of options exercise price price price Opening balance at beginning of financial year 20,985,450 A$ 0.12 6,364,550 A$ 0.40 7,686,550 A$ 0.41 Granted during the financial year 61,216,767 A$ 0.18 15,500,000 A$ 0.04 - - Forfeited during the financial year - - ( 5,000 ) A$ 0.41 ( 582,500 ) A$ 0.44 Exercised during the financial year ( 2,000,000 ) A$ 0.01 - - - - Expired during the financial year ( 1,145,600 ) A$ 0.42 ( 874,100 ) A$ 0.45 ( 739,500 ) A$ 0.45 Closing balance at June 30 79,056,617 A$ 0.16 20,985,450 A$ 0.12 6,364,550 A$ 0.40
Summary of Options Issued	The options were issued on December 22, 2021, details of the issue are set out below: Exercise Fair value at Grant date Vesting date Expiry date price Number date of issue 2-Dec-21 30-Sep-21 30-Sep-26 A$ 0.2014 2,986,663 A$ 0.0740 2-Dec-21 31-Dec-21 31-Dec-26 A$ 0.2014 2,986,663 A$ 0.0760 2-Dec-21 31-Mar-22 31-Mar-27 A$ 0.2014 2,986,663 A$ 0.0780 2-Dec-21 30-Jun-22 30-Jun-27 A$ 0.2014 2,986,663 A$ 0.0790 2-Dec-21 30-Sep-22 30-Sep-27 A$ 0.2014 2,986,663 A$ 0.0810 2-Dec-21 31-Dec-22 31-Dec-27 A$ 0.2014 2,986,663 A$ 0.0820 2-Dec-21 31-Mar-23 31-Mar-28 A$ 0.2014 2,986,663 A$ 0.0840 2-Dec-21 30-Jun-23 30-Jun-28 A$ 0.2014 2,986,663 A$ 0.0850 2-Dec-21 30-Sep-23 30-Sep-28 A$ 0.2014 2,986,663 A$ 0.0860 2-Dec-21 31-Dec-23 31-Dec-28 A$ 0.2014 2,986,663 A$ 0.0880 2-Dec-21 31-Mar-24 31-Mar-24 A$ 0.2014 2,986,663 A$ 0.0890 2-Dec-21 30-Jun-24 30-Jun-24 A$ 0.2014 2,986,663 A$ 0.0900 2-Dec-21 30-Sep-24 30-Jun-24 A$ 0.2014 2,986,663 A$ 0.0910 2-Dec-21 31-Dec-24 31-Dec-29 A$ 0.2014 2,986,663 A$ 0.0920 2-Dec-21 31-Mar-25 31-Mar-30 A$ 0.2014 2,986,663 A$ 0.0930 2-Dec-21 30-Jun-25 30-Jun-30 A$ 0.2014 2,986,662 A$ 0.0940 47,786,607 The options were issued on 22 December 2021, details of the issue are set out below: Exercise Fair value at Grant date Vesting date Expiry date price Number date of issue 2-Dec-21 31-Mar-22 31-Mar-27 A$ 0.09645 839,385 A$ 0.0900 2-Dec-21 30-Jun-22 30-Jun-27 A$ 0.09645 839,385 A$ 0.0910 2-Dec-21 30-Sep-22 30-Sep-27 A$ 0.09645 839,385 A$ 0.0920 2-Dec-21 31-Dec-22 31-Dec-27 A$ 0.09645 839,385 A$ 0.0940 2-Dec-21 31-Mar-23 31-Mar-28 A$ 0.09645 839,385 A$ 0.0950 2-Dec-21 30-Jun-23 30-Jun-28 A$ 0.09645 839,385 A$ 0.0960 2-Dec-21 30-Sep-23 30-Sep-28 A$ 0.09645 839,385 A$ 0.0970 2-Dec-21 31-Dec-23 31-Dec-28 A$ 0.09645 839,385 A$ 0.0980 2-Dec-21 31-Mar-24 31-Mar-29 A$ 0.09645 839,385 A$ 0.0980 2-Dec-21 30-Jun-24 30-Jun-29 A$ 0.09645 839,385 A$ 0.0990 2-Dec-21 30-Sep-24 30-Sep-29 A$ 0.09645 839,385 A$ 0.1000 2-Dec-21 31-Dec-24 31-Dec-29 A$ 0.09645 839,385 A$ 0.1010 2-Dec-21 31-Mar-25 31-Mar-30 A$ 0.09645 839,385 A$ 0.1020 2-Dec-21 30-Jun-25 30-Jun-30 A$ 0.09645 839,385 A$ 0.1020 2-Dec-21 30-Sep-25 30-Sep-30 A$ 0.09645 839,385 A$ 0.1030 2-Dec-21 31-Dec-25 31-Dec-30 A$ 0.09645 839,385 A$ 0.1040 13,430,160 Grant date Vesting date Expiry date Exercise price Number Fair value at date of issue 20-Nov-20 20-Oct-21 20-Oct-26 as at 06/30/20 A$ 0.1687 100,000 A$ 0.089 20-Nov-20 20-Oct-22 20-Oct-27 A$ 0.1687 100,000 A$ 0.095 20-Nov-20 20-Oct-23 20-Oct-28 A$ 0.1687 100,000 A$ 0.099 20-Nov-20 20-Oct-24 20-Oct-29 A$ 0.1687 100,000 A$ 0.103 20-Nov-20 20-Oct-25 20 Oct-30 A$ 0.1687 100,000 A$ 0.107
Summary of Inputs Used	A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below: Share price at date of issue A$ 0.125 Exercise price A$ 0.2014 Bionomics share volatility 85.53 % Risk free interest rate 0.413 % A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below Share price at date of issue A$ 0.125 Exercise price A$ 0.0965 Bionomics share volatility 85.53 % Risk free interest rate 0.413 %
Unlisted Share Options Issued	On August 28, 2020, the Company issued 15 million share options to subscribe for 15 million shares at A$ 0.04 per share expiring on August 28, 2025 to key management personnel, details of the issue are set out below: KMP Number Vesting conditions Fair value at Dr Errol De Souza 6,000,000 Company’s share price reaching $0.14 per share A$ 0.075 Dr Errol De Souza 6,000,000 Company’s share price reaching $0.24 per share A$ 0.071 Mr Jack Moschakis 1,000,000 Company’s share price reaching $0.14 per share A$ 0.133 Mr Jack Moschakis 1,000,000 Company’s share price reaching $0.24 per share A$ 0.118 Ms Liz Doolin 500,000 Company’s share price reaching $0.14 per share A$ 0.133 Ms Liz Doolin 500,000 Company’s share price reaching $0.24 per share A$ 0.118
Summery of Inputs Used to a Black-Scholes Model Used to Obtain Fair Value of Above Share Options	Dr Errol De Souza Mr Jack Moschakis Share price at date of issue A$ 0.11 A$ 0.15 Exercise price A$ 0.04 A$ 0.04 Bionomics share volatility 105 % 105 % Risk free interest rate 0.42 % 0.43 % Share price at date of issue A$ 0.13 Exercise price A$ 0.1687 Bionomics share volatility 89 % Risk free interest rate 0.30 %
Summery of Share Options Outstanding	The table below lists share options outstanding at June 30, 2022: Grant date Expiry date Exercise price Number of options Fair value 20-Jul-15 20-Jul-22 A$ 0.4077 15,000 A$ 0.2371 5-Sep-17 5-Sep-22 A$ 0.4136 368,050 A$ 0.2839 9-Oct-15 9-Oct-22 A$ 0.4311 5,000 A$ 0.3216 10-Oct-13 10-Oct-22 A$ 0.5750 15,000 A$ 0.5233 28-Nov-16 28-Nov-22 A$ 0.2349 200,000 A$ 0.2505 28-Nov-16 28-Nov-22 A$ 0.2866 100,000 A$ 0.2377 28-Nov-16 28-Nov-22 A$ 0.3556 5,000 A$ 0.2227 11-Dec-12 11-Dec-22 A$ 0.2912 100,000 A$ 0.2155 17-Dec-13 11-Dec-22 A$ 0.6960 100,000 A$ 0.4318 17-Dec-13 17-Dec-22 A$ 0.6611 4,000 A$ 0.4385 18-Dec-12 18-Dec-22 A$ 0.2912 5,000 A$ 0.2535 24-Dec-15 24-Dec-22 A$ 0.5125 100,000 A$ 0.1658 30-Dec-15 30-Dec-22 A$ 0.4838 50,000 A$ 0.1772 27-Apr-15 27-Apr-23 A$ 0.4765 4,000 A$ 0.2466 1-May-13 1-May-23 A$ 0.3481 64,000 A$ 0.2697 6-May-16 6-May-23 A$ 0.2936 50,000 A$ 0.1961 25-May-15 25-May-23 A$ 0.3982 260,600 A$ 0.2654 20-Jul-15 20-Jul-23 A$ 0.4077 15,000 A$ 0.2513 5-Sep-17 5-Sep-23 A$ 0.4136 10,000 A$ 0.3062 9-Oct-15 9-Oct-23 A$ 0.4311 5,000 A$ 0.3376 10-Oct-13 10-Oct-23 A$ 0.5750 5,000 A$ 0.5415 10-Oct-13 10-Oct-23 A$ 0.5750 10,000 A$ 0.5415 4-Nov-16 4-Nov-23 A$ 0.2327 4,000 A$ 0.2448 28-Nov-16 28-Nov-23 A$ 0.2349 200,000 A$ 0.2621 28-Nov-16 28-Nov-23 A$ 0.2866 200,000 A$ 0.2504 28-Nov-16 28-Nov-23 A$ 0.3556 5,000 A$ 0.2370 17-Dec-13 17-Dec-23 A$ 0.6611 4,000 A$ 0.4573 24-Dec-15 24-Dec-23 A$ 0.5125 100,000 A$ 0.1798 30-Dec-15 30-Dec-23 A$ 0.4838 50,000 A$ 0.1912 2-Dec-21 31-Mar-24 A$ 0.2014 2,986,663 A$ 0.0890 27-Apr-15 27-Apr-24 A$ 0.4765 4,000 A$ 0.2601 6-May-16 6-May-24 A$ 0.2936 50,000 A$ 0.2068 25-May-15 25-May-24 A$ 0.3982 260,600 A$ 0.2780 2-Dec-21 30-Jun-24 A$ 0.2014 2,986,663 A$ 0.0900 2-Dec-21 30-Jun-24 A$ 0.2014 2,986,663 A$ 0.0910 20-Jul-15 20-Jul-24 A$ 0.4077 15,000 A$ 0.2640 5-Sep-17 5-Sep-24 A$ 0.4136 10,000 A$ 0.3236 9-Oct-15 9-Oct-24 A$ 0.4311 5,000 A$ 0.3521 4-Nov-16 4-Nov-24 A$ 0.2327 4,000 A$ 0.2546 28-Nov-16 28-Nov-24 A$ 0.2349 200,000 A$ 0.2721 Grant date Expiry date Exercise price Number of options Fair value 28-Nov-16 28-Nov-24 A$ 0.2866 200,000 A$ 0.2616 28-Nov-16 28-Nov-24 A$ 0.3556 5,000 A$ 0.2495 24-Dec-15 24-Dec-24 A$ 0.5125 100,000 A$ 0.1925 30-Dec-15 30-Dec-24 A$ 0.4838 50,000 A$ 0.2038 27-Apr-15 27-Apr-25 A$ 0.4765 4,000 A$ 0.2722 6-May-16 6-May-25 A$ 0.2936 50,000 A$ 0.2164 25-May-15 25-May-25 A$ 0.3982 260,600 A$ 0.2893 20-Jul-15 20-Jul-25 A$ 0.4077 15,000 A$ 0.2756 28-Aug-20 28-Aug-25 A$ 0.0136 6,000,000 A$ 0.0750 28-Aug-20 28-Aug-25 A$ 0.0136 6,000,000 A$ 0.0710 28-Aug-20 28-Aug-25 A$ 0.0136 500,000 A$ 0.1330 28-Aug-20 28-Aug-25 A$ 0.0136 500,000 A$ 0.1180 5-Sep-17 5-Sep-25 A$ 0.4136 10,000 A$ 0.3388 9-Oct-15 9-Oct-25 A$ 0.4311 5,000 A$ 0.3653 4-Nov-16 4-Nov-25 A$ 0.2327 4,000 A$ 0.2633 28-Nov-16 28-Nov-25 A$ 0.2349 200,000 A$ 0.2810 28-Nov-16 28-Nov-25 A$ 0.2866 200,000 A$ 0.2716 28-Nov-16 28-Nov-25 A4 0.3556 5,000 A$ 0.2605 24-Dec-15 24-Dec-25 A4 0.5125 100,000 A$ 0.2039 30-Dec-15 30-Dec-25 A$ 0.4838 50,000 A$ 0.2152 6-May-16 6-May-26 A$ 0.2936 50,000 A$ 0.2251 5-Sep-17 5-Sep-26 A$ 0.4136 10,000 A$ 0.3520 2-Dec-21 30-Sep-26 A$ 0.2014 2,986,663 A$ 0.0740 20-Nov-20 20-Oct-26 A$ 0.1519 100,000 A$ 0.0890 4-Nov-16 4-Nov-26 A4 0.2327 4,000 A$ 0.2710 28-Nov-16 28-Nov-26 A4 0.2349 200,000 A$ 0.2890 28-Nov-16 28-Nov-26 A$ 0.2866 200,000 A$ 0.2804 28-Nov-16 28-Nov-26 A 40.3556 5,000 A$ 0.2703 2-Dec-21 31-Dec-26 A$ 0.2014 2,986,663 A$ 0.0760 2-Dec-21 31-Mar-27 A4 0.2014 2,986,663 A$ 0.0780 2-Dec-21 31-Mar-27 A$ 0.0965 839,385 A$ 0.0900 2-Dec-21 30-Jun-27 A$ 0.2014 2,986,663 A$ 0.0790 2-Dec-21 30-Jun-27 A$ 0.0965 839,385 A$ 0.0910 5-Sep-17 5-Sep-27 A$ 0.4136 10,000 A$ 0.3636 2-Dec-21 30-Sep-27 A$ 0.2014 2,986,663 A$ 0.0810 2-Dec-21 30-Sep-27 A$ 0.0965 839,385 A$ 0.0920 20-Nov-20 20-Oct-27 A$ 0.1519 100,000 A$ 0.0950 2-Dec-21 31-Dec-27 A$ 0.2014 2,986,663 A$ 0.0820 2-Dec-21 31-Dec-27 A$ 0.0965 839,385 A$ 0.0940 2-Dec-21 31-Mar-28 A$ 0.2014 2,986,663 A$ 0.0840 2-Dec-21 31-Mar-28 A$ 0.0965 839,385 A$ 0.0950 2-Dec-21 30-Jun-28 A$ 0.2014 2,986,663 A$ 0.0850 2-Dec-21 30-Jun-28 A$ 0.0965 839,385 A$ 0.0960 2-Dec-21 30-Sep-28 A$ 0.2014 2,986,663 A$ 0.0860 2-Dec-21 30-Sep-28 A$ 0.0965 839,385 A$ 0.0970 20-Nov-20 20-Oct-28 A$ 0.1519 100,000 A$ 0.0990 2-Dec-21 31-Dec-28 A$ 0.2014 2,986,663 A$ 0.0880 2-Dec-21 31-Dec-28 A$ 0.0965 839,385 A$ 0.0980 2-Dec-21 31-Mar-29 A$ 0.0965 839,385 A$ 0.0980 2-Dec-21 30-Jun-29 A$ 0.0965 839,385 A$ 0.0990 2-Dec-21 30-Sep-29 A$ 0.0965 839,385 A$ 0.1000 20-Nov-20 20-Oct-29 A$ 0.1519 100,000 A$ 0.1030 2-Dec-21 31-Dec-29 A$ 0.2014 2,986,663 A$ 0.0920 Grant date Expiry date Exercise price Number of options Fair value 2-Dec-21 31-Dec-29 A$ 0.0965 839,385 A$ 0.1010 2-Dec-21 31-Mar-30 A$ 0.2014 2,986,663 A$ 0.0930 2-Dec-21 31-Mar-30 A$ 0.0965 839,385 A$ 0.1020 2-Dec-21 30-Jun-30 A$ 0.2014 2,986,662 A$ 0.0940 2-Dec-21 30-Jun-30 A$ 0.0965 839,385 A$ 0.1020 2-Dec-21 30-Sep-30 A$ 0.0965 839,385 A$ 0.1030 20-Nov-20 20-Oct-30 A$ 0.1519 100,000 A$ 0.1070 2-Dec-21 31-Dec-30 A$ 0.0965 839,385 A$ 0.1040 79,056,617
Summery of Movement in Unlisted Share Warrants	Movement in unlisted share warrants: 2022 2021 2020 Weighted Weighted Weighted Number average Number average Number average of warrants exercise of warrants exercise of warrants exercise price price price Opening balance at beginning of financial year 166,082,988 A$ 0.11 40,207,472 A$ 0.59 40,207,472 A$ 0.59 Granted during the financial year - - 150,000,000 A$ 0.06 - - Forfeited during the financial year - - - - - - Exercised during the financial year ( 8,000,000 ) A$ 0.06 - - - - Expired during the financial year ( 16,082,988 ) A$ 0.57 ( 24,124,484 ) A$ 0.59 - - Closing balance at June 30 142,000,000 A$ 0.06 166,082,988 A$ 0.11 40,207,472 A$ 0.59
Summery of Lists of Warrants Outstanding	The table below lists warrants outstanding at June 30, 2022. Grant Date Expiry date Exercise Price No of options Fair Value 26-Aug-20 26-Aug-23 A$ 0.06 142,000,000 A$ 0.01

Reserves (Tables)

Reserves (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure of reserves within equity [abstract]
Summary of Reserves	2022 2021 Foreign Currency Translation Reserve (a) 6,186,334 5,119,200 Share-based Payments Reserve (b) 6,337,264 6,328,691 Total Reserves 12,523,598 11,447,891 (a) Foreign Currency Translation Reserve Exchange differences arising on translation of the foreign controlled entities are taken to the foreign currency translation reserve, as described in Note 2(i). The reserve is recognised in profit or loss when the investment is disposed of. (b) Share-based Payments Reserve The share-based payments reserve is used to recognise the fair value of options and warrants issued over the vesting period or the period of the Consultancy Agreement, as applicable. Further information about share-based payments is set out in Note 21.

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure of detailed information about financial instruments [abstract]
Categories of Financial Instruments	(b) Categories of Financial Instruments 2022 2021 Financial Assets Cash and cash equivalents 33,564,857 28,499,449 Receivables 6,784,121 1,128,285 Other financial assets 119,000 554,640 40,467,978 30,182,374 Financial Liabilities Trade and other payables 2,786,280 1,814,390 Lease liability – rental property 693,623 867,841 Contingent consideration at fair value 2,699,010 1,762,656 6,178,913 4,444,887
Disclosure of Foreign Currency Risk Management	The Group’s exposure to foreign currency risk at the end of the reporting period, expressed in Australian dollars is as follows: 2022 2021 Denominated in USD Monetary items Cash and cash equivalents 17,786,031 624,819 Trade and other payables ( 1,298,425 ) ( 672,353 ) Contingent consideration liability ( 2,699,010 ) ( 1,762,656 ) Total monetary items 13,788,596 ( 1,810,190 ) Non-monetary items Goodwill 5,921,027 5,453,648 Other intangible assets 9,838,274 9,945,755 Deferred tax liability ( 1,798,625 ) ( 1,842,303 ) Total non-monetary items 13,960,676 13,557,100 Total denominated in USD 27,749,272 11,746,910
Summary of Foreign Currency Sensitivity Analysis	The following table details the Group’s sensitivity to a 10% increase and decrease in the Australian dollar against the US dollar. 10 % is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management’s assessment of the reasonably possible change in foreign currency rates. The sensitivity analysis below includes only outstanding foreign currency denominated monetary items and adjusts their translation at the year-end for a 10% change in foreign currency rates. A positive number below indicates an increase in profit or equity where the Australian dollar strengthens 10% against the relevant currency. For a 10% weakening of the Australian dollar against the relevant currency, there would be a comparable impact on the profit or equity with the balances being the opposite. 2022 2021 2020 Profit or loss (i) 1,796,641 ( 222,678 ) ( 2,181,987 ) Equity (ii) 18,815 3,135 10,403 (i) This is attributable to the exposure to outstanding USD net monetary assets at the end of the reporting period. (ii) This is attributable to the exposure to outstanding USD net monetary assets at the end of the reporting period in the subsidiaries which is denominated in USD and reflected in the foreign currency translation reserve.
Summary of Remaining Contractual Maturity for Financial Liabilities	The following tables detail the Group’s remaining contractual maturity for its financial liabilities with agreed repayment terms. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Group can be required to pay. To the extent that interest flows are at a variable rate, the undiscounted amount is derived from interest rate applicable at the end of the reporting period. The tables include both interest and principal cash flows. 2022 Weighted Less than 1 – 3 3 – 12 1 to 5 5 + Total Trade and other payables - 2,786,280 - - - - 2,786,280 Lease liability – rental property (fixed interest rate) 3.56 15,069 45,206 121,043 563,262 - 744,580 2,801,349 45,206 121,043 563,262 - 3,530,860 2021 Weighted Less than 1 – 3 3 – 12 1 to 5 5 + Total Trade and other payables - 1,814,390 - - - - 1,814,390 Lease liability – rental property (fixed interest rate) 3.56 40,141 43,764 117,184 744,579 - 945,668 1,854,531 43,764 117,184 744,579 - 2,760,058
Summary of Fair Value of Financial Instruments	The following table gives information about how the fair value of the financial liability is determined. Financial Liabilities Fair value as at 30 June Fair value as at 30 June Fair value Valuation Significant Relationship Contingent consideration in a business combination (Note 31) 2,699,010 1,762,656 Level 3 Discounted cash flow Discount rate of 25% (pre-tax) and probability adjusted revenue projections. The higher the discount rate, the lower the value. The higher the possible revenue the higher value.
Summary of Reconciliation of Level 3 Fair Value Measurements	Reconciliation of Level 3 fair value measurements 2022 2021 Contingent Contingent Opening balance 1,762,656 4,975,159 - in profit or loss 936,354 ( 3,212,503 ) Closing balance 2,699,010 1,762,656

Key Management Personnel Comp_2

Key Management Personnel Compensation (Tables)	12 Months Ended
	Jun. 30, 2022
Key Management Personnel Compensation [Abstract]
Disclosure of Key Management Personnel Compensation	The aggregate compensation made to Directors and other members of key management personnel of the Group is set out below: 2022 2021 2020 Short-term employee benefits 2,535,560 2,269,030 1,527,499 Post-employment benefits 69,039 51,982 52,106 Other long-term benefits 22,241 9,480 16,434 Share-based payments 2,819,133 1,298,208 68,518 Total key management personnel compensation 5,445,973 3,628,700 1,664,557

Commitments For Expenditure (Ta

Commitments For Expenditure (Tables)	12 Months Ended
	Jun. 30, 2022
Commitments For Expenditure [Abstract]
Summary of Non cancellable Operating Lease Commitments	The following table gives information about this lease commitment, which are not included in the lease liability due to the application of the practical expedients to exclude low value leases from lease liabilities. 2022 2021 Non-cancellable Operating Lease Commitments Within one year 5,064 5,064 Later than one year but not greater than five 13,504 19,412 Later than five years - - Minimum lease payments 18,568 24,476
Summary of Future Rental Income Receivable	The following table gives information about future rental income. 2022 2021 Within one year - 6,549 Later than one year but not greater than five - - - 6,549

Remuneration of Auditors (Table

Remuneration of Auditors (Tables)	12 Months Ended
	Jun. 30, 2022
Auditor's remuneration [abstract]
Schedule of Auditors Remuneration Explanatory	2022 2021 2020 Audit or Review of Financial Reports - Group 969,726 86,500 110,000 - French subsidiaries - - 74,972 Other Assurance Services Agreed upon procedures in relation to French subsidiaries cash statement and debt statement as at February 28, 2020 - - 27,109 969,726 86,500 212,081

Cash Flow Information (Tables)

Cash Flow Information (Tables)	12 Months Ended
	Jun. 30, 2022
Statement of cash flows [abstract]
Summary of Cash Flow Information	For the purposes of the consolidated statement of cash flows, cash and cash equivalents include cash on hand and in banks, net of outstanding bank overdrafts. Cash and cash equivalents at the end of the reporting period as shown in the consolidated statement of cash flows can be reconciled to the related items in the consolidated statement of financial position as follows: 2022 2021 2020 Cash and cash equivalents 33,564,857 28,499,449 4,577,747 (b) Reconciliation of Operating Loss to Net Cash Outflow from Operating Activities 2022 2021 2020 (Loss) for the year ( 21,759,358 ) ( 8,697,037 ) ( 7,118,288 ) Items in loss Depreciation and amortisation 1,109,412 1,700,878 2,443,386 Share-based payments 2,829,689 1,308,349 55,355 Loss/(Gain) on asset disposals 1,827 21,010 ( 173,934 ) Contingent consideration – change in fair value 936,354 ( 3,212,503 ) ( 4,823,874 ) Amortisation of transaction costs - 252,019 29,649 Net gain arising on modification of borrowings measured at amortised costs that were not derecognized - - 544,357 Accrual of final borrowing payment - 528,819 ( 199,089 ) Net foreign exchange differences 738,423 ( 1,067,746 ) 558,645 Loss on disposal of French operations - - 802,502 Interest received ( 9,869 ) ( 5,756 ) ( 58,369 ) Changes in Operating Assets and Liabilities (Increase)/Decrease) in receivables ( 39,148 ) 34,078 ( 202,257 ) (Increase)/Decrease in research and development incentive receivable ( 5,791,688 ) 1,991,468 4,145,659 (Increase)/Decrease in other assets ( 600,285 ) ( 85,648 ) 348,768 (Increase) in inventory - - ( 28,291 ) Increase/(Decrease) in payables 979,902 ( 63,305 ) 127,451 Increase/(Decrease) in provisions 41,062 ( 55,923 ) ( 85,407 ) (Decrease) in other liabilities - - ( 20,876 ) (Decrease) in deferred tax liability ( 191,808 ) ( 187,427 ) ( 248,580 ) Net cash outflows from operating activities ( 21,755,487 ) ( 7,538,724 ) ( 3,903,193 )

Contingent Consideration (Table

Contingent Consideration (Tables)	12 Months Ended
	Jun. 30, 2022
Contingent consideration [abstract]
Disclosure of Contingent Consideration	2022 2021 Opening balance 1,762,656 4,975,159 Change in fair value 936,354 ( 3,212,503 ) Closing balance 2,699,010 1,762,656

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Jun. 30, 2022
Earnings per share [abstract]
Summary of Computation of Basic and Diluted Loss Per Share	2022 2021 2020 From continuing and discontinuing operations Basic loss per share (A$ 0.02 ) (A$ 0.01 ) (A$ 0.01 ) Diluted loss per share (A$ 0.02 (A$ 0.01 (A$ 0.01 The basic and diluted loss per share amounts have been calculated using the ‘Loss after income tax’ figure in the consolidated statement of profit or and other comprehensive income. 2022 2021 2021 Loss Per Share (Basic and Diluted): Loss after tax for the year from continuing and discontinuing operations ( 21,759,358 ) ( 8,697,037 ) ( 7,118,288 ) Loss after tax for the year from continuing operations ( 21,759,358 ) ( 8,697,037 ) ( 5,818,975 ) 2022 2021 2010 Weighted Average Number of Ordinary Shares - Basic Weighted average number of ordinary shares used in calculating basic loss per share: 1,353,350,744 779,941,036 544,871,870 Weighted Average Number of Ordinary Shares – Diluted Weighted average number of ordinary shares used in calculating basic loss per share: 1,353,350,744 779,941,036 544,871,870 Shares deemed to be issued for no consideration in respect of employee options 31,065,272 20,056,450 5,296,550 Potential ordinary shares which are anti-dilutive and excluded ( 31,065,272 ) ( 20,056,450 ) ( 5,296,550 ) Shares deemed to be issued for no consideration in respect of warrants 142,000,000 166,082,988 40,207,472 Potential ordinary shares which are anti-dilutive and excluded ( 142,000,000 ) ( 166,082,988 ) ( 40,207,472 ) Weighted average number of ordinary shares used in the calculation of diluted loss per share 1,353,350,744 779,941,036 544,871,870
Summary of Number Of Potential Anti Dilutive Ordinary Shares Excluded From Computation Of Loss Per Share	The following potential ordinary shares are anti-dilutive and are therefore excluded from the weighted average number of ordinary shares for the purposes of diluted loss per share. 2022 2021 2020 Employee options 31,065,272 20,056,450 5,296,550 Warrants 142,000,000 166,082,988 40,207,472

Events Occurring After Report_2

Events Occurring After Reporting Date (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure of transactions between related parties [line items]
Summary of Share Options Issued to KMPs	Dr Errol De Souza Mr Jack Moschakis Share price at date of issue A$ 0.11 A$ 0.15 Exercise price A$ 0.04 A$ 0.04 Bionomics share volatility 105 % 105 % Risk free interest rate 0.42 % 0.43 % Share price at date of issue A$ 0.13 Exercise price A$ 0.1687 Bionomics share volatility 89 % Risk free interest rate 0.30 %
Key Management Personnel
Disclosure of transactions between related parties [line items]
Summary of Share Options Issued to KMPs	Details of share options that were issued to the KMPs are set out below: KMP Number Mr Adrian Hinton 2,000,000 Mr Connor Bernstein 3,500,000 Ms Liz Doolin 2,000,000

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Jun. 30, 2022
Disclosure of analysis of single amount of discontinued operations [abstract]
Summary of Discontinued Operations	(a) Analysis Assets and Liabilities Over Which Control Was Lost Year ended A$ Current assets Cash and cash equivalents 800,849 Trade and other receivables 1,047,259 Research and development incentives receivable 770,054 Inventories 692,832 Other assets 85,115 Non-current assets Property, plant and equipment 2,006,977 Right-to-use asset – rented property 1,424,365 Other intangible assets 574 Current liabilities Trade and other payables ( 2,312,900 ) Lease liability – rented property ( 161,723 ) Provisions ( 446,148 ) Other liabilities ( 204,860 ) Non-current liabilities Other payables ( 816,663 ) Lease liability – rented property ( 1,278,599 ) Deferred tax liabilities ( 514,962 ) Net assets disposed of 1,092,170 (b) Loss on Disposal of Subsidiary 2020 A$ Net assets disposed of ( 1,092,170 ) Costs relating to the disposal incurred by the Company ( 207,143 ) Loss on disposal ( 1,299,313 ) (c) Net Cash Outflow on Disposal of Subsidiaries 2020 A$ Cash and cash equivalent balances disposed of ( 800,849 ) Costs relating to the disposal incurred by the Company ( 207,143 ) Net cash outflow ( 1,007,992 ) (d) Analysis of (Loss)/Profit for the Year from Discontinued Operations The combined results of the discontinued operation (contract service business) included in the loss for the year ended June 30, 2020 are set out below. 2020 A$ Revenue 3,422,584 Other income 391,505 3,814,089 Expenses ( 4,242,502 ) Loss before income tax benefit ( 428,413 ) Income tax benefit 40,968 ( 387,445 ) Loss on disposal of operations including a cumulative gain of A$ 496,811 recycled from foreign currency translation reserve to profit and loss ( 911,868 ) Attributable income tax expenses - ( 911,868 ) Loss from discontinued operations ( 1,299,313 ) (e) Analysis of Cash Flows from Discontinued Operations The cash flows from discontinued operations for the year ended June 30, 2020 are set out below: Cash flows for the year from discontinued operations 2020 A$ Inflows from operating activities 470,767 Outflows from investing activities ( 7,704 ) Outflows from financing activities ( 100,489 ) Net cash flow 362,574

General Information - Additiona

General Information - Additional Information (Details)	12 Months Ended
	Jun. 30, 2022
General information [abstract]
Address of registered office	200 Greenhill Road
Principal place of business	Eastwood, South Australia, 5063

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of voluntary change in accounting policy [line items]
Cash consideration under the EEP	$ 5,997,505	$ 4,034,965	$ 3,367,073
Vesting period	five years
Useful life of right-to-use assets	5 years
Bottom of Range | Plant and Equipment
Disclosure of voluntary change in accounting policy [line items]
Depreciation rates for plant and equipment	20%
Top of Range | Plant and Equipment
Disclosure of voluntary change in accounting policy [line items]
Depreciation rates for plant and equipment	40%
Intellectual Property | Bottom of Range
Disclosure of voluntary change in accounting policy [line items]
Intangible assets, useful life	15 years
Intellectual Property | Top of Range
Disclosure of voluntary change in accounting policy [line items]
Intangible assets, useful life	20 years
Executive Chairman
Disclosure of voluntary change in accounting policy [line items]
Cash consideration under the EEP	$ 0

Segment Information - Additiona

Segment Information - Additional Information (Details)	12 Months Ended
	Jun. 30, 2022 Segment
Segment information [abstract]
Number of operating segment	1

Revenue, Other Income and Oth_3

Revenue, Other Income and Other Gains and Losses - Summary of Revenue from Continuing Operations (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from Continuing Operations	$ 263,634	$ 46,662
Licenses
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from Continuing Operations	$ 263,634	$ 46,662

Revenue, Other Income and Oth_4

Revenue, Other Income and Other Gains and Losses - Summary of Other Income from Continuing Operations (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Interest income	$ 9,869	$ 5,756	$ 58,369
Rent	6,674	203,014	200,284
Government Research And Development Incentives	5,791,688	928,073	2,945,600
Other Income from Continuing Operations	$ 5,808,231	1,308,343	3,312,753
Cash Flow Boost Grants
Disclosure of disaggregation of revenue from contracts with customers [line items]
Government assistance COVID-19		50,000	50,000
Jobkeeper Grants
Disclosure of disaggregation of revenue from contracts with customers [line items]
Government assistance COVID-19		$ 121,500	$ 58,500

Revenue, Other Income and Oth_5

Revenue, Other Income and Other Gains and Losses - Summary Of Other Income From Continuing Operations (Parenthetical) (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Refundable tax offset rate	43.50%	43.50%	43.50%
Top of Range
Disclosure of disaggregation of revenue from contracts with customers [line items]
Annual revenue eligible for government grants	$ 20,000,000

Revenue, Other Income and Oth_6

Revenue, Other Income and Other Gains and Losses - Summary of Other gains and losses from Continuing Operations (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net (loss)/gain arising on changes in fair value of contingent consideration (Note 31)	$ (936,354)	$ 3,212,503	$ 4,823,874
Net gain arising on modification of borrowings measured at amortised costs that were not derecognized (Note 18)			199,089
Net realised and unrealised foreign currency gains	356,166	1,081,438	(621,016)
(Loss) on disposal of plant and equipment	1,827	21,010	(173,934)
Other gains and losses from Continuing Operations	$ (582,015)	$ 4,272,931	$ 4,575,881

Expenses Related to Continuing

Expenses Related to Continuing Operations - Schedule of Expenses Related to Continuing Operations (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Expenses by nature [abstract]
Interest expense on bank and other loans		$ 618,586	$ 1,170,027
Interest expense on lease liabilities	$ 26,872	26,934	79,938
Amortisation of transaction costs		252,019	29,649
Accrual of final payment		528,819	544,357
Bank fees	17,293	17,527	22,496
Finance expenses, Total	44,165	1,443,885	1,846,467
Wages and salaries	2,901,689	2,577,954	3,097,949
Superannuation	266,127	148,662	213,769
Share-based payments	2,829,689	1,308,349	55,355
Employment benefit expenses, Total	5,997,505	4,034,965	3,367,073
Plant and equipment	2,681	45,553	91,860
Right-of-use assets (rental property)	193,358	762,813	748,571
Intellectual property	913,373	892,512	1,328,244
Amortisation and Depreciation, Total	1,109,412	1,700,878	2,168,675
Minimum lease payments	$ 5,260	$ 7,277	$ 7,506

Income Taxes Relating to Cont_3

Income Taxes Relating to Continuing Operations - Summary of Income Tax Recognised in Profit or Loss (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Deferred tax
Recognised in current year	$ (191,808)	$ (187,427)	$ (207,612)
Deferred tax	(191,808)	(187,427)	(207,612)
Total income tax benefit	$ (191,808)	$ (187,427)	$ (207,612)

Income Taxes Relating to Cont_4

Income Taxes Relating to Continuing Operations - Summary of Reconciliation to Accounting Loss (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Loss from continuing operations	$ (21,951,166)	$ (8,884,464)	$ (6,026,587)
Tax at the Australian tax rate of 25% (2021 & 2020: 30%)	(5,487,792)	(2,665,339)	(1,807,976)
Tax effect of non-deductible / non-assessable amounts
Exempt income from government assistance	(1,447,922)	(293,422)	(898,680)
Entertainment expenses	1,231	727	1,355
Net gain arising on changes in fair value of contingent	234,089	(963,751)	(1,447,162)
Share-based payments	707,422	392,505	16,607
Research and development expenditure	3,328,556	640,050	2,013,477
Amortisation of share issue costs	(285,631)
Temporary differences not recorded as an asset	(58,374)	(632,779)	(68,181)
Tax losses not recorded	2,779,547	3,253,265	1,981,695
Effect of different tax rates in other jurisdictions	37,066	81,317	1,253
Total income tax benefit	$ (191,808)	$ (187,427)	$ (207,612)

Income Taxes Relating to Cont_5

Income Taxes Relating to Continuing Operations - Summary of Reconciliation to Accounting Loss (Parenthetical) (Details)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Australian tax rate	25%	30%	30%

Income Taxes Relating to Cont_6

Income Taxes Relating to Continuing Operations - Summary of Net Deferred Tax Liability Recognised (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Reconciliation of changes in deferred tax liability (asset) [abstract]
Intangibles denominated in USD	$ (2,066,037)	$ (2,088,608)
Tax losses denominated in USD	267,412	246,305
Net deferred tax liability	(1,798,625)	(1,842,303)
Net Deferred Tax Liability, Begining balance	(1,842,303)	(2,203,340)
Recognized in income, Continuing operations	191,808	187,427
Recognized in equity	(148,130)	173,610
Net Deferred Tax Liability, Ending balance	$ (1,798,625)	$ (1,842,303)

Income Taxes Relating to Cont_7

Income Taxes Relating to Continuing Operations - Summary of Net Deferred Tax Asset Not Recognised (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Changes in deferred tax liability (asset) [abstract]
Revenue tax losses	$ 25,439,594	$ 27,181,188
Net temporary difference	3,460,261	2,851,336
Net deferred tax asset not recognised	$ 28,899,855	$ 30,032,524

Cash and Cash Equivalents - Dis

Cash and Cash Equivalents - Disclosure of Detailed Information About Cash and Cash Equivalents (Details) - AUD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Cash and cash equivalents [abstract]
Cash at bank and on hand	$ 33,564,857	$ 28,499,449
Cash and cash equivalents	$ 33,564,857	$ 28,499,449	$ 4,577,747	$ 13,985,477

Cash and Cash Equivalents (Addi

Cash and Cash Equivalents (Additional Information) (Details)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash and cash equivalents [abstract]
Weighted average interest rate on deposits	1.15%	0.10%

Other Financial Assets - Schedu

Other Financial Assets - Schedule of Other Financial Assets (Details) - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
Disclosure of financial assets [abstract]
Restricted deposits held as security and not available for use	$ 119,000	$ 554,640
Current assets		435,640
Non-current assets	119,000	119,000
Other financial assets, Total	$ 119,000	$ 554,640

Other Financial Assets - Additi

Other Financial Assets - Additional Information (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of financial assets [line items]
Restricted term deposit	$ 119,000	$ 554,640
Effective interest rate on deposits	1.95%	0.71%
Maturity Date of June 3, 2023
Disclosure of financial assets [line items]
Restricted term deposit	$ 119,000
Restricted term deposit maturity date	Jun. 03, 2023
Maturity Date of September 11, 2021
Disclosure of financial assets [line items]
Restricted term deposit		$ 383,883
Restricted term deposit maturity date		Sep. 11, 2021
Maturity Date of September 23, 2021
Disclosure of financial assets [line items]
Restricted term deposit		$ 51,757
Restricted term deposit maturity date		Sep. 23, 2021
Maturity Date of June 3, 2022
Disclosure of financial assets [line items]
Restricted term deposit		$ 119,000
Restricted term deposit maturity date		Jun. 03, 2022

Trade and Other Receivables - S

Trade and Other Receivables - Summary of Trade and Other Receivables (Details) - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
Current
Other receivables	$ 42,483	$ 192,885
Loss allowance
Trade and other receivable, Before tax	42,483	192,885
GST Receivables	21,877	7,327
Trade and other receivable, Net	$ 64,360	$ 200,212

Other Assets - Summary of Detai

Other Assets - Summary of Detailed Information About Other Current Assets (Details) - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
Miscellaneous current assets [abstract]
Prepayments	$ 1,461,078	$ 860,793
Accrued income	190	2,837
Other Assets, Net	$ 1,461,268	$ 863,630

Subsidiaries - Summary of Group

Subsidiaries - Summary of Group Subsidiaries (Details)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of subsidiaries [line items]
Principal activity	Research and Development
Country of incorporation	Australia
Iliad Chemicals Pty Ltd
Disclosure of subsidiaries [line items]
Subsidiaries of Bionomics Limited	Iliad Chemicals Pty Ltd
Principal activity	Asset owner
Country of incorporation	Australia
Percentage owned	100%	100%
Bionomics Inc
Disclosure of subsidiaries [line items]
Subsidiaries of Bionomics Limited	Bionomics Inc
Principal activity	Asset owner
Country of incorporation	United States
Percentage owned	100%	100%

Property, Plant And Equipment -

Property, Plant And Equipment - Schedule of Detailed Information About Property Plant And Equipment (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	$ 8,227
Depreciation	(2,681)	$ (45,553)	$ (91,860)
Property, plant and equipment at end of period	5,172	8,227
Cost
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	106,753	1,373,704
Additions	1,544	1,468
Disposals	(36,262)	(1,268,419)
Property, plant and equipment at end of period	72,035	106,753	1,373,704
Accumulated depreciation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(98,526)	(1,089,748)
Depreciation	(2,681)	(45,553)	(204,869)
Disposals	34,344	1,036,775
Property, plant and equipment at end of period	(66,863)	(98,526)	(1,089,748)
Depreciation property plant and equipment continuing operation	2,681	45,553	91,860
Depreciation property plant and equipment discontinued operation			113,009
Plant and Equipment at cost
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	8,227
Property, plant and equipment at end of period	5,172	8,227
Plant and Equipment at cost | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	106,753	1,373,704
Additions	1,544	1,468
Disposals	(36,262)	(1,268,419)
Property, plant and equipment at end of period	72,035	106,753	1,373,704
Plant and Equipment at cost | Accumulated depreciation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(98,526)	(1,089,748)
Depreciation	(2,681)	(45,553)
Disposals	34,344	1,036,775
Property, plant and equipment at end of period	$ (66,863)	$ (98,526)	$ (1,089,748)

Right-of-Use Assets - Summary o

Right-of-Use Assets - Summary of Right-of-Use Assets (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of quantitative information about right-of-use assets [line items]
Opening balance July 1	$ 862,716
Depreciation	(193,358)	$ (762,813)	$ (748,571)
Closing balance June 30	669,358	862,716
Right-of-use Assets
Disclosure of quantitative information about right-of-use assets [line items]
Opening balance July 1	862,716	771,029
Addition of new property being rented		854,500
Depreciation	(193,358)	(762,813)
Closing balance June 30	669,358	862,716	$ 771,029
Right-of-use Assets | Cost
Disclosure of quantitative information about right-of-use assets [line items]
Opening balance July 1	2,374,100
Closing balance June 30	854,500	2,374,100
Right-of-use Assets | Accumulated depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Opening balance July 1	(1,511,384)
Closing balance June 30	$ (185,142)	$ (1,511,384)

Right-of-Use Assets - Summary_2

Right-of-Use Assets - Summary of Depreciation Disclosed in Consolidated Statement of Profit or Loss and Other Comprehensive Income (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of attribution of expenses by nature to their function [line items]
Depreciation and amortisation expense	$ 1,109,412	$ 1,700,878	$ 2,168,675
Right-of-use assets [member]
Disclosure of attribution of expenses by nature to their function [line items]
Depreciation and amortisation expense continuing operations	193,358	762,813	748,571
Depreciation and amortisation expense discontinued operations			116,075
Depreciation and amortisation expense	$ 193,358	$ 762,813	$ 864,646

Goodwill - Schedule of Changes

Goodwill - Schedule of Changes in Goodwill (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of reconciliation of changes in goodwill [abstract]
Goodwill at beginning of period	$ 12,400,743	$ 12,872,387
Foreign currency exchange differences	467,379	(471,644)
Goodwill at end of period	$ 12,868,122	$ 12,400,743

Goodwill - Additional Informati

Goodwill - Additional Information (Details)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of reconciliation of changes in goodwill [abstract]
Description of basis on which unit's recoverable amount has been determined	The recoverable amount of the drug development CGU is determined based on a value in use calculation which uses cash flow projections based on observable market comparables for drug compounds within the CGU over a period of twenty years covering drug discovery, development, approval and marketing, and a post-tax discount rate of 17% (2021: 15%).
Post-tax discount rate	17%	15%
Growth rates	0%

Other Intangible Assets - Summa

Other Intangible Assets - Summary of Carrying Amounts of Each Class of Other Intangible Assets (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	$ 9,945,755
Amortisation	913,373	$ 892,512	$ 1,328,244
Other Intangible Assets, Ending balance	9,838,274	9,945,755
Net carrying amount	9,838,274	9,945,755
Continuing operations	913,373	892,512	1,328,244
Discontinued operations			45,627
Profit (loss), attributable to owners of parent	913,373	892,512	1,373,871
Cancer Stem Cell Technology
Disclosure of detailed information about intangible assets [line items]
Net carrying amount	9,838,274	9,945,755
Gross Carrying Amount
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	22,776,020	24,305,144
Foreign currency exchange differences	1,515,296	(1,529,124)
Other Intangible Assets, Ending balance	24,291,316	22,776,020	24,305,144
Gross Carrying Amount | KV1.3 Compound
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	1,546,542	1,546,542
Other Intangible Assets, Ending balance	1,546,542	1,546,542	1,546,542
Gross Carrying Amount | VDA Compound
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	2,282,527	2,282,527
Other Intangible Assets, Ending balance	2,282,527	2,282,527	2,282,527
Gross Carrying Amount | MultiCoreTechnology
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	1,265,590	1,265,590
Other Intangible Assets, Ending balance	1,265,590	1,265,590	1,265,590
Gross Carrying Amount | Cancer Stem Cell Technology
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	17,681,361	19,210,485
Foreign currency exchange differences	1,515,296	(1,529,124)
Other Intangible Assets, Ending balance	19,196,657	17,681,361	19,210,485
Accumulated Amortisation
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	(12,830,265)	(12,538,732)
Foreign currency exchange differences	(709,404)	600,979
Amortisation	(913,373)	(892,512)
Other Intangible Assets, Ending balance	(14,453,042)	(12,830,265)	(12,538,732)
Accumulated Amortisation | KV1.3 Compound
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	(1,546,542)	(1,546,542)
Other Intangible Assets, Ending balance	(1,546,542)	(1,546,542)	(1,546,542)
Accumulated Amortisation | VDA Compound
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	(2,282,527)	(2,282,527)
Other Intangible Assets, Ending balance	(2,282,527)	(2,282,527)	(2,282,527)
Accumulated Amortisation | MultiCoreTechnology
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	(1,265,590)	(1,265,590)
Other Intangible Assets, Ending balance	(1,265,590)	(1,265,590)	(1,265,590)
Accumulated Amortisation | Cancer Stem Cell Technology
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	(7,735,606)	(7,444,073)
Foreign currency exchange differences	(709,404)	600,979
Amortisation	(913,373)	(892,512)
Other Intangible Assets, Ending balance	$ (9,358,383)	$ (7,735,606)	$ (7,444,073)

Trade and Other Payables - Disc

Trade and Other Payables - Disclosure of Trade and Other Payables (Details) - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
Current
Trade payables	$ 1,556,881	$ 1,028,744
Accrued expenses	1,229,399	785,646
Total trade and other current payables	$ 2,786,280	$ 1,814,390

Trade and Other Payables - Addi

Trade and Other Payables - Additional Information (Details)	12 Months Ended
	Jun. 30, 2022 AUD ($)
Trade and other payables [abstract]
Average credit period on purchases of goods	45 days
Interest paid on trade payables	$ 0

Borrowings - Summary of Loan Mo

Borrowings - Summary of Loan Movement Schedule (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of detailed information about borrowings [line items]
Foreign currency exchange differences	$ 1,796,641	$ (222,678)	$ (2,181,987)
Equipment Mortgage Loans and Bank Loan
Disclosure of detailed information about borrowings [line items]
Opening Balance - July 1		11,444,129
Accrual of bank loan final payment		528,819
Repayments - principal		(9,170,741)
Repayments - final payment		(1,916,398)
Amortisation of costs		252,019
Foreign currency exchange differences		$ (1,137,828)
Closing Balance - June 30			$ 11,444,129

Borrowings - Summary of Loan _2

Borrowings - Summary of Loan Movement Schedule (Parenthetical) (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of detailed information about borrowings [abstract]
Loan amount accrued	$ 1,477,500	$ 1,079,030

Lease Liabilities - Schedule of

Lease Liabilities - Schedule of Lease Liabilities Secured at Amortised Costs (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Lease liabilities [abstract]
Opening Balance - July 1	$ 867,841	$ 793,148
Adoption of new leasing accounting standard			$ 2,993,675
New lease for new property - being rented		854,500
Repayments	(174,218)	(779,807)	(826,942)
Derecognized on disposal of subsidiaries (Note 35)			(1,440,322)
Effect of foreign currency exchange differences			66,737
Closing Balance - June 30	693,623	867,841	793,148
Current liabilities	160,040	174,218	767,711
Non-current liabilities	533,583	693,623	25,437
Total lease liabilities	$ 693,623	$ 867,841	$ 793,148

Lease Liabilities - Schedule _2

Lease Liabilities - Schedule of Total Group Cash Outflows for Leases (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of quantitative information about leases for lessee [abstract]
Principal element of lease payments	$ 174,218	$ 779,807	$ 826,942
Interest element of lease payments - continuing operations	26,872	26,934	79,938
Interest element of lease payments - discontinuing operations			33,176
Total cash outflows for leases	$ 201,090	$ 806,741	$ 940,056

Lease Liabilities - Schedule _3

Lease Liabilities - Schedule of Undiscounted Potential Future Rental Payments (Details) - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
Disclosure of maturity analysis of operating lease payments [line items]
Extension options expected not to be exercised	$ 1,183,105	$ 1,183,105
More than five years
Disclosure of maturity analysis of operating lease payments [line items]
Extension options expected not to be exercised	$ 1,183,105	$ 1,183,105

Provisions - Summary of Detaile

Provisions - Summary of Detailed Information About Provisions (Details) - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Provision Abstract
Current Employee benefits	$ 409,320	$ 371,936
Non-Current Employee benefits	$ 10,460	$ 6,782

Issued Capital - Summary of Mov

Issued Capital - Summary of Movements in Ordinary Shares (Details)		12 Months Ended
	Sep. 02, 2021 shares	Jun. 30, 2022 AUD ($) shares	Jun. 30, 2021 AUD ($) shares	Jun. 30, 2020 AUD ($) shares
Disclosure of classes of share capital [line items]
Share issue - rights | $		$ 480,000	$ 22,606,257
Shares issued to employees | $			$ 60,750
Shares issued on exercise of options, shares | shares	2,000,000	2,000,000
Shares issued on exercise of warrants, shares | shares		8,000,000
Closing balance, shares | shares		1,353,350,744
Closing balance | $		$ 217,695,759
Ordinary Shares
Disclosure of classes of share capital [line items]
Opening balance, shares | shares		1,007,596,744	626,185,872	544,647,747
Opening balance | $		$ 190,190,147	$ 148,156,005	$ 144,944,233
Share issue - share placement, shares | shares			185,757,511	81,500,000
Share issue - share placement | $			$ 21,229,874	$ 3,260,000
Transfer from treasury stock, shares | shares				38,125
Share issue - rights, shares | shares			195,229,129
Share issue - rights | $			$ 22,606,257
Shares issued to employees, shares | shares			424,232
Shares issued to employees | $			$ 60,750
Shares issued on exercise of options, shares | shares		2,000,000
Shares issued on exercise of options | $		$ 27,200
Shares issued on exercise of warrants, shares | shares		8,000,000
Shares issued on exercise of warrants | $		$ 480,000
Transfer from share-based payments reserve as result of options and warrants being exercised | $		$ 327,760
Share issue in a US IPO and NASDAQ listing, shares | shares		335,754,000
Share issue in a US IPO and NASDAQ listing | $		$ 32,383,263
Share issue costs | $		$ (5,712,611)	(423,492)	$ (48,228)
Warrants issued - underwriting fee | $			$ (1,439,247)
Closing balance, shares | shares		1,353,350,744	1,007,596,744	626,185,872
Closing balance | $		$ 217,695,759	$ 190,190,147	$ 148,156,005
Treasury Stock
Disclosure of classes of share capital [line items]
Opening balance, shares | shares				38,125
Share issue - Employee Share Plan Loan Agreements | shares				(38,125)

Issues Capital - Summary of Mov

Issues Capital - Summary of Movements in Ordinary Shares (Parenthetical) (Details)				12 Months Ended
	Sep. 02, 2021 shares $ / shares	Mar. 03, 2021 AUD ($)	Aug. 26, 2020 AUD ($) $ / shares shares	Jun. 30, 2022 AUD ($) shares $ / shares	Jun. 30, 2021 AUD ($) $ / shares shares	Jun. 30, 2020 AUD ($)
Disclosure of classes of share capital [line items]
Number of shares issued				1,353,350,744
Share price | $ / shares	$ 0.19
Proceeds from issuing shares | $				$ 32,890,463	$ 43,836,131	$ 3,260,000
Minimum proceeds from warrants | $			$ 15,000,000
Number of options Exercised during the financial year	2,000,000			2,000,000
Shares issued on exercise of options, exercise price | $ / shares	$ 0.0136			$ 0.0136
Number of shares issued on exercise of warrants				8,000,000
Shares issued on exercise of warrants, exercise price | $ / shares				$ 0.06
Number of shares issued in US IPO and NASDAQ listing				335,754,000
Description of ordinary shares voting rights				every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote and upon a poll each share is entitled to one vote
Apeiron
Disclosure of classes of share capital [line items]
Number of shares issued				7,287,480	54,333,000
Proceeds from issuing shares | $			$ 15,000,000
Shares issued price per share | $ / shares			$ 0.06		$ 0.04
Number of warrants issued			150,000,000
Share Placement Tranche One
Disclosure of classes of share capital [line items]
Number of shares issued					54,333,000
Share price | $ / shares					$ 0.04
Proceeds from issuing shares | $					$ 2,173,320
Share Placement Tranche Two
Disclosure of classes of share capital [line items]
Number of shares issued					131,424,511
Share price | $ / shares					$ 0.145
Proceeds from issuing shares | $					$ 19,056,554
Rights Issues Tranche One
Disclosure of classes of share capital [line items]
Number of shares issued					54,304,446
Proceeds from issuing shares | $					$ 2,172,178
Shares issued price per share | $ / shares					$ 0.04
Rights Issues Tranche Two
Disclosure of classes of share capital [line items]
Number of shares issued					140,924,683
Proceeds from issuing shares | $					$ 20,434,079
Shares issued price per share | $ / shares					$ 0.145
Share Placement | Apeiron
Disclosure of classes of share capital [line items]
Proceeds from vesting of warrants | $		$ 15,991,634

Issued Capital - Additional Inf

Issued Capital - Additional Information (Details)							12 Months Ended
	Dec. 02, 2021 $ / shares shares	Nov. 11, 2021 shares $ / shares	Sep. 02, 2021 shares $ / shares	Nov. 20, 2020 $ / shares shares	Aug. 28, 2020 $ / shares shares	Aug. 26, 2020 AUD ($) $ / shares shares	Jun. 30, 2022 shares $ / shares	Jun. 30, 2022 shares $ / shares $ / shares	Jun. 30, 2021 AUD ($) shares	Dec. 02, 2021 $ / shares shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of conversion of option exercised							When exercised, each option is convertible into one ordinary share.	When exercised, each option is convertible into one ordinary share.
Vested and exercisable							31,065,275	31,065,275	20,056,450
Weighted average remaining contractual life of unlisted share options outstanding							4 years 11 months 4 days	4 years 11 months 4 days	3 years 9 months 18 days
Share options issued							1,353,350,744	1,353,350,744
Number of share options exercised in share-based payment arrangement			2,000,000				2,000,000	2,000,000
Shares issued on exercise of options, exercise price | $ / shares			$ 0.0136				$ 0.0136
Share price | $ / shares			$ 0.19
Warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vested and exercisable							142,000,000	142,000,000	166,082,988
Weighted average remaining contractual life of unlisted share options outstanding							1 year 1 month 28 days	1 year 1 month 28 days	2 years 7 months 6 days
Shares issued price per share | $ / shares							$ 0.01	$ 0.01
Share price | $ / shares		$ 0.125
Number of shares exercised		2,000,000					8,000,000	8,000,000
Weighted average exercise price Exercised during the financial year | $ / shares		$ 0.06					$ 0.06
Warrants | Apeiron
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued						150,000,000
Share price | $ / shares						$ 0.06
Share issuance price | $						$ 15,000,000
Warrants expiry date						Aug. 26, 2023
Placement of shares amount | $									$ 15,991,634
Percentage of risk adjusted estimated fee									9%
Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price | (per share)				$ 0.13				$ 0.14
Monte Carlo Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price | $ / shares							$ 0.24
Dr Jane Ryan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued				500,000
Share options subscribed				500,000
Shares issued price per share | $ / shares				$ 0.1687
Share Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued					15,000,000
Share options subscribed					15,000,000
Exercise price | $ / shares					$ 0.04
Share Options | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Shares issued price per share | $ / shares	$ 0.125
Exercise price | $ / shares	$ 0.2014
Share Options | Dr Errol De Souza
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued	47,786,607									47,786,607
Share options subscribed	47,786,607									47,786,607
Shares issued price per share | $ / shares										$ 0.2014
Share Options | Dr Errol De Souza | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued	13,430,160									13,430,160
Share options subscribed	13,430,160									13,430,160
Shares issued price per share | $ / shares	$ 0.09645

Issued Capital - Summary of M_2

Issued Capital - Summary of Movement in Unlisted Share Options (Details)		12 Months Ended
	Sep. 02, 2021 shares $ / shares	Jun. 30, 2022 shares $ / shares	Jun. 30, 2021 shares $ / shares	Jun. 30, 2020 shares $ / shares
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Number of options Opening balance | shares		20,985,450	6,364,550	7,686,550
Number of options Granted during the financial year | shares		61,216,767	15,500,000
Number of options Forfeited during the financial year | shares			(5,000)	(582,500)
Number of options Exercised during the financial year | shares	(2,000,000)	(2,000,000)
Number of options Expired during the financial year | shares		(1,145,600)	(874,100)	(739,500)
Number of options Closing balance | shares		79,056,617	20,985,450	6,364,550
Weighted average exercise price Opening balance | $ / shares		$ 0.12	$ 0.40	$ 0.41
Weighted average exercise price Granted during the financial year | $ / shares		0.18	0.04
Weighted average exercise price Forfeited during the financial year | $ / shares			0.41	0.44
Weighted average exercise price Exercised during the financial year | $ / shares	$ 0.0136	0.0136
Weighted average exercise price Expired during the financial year | $ / shares		0.42	0.45	0.45
Weighted average exercise price Closing balance | $ / shares		$ 0.16	$ 0.12	$ 0.40

Issued Capital - Summary of Opt

Issued Capital - Summary of Options Issued (Details)			12 Months Ended
	Dec. 22, 2021 shares $ / shares	Nov. 20, 2020 shares $ / shares	Jun. 30, 2022 shares $ / shares	Jun. 30, 2021 shares	Jun. 30, 2020 shares	Jun. 30, 2019 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting date			five years
Number | shares	47,786,607		79,056,617	20,985,450	6,364,550	7,686,550
Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price		$ 0.1687
Number | shares	13,430,160
Tranche 1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	20-Nov-20
Vesting date	30-Sep-21	20-Oct-21
Expiry date	30-Sep-26
Exercise price	$ 0.2014	$ 0.1687
Number | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0740	$ 0.089
Tranche 1 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	31-Mar-22
Expiry date	31-Mar-27
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.0900
Tranche 2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	20-Nov-20
Vesting date	31-Dec-21	20-Oct-22
Expiry date	31-Dec-26
Exercise price	$ 0.2014	$ 0.1687
Number | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0760	$ 0.095
Tranche 2 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	30-Jun-22
Expiry date	30-Jun-27
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.0910
Tranche 3
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	20-Nov-20
Vesting date	31-Mar-22	20-Oct-23
Expiry date	31-Mar-27
Exercise price	$ 0.2014	$ 0.1687
Number | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0780	$ 0.099
Tranche 3 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	30-Sep-22
Expiry date	30-Sep-27
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.0920
Tranche 4
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	20-Nov-20
Vesting date	30-Jun-22	20-Oct-24
Expiry date	30-Jun-27
Exercise price	$ 0.2014	$ 0.1687
Number | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0790	$ 0.103
Tranche 4 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	31-Dec-22
Expiry date	31-Dec-27
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.0940
Tranche 5
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	20-Nov-20
Vesting date	30-Sep-22	20-Oct-25
Expiry date	30-Sep-27
Exercise price	$ 0.2014	$ 0.1687
Number | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0810	$ 0.107
Tranche 5 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	31-Mar-23
Expiry date	31-Mar-28
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.0950
Tranche 6
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21		20-Jul-15
Vesting date	31-Dec-22
Expiry date	31-Dec-27
Exercise price	$ 0.2014		$ 0.4077
Number | shares	2,986,663		15,000
Fair value at date of issue	$ 0.0820		$ 0.2371
Tranche 6 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	30-Jun-23
Expiry date	30-Jun-28
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.0960
Tranche 7
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21		5-Sep-17
Vesting date	31-Mar-23
Expiry date	31-Mar-28
Exercise price	$ 0.2014		$ 0.4136
Number | shares	2,986,663		368,050
Fair value at date of issue	$ 0.0840		$ 0.2839
Tranche 7 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	30-Sep-23
Expiry date	30-Sep-28
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.0970
Tranche 8
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21		9-Oct-15
Vesting date	30-Jun-23
Expiry date	30-Jun-28
Exercise price	$ 0.2014		$ 0.4311
Number | shares	2,986,663		5,000
Fair value at date of issue	$ 0.0850		$ 0.3216
Tranche 8 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	31-Dec-23
Expiry date	31-Dec-28
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.0980
Tranche 9
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21		10-Oct-13
Vesting date	30-Sep-23
Expiry date	30-Sep-28
Exercise price	$ 0.2014		$ 0.5750
Number | shares	2,986,663		15,000
Fair value at date of issue	$ 0.0860		$ 0.5233
Tranche 9 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	31-Mar-24
Expiry date	31-Mar-29
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.0980
Tranche 10
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21		28-Nov-16
Vesting date	31-Dec-23
Expiry date	31-Dec-28
Exercise price	$ 0.2014		$ 0.2349
Number | shares	2,986,663		200,000
Fair value at date of issue	$ 0.0880		$ 0.2505
Tranche 10 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	30-Jun-24
Expiry date	30-Jun-29
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.0990
Tranche 11
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21		28-Nov-16
Vesting date	31-Mar-24
Expiry date	31-Mar-24
Exercise price	$ 0.2014		$ 0.2866
Number | shares	2,986,663		100,000
Fair value at date of issue	$ 0.0890		$ 0.2377
Tranche 11 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	30-Sep-24
Expiry date	30-Sep-29
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.1000
Tranche 12
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21		28-Nov-16
Vesting date	30-Jun-24
Expiry date	30-Jun-24
Exercise price	$ 0.2014		$ 0.3556
Number | shares	2,986,663		5,000
Fair value at date of issue	$ 0.0900		$ 0.2227
Tranche 12 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	31-Dec-24
Expiry date	31-Dec-29
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.1010
Tranche 13
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21		11-Dec-12
Vesting date	30-Sep-24
Expiry date	30-Jun-24
Exercise price	$ 0.2014		$ 0.2912
Number | shares	2,986,663		100,000
Fair value at date of issue	$ 0.0910		$ 0.2155
Tranche 13 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	31-Mar-25
Expiry date	31-Mar-30
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.1020
Tranche 14
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21		17-Dec-13
Vesting date	31-Dec-24
Expiry date	31-Dec-29
Exercise price	$ 0.2014		$ 0.6960
Number | shares	2,986,663		100,000
Fair value at date of issue	$ 0.0920		$ 0.4318
Tranche 14 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	30-Jun-25
Expiry date	30-Jun-30
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.1020
Tranche 15
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21		17-Dec-13
Vesting date	31-Mar-25
Expiry date	31-Mar-30
Exercise price	$ 0.2014		$ 0.6611
Number | shares	2,986,663		4,000
Fair value at date of issue	$ 0.0930		$ 0.4385
Tranche 15 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	30-Sep-25
Expiry date	30-Sep-30
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.1030
Tranche 16
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21		18-Dec-12
Vesting date	30-Jun-25
Expiry date	30-Jun-30
Exercise price	$ 0.2014		$ 0.2912
Number | shares	2,986,662		5,000
Fair value at date of issue	$ 0.0940		$ 0.2535
Tranche 16 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21
Vesting date	31-Dec-25
Expiry date	31-Dec-30
Exercise price	$ 0.09645
Number | shares	839,385
Fair value at date of issue	$ 0.1040

Issued Capital - Summary of Inp

Issued Capital - Summary of Inputs Used (Details) - $ / shares	Dec. 02, 2021	Nov. 20, 2020	Aug. 28, 2020
Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free interest rate		0.30%
Share Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price			$ 0.04
Share Options | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price at date of issue	$ 0.125
Exercise price	$ 0.2014
Bionomics share volatility	85.53%
Risk free interest rate	0.413%
Share Options 1 | Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price at date of issue	$ 0.125
Exercise price	$ 0.0965
Bionomics share volatility	85.53%
Risk free interest rate	0.413%

Issued Capital - Unlisted Share

Issued Capital - Unlisted Share Options Issued (Details) - $ / shares		12 Months Ended
	Aug. 28, 2020	Jun. 30, 2022
Disclosure of classes of share capital [line items]
Share options issued		1,353,350,744
Vesting period		five years
Dr Errol De Souza | Share Price Reaching Dollar 0.14 Per Share
Disclosure of classes of share capital [line items]
Share options issued	6,000,000
Vesting period	Company’s share price reaching $0.14 per share
Fair value at date of issue	$ 0.075
Dr Errol De Souza | Share Price Reaching Dollar 0.24 Per Share
Disclosure of classes of share capital [line items]
Share options issued	6,000,000
Vesting period	Company’s share price reaching $0.24 per share
Fair value at date of issue	$ 0.071
Mr Jack Moschakis | Share Price Reaching Dollar 0.14 Per Share
Disclosure of classes of share capital [line items]
Share options issued	1,000,000
Vesting period	Company’s share price reaching $0.14 per share
Fair value at date of issue	$ 0.133
Mr Jack Moschakis | Share Price Reaching Dollar 0.24 Per Share
Disclosure of classes of share capital [line items]
Share options issued	1,000,000
Vesting period	Company’s share price reaching $0.24 per share
Fair value at date of issue	$ 0.118
Ms Liz Doolin | Share Price Reaching Dollar 0.14 Per Share
Disclosure of classes of share capital [line items]
Share options issued	500,000
Vesting period	Company’s share price reaching $0.14 per share
Fair value at date of issue	$ 0.133
Ms Liz Doolin | Share Price Reaching Dollar 0.24 Per Share
Disclosure of classes of share capital [line items]
Share options issued	500,000
Vesting period	Company’s share price reaching $0.24 per share
Fair value at date of issue	$ 0.118

Issued Capital - Share Options

Issued Capital - Share Options Issued (Details) - $ / shares		12 Months Ended
	Sep. 02, 2021	Jun. 30, 2022
Disclosure of classes of share capital [line items]
Share price at date of issue	$ 0.19
Dr Errol De Souza Share Options | Share Price Reaching Dollar 0.14 Per Share
Disclosure of classes of share capital [line items]
Share price at date of issue		$ 0.11
Exercise price		$ 0.04
Bionomics share volatility		105%
Risk free interest rate		0.42%
Mr Jack Moschakis And Ms Liz Doolin Share Options | Share Price Reaching Dollar 0.14 Per Share
Disclosure of classes of share capital [line items]
Share price at date of issue		$ 0.15
Exercise price		$ 0.04
Bionomics share volatility		105%
Risk free interest rate		0.43%

Issued Capital - Summary of Sha

Issued Capital - Summary of Share Options Issue (Details)			12 Months Ended
	Dec. 22, 2021 shares $ / shares	Nov. 20, 2020 shares $ / shares	Jun. 30, 2022 shares	Jun. 30, 2021 shares	Jun. 30, 2020 shares	Jun. 30, 2019 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting date			five years
Number | shares	47,786,607		79,056,617	20,985,450	6,364,550	7,686,550
Tranche 1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	20-Nov-20
Vesting date	30-Sep-21	20-Oct-21
Expiry date		Oct. 20, 2026
Exercise price	$ 0.2014	$ 0.1687
Number | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0740	$ 0.089
Tranche 2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	20-Nov-20
Vesting date	31-Dec-21	20-Oct-22
Expiry date		Oct. 20, 2027
Exercise price	$ 0.2014	$ 0.1687
Number | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0760	$ 0.095
Tranche 3
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	20-Nov-20
Vesting date	31-Mar-22	20-Oct-23
Expiry date		Oct. 20, 2028
Exercise price	$ 0.2014	$ 0.1687
Number | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0780	$ 0.099
Tranche 4
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	20-Nov-20
Vesting date	30-Jun-22	20-Oct-24
Expiry date		Oct. 20, 2029
Exercise price	$ 0.2014	$ 0.1687
Number | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0790	$ 0.103
Tranche 5
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	20-Nov-20
Vesting date	30-Sep-22	20-Oct-25
Expiry date		Oct. 20, 2030
Exercise price	$ 0.2014	$ 0.1687
Number | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0810	$ 0.107

Issued Capital - Summary of I_2

Issued Capital - Summary of Inputs Used to a Black-Scholes Model Used to Obtain Fair Value of Above Share Options (Details)			12 Months Ended
	Sep. 02, 2021 $ / shares	Nov. 20, 2020 $ / shares	Jun. 30, 2022 $ / shares
Disclosure of classes of share capital [line items]
Share price at date of issue	$ 0.19
Black Scholes Model
Disclosure of classes of share capital [line items]
Share price at date of issue | (per share)		$ 0.13	$ 0.14
Exercise price		$ 0.1687
Bionomics share volatility		89%
Risk free interest rate		0.30%

Issued Capital - Summary of S_2

Issued Capital - Summary of Share Options Outstanding (Details)		12 Months Ended
	Dec. 22, 2021 shares $ / shares	Jun. 30, 2022 shares $ / shares	Jun. 30, 2021 shares	Jun. 30, 2020 shares	Jun. 30, 2019 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options | shares	47,786,607	79,056,617	20,985,450	6,364,550	7,686,550
Tranche 6
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	20-Jul-15
Expiry date		Jul. 20, 2022
Exercise price	$ 0.2014	$ 0.4077
Number of options | shares	2,986,663	15,000
Fair value at date of issue	$ 0.0820	$ 0.2371
Tranche 7
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	5-Sep-17
Expiry date		Sep. 05, 2022
Exercise price	$ 0.2014	$ 0.4136
Number of options | shares	2,986,663	368,050
Fair value at date of issue	$ 0.0840	$ 0.2839
Tranche 8
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	9-Oct-15
Expiry date		Oct. 09, 2022
Exercise price	$ 0.2014	$ 0.4311
Number of options | shares	2,986,663	5,000
Fair value at date of issue	$ 0.0850	$ 0.3216
Tranche 9
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	10-Oct-13
Expiry date		Oct. 10, 2022
Exercise price	$ 0.2014	$ 0.5750
Number of options | shares	2,986,663	15,000
Fair value at date of issue	$ 0.0860	$ 0.5233
Tranche 10
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	28-Nov-16
Expiry date		Nov. 28, 2022
Exercise price	$ 0.2014	$ 0.2349
Number of options | shares	2,986,663	200,000
Fair value at date of issue	$ 0.0880	$ 0.2505
Tranche 11
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	28-Nov-16
Expiry date		Nov. 28, 2022
Exercise price	$ 0.2014	$ 0.2866
Number of options | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0890	$ 0.2377
Tranche 12
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	28-Nov-16
Expiry date		Nov. 28, 2022
Exercise price	$ 0.2014	$ 0.3556
Number of options | shares	2,986,663	5,000
Fair value at date of issue	$ 0.0900	$ 0.2227
Tranche 13
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	11-Dec-12
Expiry date		Dec. 11, 2022
Exercise price	$ 0.2014	$ 0.2912
Number of options | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0910	$ 0.2155
Tranche 14
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	17-Dec-13
Expiry date		Dec. 11, 2022
Exercise price	$ 0.2014	$ 0.6960
Number of options | shares	2,986,663	100,000
Fair value at date of issue	$ 0.0920	$ 0.4318
Tranche 15
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	17-Dec-13
Expiry date		Dec. 17, 2022
Exercise price	$ 0.2014	$ 0.6611
Number of options | shares	2,986,663	4,000
Fair value at date of issue	$ 0.0930	$ 0.4385
Tranche 16
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	2-Dec-21	18-Dec-12
Expiry date		Dec. 18, 2022
Exercise price	$ 0.2014	$ 0.2912
Number of options | shares	2,986,662	5,000
Fair value at date of issue	$ 0.0940	$ 0.2535
Tranche 17
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		24-Dec-15
Expiry date		Dec. 24, 2022
Exercise price		$ 0.5125
Number of options | shares		100,000
Fair value at date of issue		$ 0.1658
Tranche 18
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		30-Dec-15
Expiry date		Dec. 30, 2022
Exercise price		$ 0.4838
Number of options | shares		50,000
Fair value at date of issue		$ 0.1772
Tranche 19
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		27-Apr-15
Expiry date		Apr. 27, 2023
Exercise price		$ 0.4765
Number of options | shares		4,000
Fair value at date of issue		$ 0.2466
Tranche 20
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		1-May-13
Expiry date		May 01, 2023
Exercise price		$ 0.3481
Number of options | shares		64,000
Fair value at date of issue		$ 0.2697
Tranche 21
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		6-May-16
Expiry date		May 06, 2023
Exercise price		$ 0.2936
Number of options | shares		50,000
Fair value at date of issue		$ 0.1961
Tranche 22
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		25-May-15
Expiry date		May 25, 2023
Exercise price		$ 0.3982
Number of options | shares		260,600
Fair value at date of issue		$ 0.2654
Tranche 23
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		20-Jul-15
Expiry date		Jul. 20, 2023
Exercise price		$ 0.4077
Number of options | shares		15,000
Fair value at date of issue		$ 0.2513
Tranche 24
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		5-Sep-17
Expiry date		Sep. 05, 2023
Exercise price		$ 0.4136
Number of options | shares		10,000
Fair value at date of issue		$ 0.3062
Tranche 25
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		9-Oct-15
Expiry date		Oct. 09, 2023
Exercise price		$ 0.4311
Number of options | shares		5,000
Fair value at date of issue		$ 0.3376
Tranche 26
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		10-Oct-13
Expiry date		Oct. 10, 2023
Exercise price		$ 0.5750
Number of options | shares		5,000
Fair value at date of issue		$ 0.5415
Tranche 27
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		10-Oct-13
Expiry date		Oct. 10, 2023
Exercise price		$ 0.5750
Number of options | shares		10,000
Fair value at date of issue		$ 0.5415
Tranche 28
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		4-Nov-16
Expiry date		Nov. 04, 2023
Exercise price		$ 0.2327
Number of options | shares		4,000
Fair value at date of issue		$ 0.2448
Tranche 29
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Nov-16
Expiry date		Nov. 28, 2023
Exercise price		$ 0.2349
Number of options | shares		200,000
Fair value at date of issue		$ 0.2621
Tranche 30
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Nov-16
Expiry date		Nov. 28, 2023
Exercise price		$ 0.2866
Number of options | shares		200,000
Fair value at date of issue		$ 0.2504
Tranche 31
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Nov-16
Expiry date		Nov. 28, 2023
Exercise price		$ 0.3556
Number of options | shares		5,000
Fair value at date of issue		$ 0.2370
Tranche 32
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		17-Dec-13
Expiry date		Dec. 17, 2023
Exercise price		$ 0.6611
Number of options | shares		4,000
Fair value at date of issue		$ 0.4573
Tranche 33
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		24-Dec-15
Expiry date		Dec. 24, 2023
Exercise price		$ 0.5125
Number of options | shares		100,000
Fair value at date of issue		$ 0.1798
Tranche 34
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		30-Dec-15
Expiry date		Dec. 30, 2023
Exercise price		$ 0.4838
Number of options | shares		50,000
Fair value at date of issue		$ 0.1912
Tranche 35
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Mar. 31, 2024
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0890
Tranche 36
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		27-Apr-15
Expiry date		Apr. 27, 2024
Exercise price		$ 0.4765
Number of options | shares		4,000
Fair value at date of issue		$ 0.2601
Tranche 37
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		6-May-16
Expiry date		May 06, 2024
Exercise price		$ 0.2936
Number of options | shares		50,000
Fair value at date of issue		$ 0.2068
Tranche 38
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		25-May-15
Expiry date		May 25, 2024
Exercise price		$ 0.3982
Number of options | shares		260,600
Fair value at date of issue		$ 0.2780
Tranche 39
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Jun. 30, 2024
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0900
Tranche 40
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Jun. 30, 2024
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0910
Tranche 41
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		20-Jul-15
Expiry date		Jul. 20, 2024
Exercise price		$ 0.4077
Number of options | shares		15,000
Fair value at date of issue		$ 0.2640
Tranche 42
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		5-Sep-17
Expiry date		Sep. 05, 2024
Exercise price		$ 0.4136
Number of options | shares		10,000
Fair value at date of issue		$ 0.3236
Tranche 43
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		9-Oct-15
Expiry date		Oct. 09, 2024
Exercise price		$ 0.4311
Number of options | shares		5,000
Fair value at date of issue		$ 0.3521
Tranche 44
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		4-Nov-16
Expiry date		Nov. 04, 2024
Exercise price		$ 0.2327
Number of options | shares		4,000
Fair value at date of issue		$ 0.2546
Tranche 45
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Nov-16
Expiry date		Nov. 28, 2024
Exercise price		$ 0.2349
Number of options | shares		200,000
Fair value at date of issue		$ 0.2721
Tranche 46
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Nov-16
Expiry date		Nov. 28, 2024
Exercise price		$ 0.2866
Number of options | shares		200,000
Fair value at date of issue		$ 0.2616
Tranche 47
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Nov-16
Expiry date		Nov. 28, 2024
Exercise price		$ 0.3556
Number of options | shares		5,000
Fair value at date of issue		$ 0.2495
Tranche 48
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		24-Dec-15
Expiry date		Dec. 24, 2024
Exercise price		$ 0.5125
Number of options | shares		100,000
Fair value at date of issue		$ 0.1925
Tranche 49
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		30-Dec-15
Expiry date		Dec. 30, 2024
Exercise price		$ 0.4838
Number of options | shares		50,000
Fair value at date of issue		$ 0.2038
Tranche 50
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		27-Apr-15
Expiry date		Apr. 27, 2025
Exercise price		$ 0.4765
Number of options | shares		4,000
Fair value at date of issue		$ 0.2722
Tranche 51
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		6-May-16
Expiry date		May 06, 2025
Exercise price		$ 0.2936
Number of options | shares		50,000
Fair value at date of issue		$ 0.2164
Tranche 52
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		25-May-15
Expiry date		May 25, 2025
Exercise price		$ 0.3982
Number of options | shares		260,600
Fair value at date of issue		$ 0.2893
Tranche 53
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		20-Jul-15
Expiry date		Jul. 20, 2025
Exercise price		$ 0.4077
Number of options | shares		15,000
Fair value at date of issue		$ 0.2756
Tranche 54
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Aug-20
Expiry date		Aug. 28, 2025
Exercise price		$ 0.0136
Number of options | shares		6,000,000
Fair value at date of issue		$ 0.0750
Tranche 55
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Aug-20
Expiry date		Aug. 28, 2025
Exercise price		$ 0.0136
Number of options | shares		6,000,000
Fair value at date of issue		$ 0.0710
Tranche 56
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Aug-20
Expiry date		Aug. 28, 2025
Exercise price		$ 0.0136
Number of options | shares		500,000
Fair value at date of issue		$ 0.1330
Tranche 57
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Aug-20
Expiry date		Aug. 28, 2025
Exercise price		$ 0.0136
Number of options | shares		500,000
Fair value at date of issue		$ 0.1180
Tranche 58
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		5-Sep-17
Expiry date		Sep. 05, 2025
Exercise price		$ 0.4136
Number of options | shares		10,000
Fair value at date of issue		$ 0.3388
Tranche 59
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		9-Oct-15
Expiry date		Oct. 09, 2025
Exercise price		$ 0.4311
Number of options | shares		5,000
Fair value at date of issue		$ 0.3653
Tranche 60
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		4-Nov-16
Expiry date		Nov. 04, 2025
Exercise price		$ 0.2327
Number of options | shares		4,000
Fair value at date of issue		$ 0.2633
Tranche 61
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Nov-16
Expiry date		Nov. 28, 2025
Exercise price		$ 0.2349
Number of options | shares		200,000
Fair value at date of issue		$ 0.2810
Tranche 62
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Nov-16
Expiry date		Nov. 28, 2025
Exercise price		$ 0.2866
Number of options | shares		200,000
Fair value at date of issue		$ 0.2716
Tranche 63
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Nov-16
Expiry date		Nov. 28, 2025
Exercise price		$ 0.3556
Number of options | shares		5,000
Fair value at date of issue		$ 0.2605
Tranche 64
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		24-Dec-15
Expiry date		Dec. 24, 2025
Exercise price		$ 0.5125
Number of options | shares		100,000
Fair value at date of issue		$ 0.2039
Tranche 65
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		30-Dec-15
Expiry date		Dec. 30, 2025
Exercise price		$ 0.4838
Number of options | shares		50,000
Fair value at date of issue		$ 0.2152
Tranche 66
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		6-May-16
Expiry date		May 06, 2026
Exercise price		$ 0.2936
Number of options | shares		50,000
Fair value at date of issue		$ 0.2251
Tranche 67
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		5-Sep-17
Expiry date		Sep. 05, 2026
Exercise price		$ 0.4136
Number of options | shares		10,000
Fair value at date of issue		$ 0.3520
Tranche 68
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Sep. 30, 2026
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0740
Tranche 69
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		20-Nov-20
Expiry date		Oct. 20, 2026
Exercise price		$ 0.1519
Number of options | shares		100,000
Fair value at date of issue		$ 0.0890
Tranche 70
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		4-Nov-16
Expiry date		Nov. 04, 2026
Exercise price		$ 0.2327
Number of options | shares		4,000
Fair value at date of issue		$ 0.2710
Tranche 71
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Nov-16
Expiry date		Nov. 28, 2026
Exercise price		$ 0.2349
Number of options | shares		200,000
Fair value at date of issue		$ 0.2890
Tranche 72
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Nov-16
Expiry date		Nov. 28, 2026
Exercise price		$ 0.2866
Number of options | shares		200,000
Fair value at date of issue		$ 0.2804
Tranche 73
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		28-Nov-16
Expiry date		Nov. 28, 2026
Exercise price		$ 40.3556
Number of options | shares		5,000
Fair value at date of issue		$ 0.2703
Tranche 74
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Dec. 31, 2026
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0760
Tranche 75
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Mar. 31, 2027
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0780
Tranche 76
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Mar. 31, 2027
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.0900
Tranche 77
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Jun. 30, 2027
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0790
Tranche 78
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Jun. 30, 2027
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.0910
Tranche 79
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		5-Sep-17
Expiry date		Sep. 05, 2027
Exercise price		$ 0.4136
Number of options | shares		10,000
Fair value at date of issue		$ 0.3636
Tranche 80
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Sep. 30, 2027
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0810
Tranche 81
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Sep. 30, 2027
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.0920
Tranche 82
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		20-Nov-20
Expiry date		Oct. 20, 2027
Exercise price		$ 0.1519
Number of options | shares		100,000
Fair value at date of issue		$ 0.0950
Tranche 83
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Dec. 31, 2027
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0820
Tranche 84
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Dec. 31, 2027
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.0940
Tranche 85
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Mar. 31, 2028
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0840
Tranche 86
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Mar. 31, 2028
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.0950
Tranche 87
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Jun. 30, 2028
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0850
Tranche 88
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Jun. 30, 2028
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.0960
Tranche 89
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Sep. 30, 2028
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0860
Tranche 90
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Sep. 30, 2028
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.0970
Tranche 91
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		20-Nov-20
Expiry date		Oct. 20, 2028
Exercise price		$ 0.1519
Number of options | shares		100,000
Fair value at date of issue		$ 0.0990
Tranche 92
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Dec. 31, 2028
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0880
Tranche 93
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Dec. 31, 2028
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.0980
Tranche 94
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Mar. 31, 2029
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.0980
Tranche 95
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Jun. 30, 2029
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.0990
Tranche 96
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Sep. 30, 2029
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.1000
Tranche 97
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		20-Nov-20
Expiry date		Oct. 20, 2029
Exercise price		$ 0.1519
Number of options | shares		100,000
Fair value at date of issue		$ 0.1030
Tranche 98
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Dec. 31, 2029
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0920
Tranche 99
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Dec. 31, 2029
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.1010
Tranche 100
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Mar. 31, 2030
Exercise price		$ 0.2014
Number of options | shares		2,986,663
Fair value at date of issue		$ 0.0930
Tranche 101
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Mar. 31, 2030
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.1020
Tranche 102
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Jun. 30, 2030
Exercise price		$ 0.2014
Number of options | shares		2,986,662
Fair value at date of issue		$ 0.0940
Tranche 103
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Jun. 30, 2030
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.1020
Tranche 104
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Sep. 30, 2030
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.1030
Tranche 105
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		20-Nov-20
Expiry date		Oct. 20, 2030
Exercise price		$ 0.1519
Number of options | shares		100,000
Fair value at date of issue		$ 0.1070
Tranche 106
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		2-Dec-21
Expiry date		Dec. 31, 2030
Exercise price		$ 0.0965
Number of options | shares		839,385
Fair value at date of issue		$ 0.1040

Issued Capital - Summary of M_3

Issued Capital - Summary of Movement in Unlisted Share Warrants (Details) - Warrants		12 Months Ended
	Nov. 11, 2021 shares $ / shares	Jun. 30, 2022 shares $ / shares	Jun. 30, 2021 shares $ / shares	Jun. 30, 2020 shares $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of warrants Opening balance | shares		166,082,988	40,207,472	40,207,472
Number of warrants Granted during the financial year | shares			150,000,000
Number of warrants Exercised during the financial year | shares	(2,000,000)	(8,000,000)
Number of warrants Expired during the financial year | shares		(16,082,988)	(24,124,484)
Number of warrants Closing balance | shares		142,000,000	166,082,988	40,207,472
Weighted average exercise price Opening balance | $ / shares		$ 0.11	$ 0.59	$ 0.59
Weighted average exercise price Granted during the financial year | $ / shares			0.06
Weighted average exercise price Exercised during the financial year | $ / shares	$ 0.06	0.06
Weighted average exercise price Expired during the financial year | $ / shares		0.57	0.59
Weighted average exercise price Closing balance | $ / shares		$ 0.06	$ 0.11	$ 0.59

Issued Capital - Summary of Lis

Issued Capital - Summary of Lists of Warrants Outstanding (Details)	12 Months Ended
	Jun. 30, 2022 shares $ / shares	Dec. 22, 2021 shares	Jun. 30, 2021 shares	Jun. 30, 2020 shares	Jun. 30, 2019 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options | shares	79,056,617	47,786,607	20,985,450	6,364,550	7,686,550
Warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	26-Aug-20
Expiry date	Aug. 26, 2023
Exercise price | $ / shares	$ 0.06
Number of options | shares	142,000,000
Fair value at date of issue | $ / shares	$ 0.01

Reserves - Summary of Reserves

Reserves - Summary of Reserves (Details) - AUD ($)	Jun. 30, 2022	Jun. 30, 2021
Disclosure of reserves within equity [abstract]
Foreign Currency Translation Reserve	$ 6,186,334	$ 5,119,200
Share-based Payments Reserve	6,337,264	6,328,691
Total Reserves	$ 12,523,598	$ 11,447,891

Financial Instruments - Categor

Financial Instruments - Categories of Financial Instruments (Details) - AUD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Disclosure of financial assets [abstract]
Cash and cash equivalents	$ 33,564,857	$ 28,499,449	$ 4,577,747	$ 13,985,477
Receivables	6,784,121	1,128,285
Other financial assets	119,000	554,640
Total financial assets	40,467,978	30,182,374
Financial Liabilities
Trade and other payables	2,786,280	1,814,390
Lease liability - rental property	693,623	867,841	$ 793,148
Contingent consideration at fair value	2,699,010	1,762,656
Total financial liabilities	$ 6,178,913	$ 4,444,887

Financial Instruments - Additio

Financial Instruments - Additional Information (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of detailed information about financial instruments [line items]
Derivative financial instruments outstanding	$ 0	$ 0
Foreign currency sensitivity rate	10%
Forward foreign currency contracts	$ 0	$ 0
Effective interest rate		10.78%

Financial Instruments - Disclos

Financial Instruments - Disclosure of Foreign Currency Risk Management (Details) - AUD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Monetary Items [Abstract]
Cash and cash equivalents	$ 33,564,857	$ 28,499,449	$ 4,577,747	$ 13,985,477
Trade and other payables	(2,786,280)	(1,814,390)
Contingent consideration	2,699,010	1,762,656
Non Monetary Items [Abstract]
Goodwill	12,868,122	12,400,743	$ 12,872,387
Deferred tax liabilities	(1,798,625)	(1,842,303)
Currency Risk
Monetary Items [Abstract]
Cash and cash equivalents	17,786,031	624,819
Trade and other payables	(1,298,425)	(672,353)
Contingent consideration	(2,699,010)	(1,762,656)
Total monetary items	13,788,596	(1,810,190)
Non Monetary Items [Abstract]
Goodwill	5,921,027	5,453,648
Other intangible assets	9,838,274	9,945,755
Deferred tax liabilities	(1,798,625)	(1,842,303)
Total non-monetary items	13,960,676	13,557,100
Total denominated in USD	$ 27,749,272	$ 11,746,910

Financial Instruments - Summary

Financial Instruments - Summary of Foreign Currency Sensitivity Analysis (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of detailed information about financial instruments [line items]
Profit or loss	$ 1,796,641	$ (222,678)	$ (2,181,987)
Equity	$ 18,815	$ 3,135	$ 10,403

Financial Instruments - Summa_2

Financial Instruments - Summary of Remaining Contractual Maturity for Financial Liabilities (Details) - Liquidity and Interest Rate Risk - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Weighted average effective interest rate	3.56%	3.56%
Trade and other payables	$ 2,786,280	$ 1,814,390
Lease liability - rental property (fixed interest rate)	744,580	945,668
Undiscounted cash flows of financial liabilities	3,530,860	2,760,058
Less Than 1 Month
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Trade and other payables	2,786,280	1,814,390
Lease liability - rental property (fixed interest rate)	15,069	40,141
Undiscounted cash flows of financial liabilities	2,801,349	1,854,531
1 - 3 Months
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Lease liability - rental property (fixed interest rate)	45,206	43,764
Undiscounted cash flows of financial liabilities	45,206	43,764
3 - 12 Months
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Lease liability - rental property (fixed interest rate)	121,043	117,184
Undiscounted cash flows of financial liabilities	121,043	117,184
1 to 5 Years
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Lease liability - rental property (fixed interest rate)	563,262	744,579
Undiscounted cash flows of financial liabilities	$ 563,262	$ 744,579

Financial Instruments - Summa_3

Financial Instruments - Summary of Fair Value of Financial Instruments (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Disclosure of detailed information about financial instruments [line items]
Contingent consideration in a business combination	$ 2,699,010	$ 1,762,656	$ 1,762,656	$ 4,975,159
Level 3
Disclosure of detailed information about financial instruments [line items]
Contingent consideration in a business combination	$ 2,699,010		$ 1,762,656	$ 4,975,159
Description of valuation technique	Discounted cash flow
Description of significant unobservable inputs	Discount rate of 25% (pre-tax) and probability adjusted revenue projections.
Description of relationship of unobservable inputs to fair value	The higher the discount rate, the lower the value. The higher the possible revenue the higher value.

Financial Instruments - Summa_4

Financial Instruments - Summary of Reconciliation of Level 3 Fair Value Measurements (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of fair value measurement of liabilities [line items]
Opening balance	$ 1,762,656	$ 4,975,159
Total (gain) or loss: - in profit or loss	936,354	(3,212,503)
Closing balance	2,699,010	1,762,656
Level 3
Disclosure of fair value measurement of liabilities [line items]
Opening balance	1,762,656	4,975,159
Total (gain) or loss: - in profit or loss	936,354	(3,212,503)
Closing balance	$ 2,699,010	$ 1,762,656

Key Management Personnel Comp_3

Key Management Personnel Compensation - Disclosure of Key Management Personnel Compensation (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Key Management Personnel Compensation [Abstract]
Short-term employee benefits	$ 2,535,560	$ 2,269,030	$ 1,527,499
Post-employment benefits	69,039	51,982	52,106
Other long-term benefits	22,241	9,480	16,434
Share-based payments	2,819,133	1,298,208	68,518
Total key management personnel compensation	$ 5,445,973	$ 3,628,700	$ 1,664,557

Commitments For Expenditure (Ad

Commitments For Expenditure (Additional Information) (Details)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Commitments For Expenditure [Abstract]
Operating lease term	4 years	5 years
Expiry date of sub let areas facility	Jul. 12, 2021

Commitments For Expenditure - S

Commitments For Expenditure - Summary of Non Cancellable Operating Lease Commitments (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of maturity analysis of operating lease payments [line items]
Non-cancellable operating lease commitments	$ 18,568	$ 24,476
Within one year
Disclosure of maturity analysis of operating lease payments [line items]
Non-cancellable operating lease commitments	5,064	5,064
Later than one year but not greater than five
Disclosure of maturity analysis of operating lease payments [line items]
Non-cancellable operating lease commitments	$ 13,504	$ 19,412

Commitments For Expenditure -_2

Commitments For Expenditure - Summary of Future Rental Income Receivable (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Disclosure of maturity analysis of operating lease payments [line items]
Future rental income receivable		$ 6,549
Within one year
Disclosure of maturity analysis of operating lease payments [line items]
Future rental income receivable		6,549
Later than one year but not greater than five
Disclosure of maturity analysis of operating lease payments [line items]
Future rental income receivable

Remuneration of Auditors - Sche

Remuneration of Auditors - Schedule of Auditors Remuneration Explanatory (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of attribution of expenses by nature to their function [line items]
Agreed upon procedures in relation to French subsidiaries cash statement and debt statement as at February 28, 2020			$ 27,109
Auditor's remuneration	$ 969,726	$ 86,500	212,081
Group
Disclosure of attribution of expenses by nature to their function [line items]
Audit or Review of Financial Reports	$ 969,726	$ 86,500	110,000
French subsidiaries
Disclosure of attribution of expenses by nature to their function [line items]
Audit or Review of Financial Reports			$ 74,972

Cash Flow Information - Summary

Cash Flow Information - Summary of Cash Flow Information (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Statement of cash flows [abstract]
Cash and cash equivalents	$ 33,564,857	$ 28,499,449	$ 4,577,747	$ 13,985,477
Reconciliation of Operating Loss to Net Cash Outflow from Operating Activities
(Loss) for the period	(21,759,358)	(8,697,037)	(7,118,288)
Depreciation and amortisation	1,109,412	1,700,878	2,443,386
Share-based payments	2,829,689	1,308,349	55,355
Loss/(Gain) on asset disposals	1,827	21,010	(173,934)
Contingent consideration - change in fair value	936,354	(3,212,503)	(4,823,874)
Amortisation of transaction costs		252,019	29,649
Net gain arising on modification of borrowings measured at amortised costs that were not derecognized			544,357
Accrual of final borrowing payment		528,819	(199,089)
Net foreign exchange differences	738,423	(1,067,746)	558,645
Loss on disposal of French operations			802,502
Interest received	(9,869)	(5,756)	(58,369)
Changes in Operating Assets and Liabilities
(Increase)/Decrease) in receivables	(39,148)	34,078	(202,257)
(Increase)/Decrease in research and development incentive receivable	(5,791,688)	1,991,468	4,145,659
(Increase)/Decrease in other assets	(600,285)	(85,648)	348,768
(Increase) in inventory			(28,291)
Increase/(Decrease) in payables	979,902	(63,305)	127,451
Increase/(Decrease) in provisions	41,062	(55,923)	(85,407)
(Decrease) in other liabilities			(20,876)
(Decrease) in deferred tax liability	(191,808)	(187,427)	(248,580)
Net cash outflows from operating activities	$ (21,755,487)	$ (7,538,724)	$ (3,903,193)

Loss Per Share - Summary of Com

Loss Per Share - Summary of Computation of Basic and Diluted Loss Per Share (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Earnings per share [line items]
Basic loss per share	$ (0.02)	$ (0.01)	$ (0.01)
Diluted loss per share	$ (0.02)	$ (0.01)	$ (0.01)
Loss Per Share (Basic and Diluted):
Loss after tax for the year from continuing and discontinuing operations	$ (21,759,358)	$ (8,697,037)	$ (7,118,288)
Loss after tax from continuing operations	$ (21,759,358)	$ (8,697,037)	$ (5,818,975)
Weighted Average Number of Ordinary Shares - Basic and Diluted
Weighted average number of ordinary shares used in calculating basic loss per share:	1,353,350,744	779,941,036	544,871,870
Weighted average number of ordinary shares used in the calculation of diluted loss per share	1,353,350,744	779,941,036	544,871,870
Employee Options
Weighted Average Number of Ordinary Shares - Basic and Diluted
Shares deemed to be issued for no consideration in respect of employee options	31,065,272	20,056,450	5,296,550
Potential ordinary shares which are anti-dilutive and excluded	(31,065,272)	(20,056,450)	(5,296,550)
Warrants
Weighted Average Number of Ordinary Shares - Basic and Diluted
Shares deemed to be issued for no consideration in respect of warrants	142,000,000	166,082,988	40,207,472
Potential ordinary shares which are anti-dilutive and excluded	(142,000,000)	(166,082,988)	(40,207,472)

Loss Per Share - Summary of Num

Loss Per Share - Summary of Number Of Potential Anti Dilutive Ordinary Shares Excluded From Computation Of Loss Per S (Details) - shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Employee Options
Earnings per share [line items]
Potential ordinary shares which are anti-dilutive and excluded from weighted average number of ordinary shares	(31,065,272)	(20,056,450)	(5,296,550)
Warrants
Earnings per share [line items]
Potential ordinary shares which are anti-dilutive and excluded from weighted average number of ordinary shares	(142,000,000)	(166,082,988)	(40,207,472)

Related Party Transactions - (A

Related Party Transactions - (Additional Information) (Details)		12 Months Ended
	Aug. 26, 2020 AUD ($) $ / shares shares	Jun. 30, 2022 AUD ($) $ / shares shares	Jun. 30, 2021 AUD ($) $ / shares shares	Jun. 30, 2020 AUD ($)	Jun. 30, 2021 $ / shares	Aug. 28, 2020 shares
Disclosure of transactions between related parties [line items]
Number of shares issued		1,353,350,744
Shares issued | $		$ 32,890,463	$ 43,836,131	$ 3,260,000
Director
Disclosure of transactions between related parties [line items]
Number of shares issued		0
Peter Turner
Disclosure of transactions between related parties [line items]
Number of shares issued			15,949
Fair value at date of issue | $ / shares			$ 0.04
David Wilson
Disclosure of transactions between related parties [line items]
Number of shares issued			15,949
Fair value at date of issue | $ / shares			$ 0.04
Jack Moschakis
Disclosure of transactions between related parties [line items]
Number of shares issued						314,246
Lizdoolin
Disclosure of transactions between related parties [line items]
Number of shares issued						109,986
Rights Issue [Member] | David Wilson
Disclosure of transactions between related parties [line items]
Number of shares issued			35,990
Fair value at date of issue | $ / shares					$ 0.145
Loans to Directors and Other Key Management Personnel
Disclosure of transactions between related parties [line items]
Loans to director or other key management personnel | $		$ 0	$ 0
Apeiron
Disclosure of transactions between related parties [line items]
Number of shares issued		7,287,480	54,333,000
Fair value at date of issue | $ / shares	$ 0.06		$ 0.04
Shares issued | $	$ 15,000,000
Number of warrants issued	150,000,000
Apeiron | Rights Issue [Member]
Disclosure of transactions between related parties [line items]
Number of shares issued			26,222,424
Fair value at date of issue | $ / shares			$ 0.145
Presight
Disclosure of transactions between related parties [line items]
Number of shares issued		109,311,660
Fair value at date of issue | $ / shares		$ 0.09645
BVF Partners
Disclosure of transactions between related parties [line items]
Number of shares issued		14,574,780	10,864,351
Fair value at date of issue | $ / shares		$ 0.09645	$ 0.04
BVF Partners | Rights Issue [Member]
Disclosure of transactions between related parties [line items]
Number of shares issued			36,115,866
Fair value at date of issue | $ / shares			$ 0.145

Contingent Consideration - Addi

Contingent Consideration - Additional Information (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Contingent consideration [abstract]
Contingent consideration liability increase (decrease)	$ 936,354	$ (3,212,503)

Contingent Consideration - Disc

Contingent Consideration - Disclosure of Contingent Consideration (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Contingent consideration [abstract]
Opening balance	$ 1,762,656	$ 4,975,159
Change in fair value	936,354	(3,212,503)
Closing balance	$ 2,699,010	$ 1,762,656

Contingent Liabilities - Additi

Contingent Liabilities - Additional Information (Details)		12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2022 AUD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 AUD ($)
Disclosure of contingent liabilities [abstract]
Restricted term deposit		$ 119,000		$ 554,640
Rent guarantee		$ 119,000		$ 554,640
Consultancy agreement paid per month	$ 43,750
Reimbursement of health care benefits per year			$ 22,000
Possibility of reimbursement contingent liabilities description		The Group has a consultancy agreement with Dr Errol De Souza who is paid US$43,750 per month (plus reimbursement of health care benefits of up to US$22,000 per year), plus a short-term incentive/bonus potential of 60% of fixed remuneration as assessed by the independent non-Executive directors against agreed financial, strategic and operational targets, for performance exceeding such applicable performance criteria the annual bonus may be increased up to 100% of Base Salary.

Events Occurring After Report_3

Events Occurring After Reporting Date (Additional Information) (Details) - AUD ($)			12 Months Ended
	Aug. 05, 2022	Jul. 15, 2022	Jun. 30, 2022
Disclosure of non-adjusting events after reporting period [line items]
Share options issued			1,353,350,744
Vesting date			five years
Share Options | Employee Equity Plan
Disclosure of non-adjusting events after reporting period [line items]
Share options issued		7,700,000
Share options subscribed		7,700,000
Exercise price per option		$ 0.0543
Share options expiry date		5 years
Vesting date		25% of the Options vest at the end of 12 months following the Offer Date (July 8, 2022), and 75% vest in 12 substantially equal instalments (6.25%) on the last day of each calendar quarter over the 4-year period following the end of the initial 12 months following the Offer Date. The share options expire on the date that is 5 years following each vesting date.
Share Options | Employee Equity Plan | Vest at End of 12 Months Following Offer Date (8 July 2022)
Disclosure of non-adjusting events after reporting period [line items]
Vesting percentage		25%
Share Options | Employee Equity Plan | Vest in 12 Substantially Equal Instalments
Disclosure of non-adjusting events after reporting period [line items]
Vesting percentage		75%
Share Options | Employee Equity Plan | Last Day of Each Calendar Quarter Over 4 Year Period Following End of Initial 12 Months Following Offer Date
Disclosure of non-adjusting events after reporting period [line items]
Vesting percentage		6.25%
Share Options | Employee Equity Plan | Key Management Personnel
Disclosure of non-adjusting events after reporting period [line items]
Share options issued		7,500,000
Tax Incentive Refund
Disclosure of non-adjusting events after reporting period [line items]
Research and development tax incentive refund received	$ 2,085,453

Events Occurring After Report_4

Events Occurring After Reporting Date - Details of Share Options That Were Issued to KMPs (Details) - shares	Jul. 15, 2022	Jun. 30, 2022
Disclosure of non-adjusting events after reporting period [line items]
Share options issued		1,353,350,744
Share Options | Key Management Personnel | Mr Adrian Hinton
Disclosure of non-adjusting events after reporting period [line items]
Share options issued	2,000,000
Share Options | Key Management Personnel | Mr Connor Bernstein
Disclosure of non-adjusting events after reporting period [line items]
Share options issued	3,500,000
Share Options | Key Management Personnel | Ms Liz Doolin
Disclosure of non-adjusting events after reporting period [line items]
Share options issued	2,000,000

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) - Mar. 03, 2020	EUR (€)	AUD ($)
Disclosure of analysis of single amount of discontinued operations [line items]
Proceeds from sale of subsidiaries | €	€ 1,790,029
Costs incurred in relation to disposal | $		$ 207,143

Discontinued Operations - Summa

Discontinued Operations - Summary of Discontinued Operations (Statements of Financial Position) (Details) - AUD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Current assets
Cash and cash equivalents	$ 33,564,857	$ 28,499,449	$ 4,577,747	$ 13,985,477
Trade and other receivables	64,360	200,212
Research and development incentives receivable	6,719,761	928,073
Other assets	1,461,268	863,630
Non-current assets
Property, plant and equipment	5,172	8,227
Right-to-use asset - rented property	669,358	862,716
Other intangible assets	9,838,274	9,945,755
Current liabilities
Trade and other payables	(2,786,280)	(1,814,390)
Lease liability - rented property	(160,040)	(174,218)	(767,711)
Provisions	(409,320)	(371,936)
Non-current liabilities
Lease liability - rented property	(533,583)	(693,623)	(25,437)
Deferred tax liabilities	(1,798,625)	(1,842,303)
Net assets disposed of	$ 65,310,172	$ 54,263,445
Discontinued Operations
Current assets
Cash and cash equivalents			800,849
Trade and other receivables			1,047,259
Research and development incentives receivable			770,054
Inventories			692,832
Other assets			85,115
Non-current assets
Property, plant and equipment			2,006,977
Right-to-use asset - rented property			1,424,365
Other intangible assets			574
Current liabilities
Trade and other payables			(2,312,900)
Lease liability - rented property			(161,723)
Provisions			(446,148)
Other liabilities			(204,860)
Non-current liabilities
Other payables			(816,663)
Lease liability - rented property			(1,278,599)
Deferred tax liabilities			(514,962)
Net assets disposed of			$ 1,092,170

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Discontinued Operations (Statements of Loss on Disposal) (Details) - AUD ($)		12 Months Ended
	Mar. 03, 2020	Jun. 30, 2020
Disclosure of analysis of single amount of discontinued operations [line items]
Costs relating to the disposal incurred by the Company	$ 207,143
Loss on disposal		$ (1,299,313)
Discontinued Operations
Disclosure of analysis of single amount of discontinued operations [line items]
Net assets disposed of		(1,092,170)
Costs relating to the disposal incurred by the Company		(207,143)
Loss on disposal		$ (1,299,313)

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Discontinued Operations (Statements of Profit or Loss) (Parenthetical) (Details)	12 Months Ended
	Jun. 30, 2020 AUD ($)
Discontinued Operations
Disclosure of analysis of single amount of discontinued operations [line items]
Cumulative gain of recycled from foreign currency translation reserve to profit and loss	$ 496,811

Discontinued Operations - Sum_4

Discontinued Operations - Summary of Discontinued Operations (Statements of Net Cash Outflow) (Details) - AUD ($)		12 Months Ended
	Mar. 03, 2020	Jun. 30, 2020
Disclosure of analysis of single amount of discontinued operations [line items]
Costs relating to the disposal incurred by the Company	$ 207,143
Discontinued Operations
Disclosure of analysis of single amount of discontinued operations [line items]
Cash and cash equivalent balances disposed of		$ (800,849)
Costs relating to the disposal incurred by the Company		(207,143)
Net cash outflow		$ (1,007,992)

Discontinued Operations - Sum_5

Discontinued Operations - Summary of Discontinued Operations (Statements of Profit or Loss) (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of analysis of single amount of discontinued operations [line items]
Revenue	$ 263,634		$ 46,662
Other income	5,808,231	$ 1,308,343	3,312,753
Loss before tax	(21,951,166)	(8,884,464)	(6,026,587)
Loss for the year	$ (21,759,358)	$ (8,697,037)	(7,118,288)
Loss on disposal			(1,299,313)
Discontinued Operations
Disclosure of analysis of single amount of discontinued operations [line items]
Revenue			3,422,584
Other income			391,505
Revenue and other income			3,814,089
Expenses			(4,242,502)
Loss before tax			(428,413)
Income tax benefit			40,968
Loss for the year			(387,445)
Loss on disposal of operations including a cumulative gain of $496,811 recycled from foreign currency translation reserve to profit and loss			(911,868)
Attributable income tax expenses			0
Loss on disposal of operations after tax			(911,868)
Loss on disposal			$ (1,299,313)

Discontinued Operations - Sum_6

Discontinued Operations - Summary of Discontinued Operations (Statements of Cash Flows from Discontinued Operations) (Details) - Discontinued Operations	12 Months Ended
	Jun. 30, 2020 AUD ($)
Disclosure of analysis of single amount of discontinued operations [line items]
Inflows from operating activities	$ 470,767
Outflows from investing activities	(7,704)
Outflows from financing activities	(100,489)
Net cash flow	$ 362,574